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Abstract 
HIV-associated sensory polyneuropathy (HIV-SN) is a distal symmetrical 
polyneuropathy that is a prevalent (approximately 40%), and often painful 
complication of HIV infection. The introduction of combination antiretroviral 
treatment (cART), transformed HIV infection from a high mortality condition 
into a chronic disease. Despite this, and the phasing-out of neurotoxic 
antiretroviral drugs, HIV-SN continues to be a significant morbidity 
experienced in HIV infection. Consequently, the understanding, prevention and 
management of HIV-SN is increasingly important.  
A systematic review and meta-analysis was undertaken to examine the 
evidence for the efficacy of pharmacological agents in the management of pain 
in HIV-SN. Of 44 studies identified, 19 were randomized controlled trials, and 
only 14 were of sufficient quality. Interventions demonstrating greater efficacy 
than placebo included smoked cannabis and recombinant nerve growth factor 
(rhNGF). However rhNGF is not clinically available and smoked cannabis 
cannot be recommended as routine therapy. 
A second study was undertaken to phenotype a cohort of HIV infected 
participants with and without HIV-SN. This study examined demographic 
factors, symptomatology, metabolic factors, sensory nerve dysfunction through 
quantitative sensory testing (QST), and intra-epidermal nerve fibre density 
(IENFD); quality of life, sleep dysfunction and psychological co-morbidity. A 
novel triumvirate definition using QST, IENFD and a structured neurological 
examination was used to define HIV-SN. 
This study showed that patterns of sensory nerve dysfunction are 
heterogeneous in HIV-SN; the most common feature being loss of sensory 
function in mechanical and vibration detection modalities. Gain of function 
sensory changes were infrequent, but were seen in a small sub-group 
demonstrating wind-up phenomenon; this group demonstrated higher levels of 
catastrophizing behaviours. Measures of quality of life were generally lower 
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than in other painful peripheral neuropathies. Sleep dysfunction was common 
in HIV-SN. Participants with HIV-SN had elevated triglycerides (TRG), 
providing further evidence for the role of dyslipidaemia in HIV-SN 
pathogenesis.  
 7 
Table of Contents 
ACKNOWLEDGMENTS ............................................................................................................................... 2 
DECLARATION AND AUTHOR CONTRIBUTIONS ........................................................................... 3 
ABSTRACT ....................................................................................................................................................... 5 
TABLE OF CONTENTS ................................................................................................................................ 7 
TABLE OF FIGURES AND TABLES ...................................................................................................... 12 
Figures ................................................................................................................. 12 
Tables ................................................................................................................... 12 
PUBLICATIONS ARISING FROM THIS WORK ................................................................................ 14 
ABBREVIATIONS ....................................................................................................................................... 15 
CHAPTER 1. INTRODUCTION TO PAINFUL HIV-ASSOCIATED SENSORY NEUROPATHY 18 
PAIN AND HIV DISEASE ......................................................................................................................... 19 
CLINICAL PRESENTATION OF HIV-SN ............................................................................................. 20 
RISK FACTORS FOR HIV-SN .................................................................................................................. 21 
Risk factors for HIV-SN in patients not exposed to anti-retrovirals .................... 21 
Risk factors for HIV-SN in patients exposed to anti-retrovirals .......................... 21 
The role of nucleoside reverse transcriptase inhibitors (NRTI)…...................21   
cART era risk factors for HIV-SN........................................................................21 
Emerging treatment associations with HIV-SN in era of cART ........................... 23 
PUTATIVE MECHANISMS OF PATHOGENESIS IN HIV-SN DEVELOPMENT ..................... 24 
Proposed pathogenesis of DSP ............................................................................ 24 
Proposed pathogenesis of ATN ............................................................................ 25 
CLINICAL ASSESSMENT OF HIV-SN .................................................................................................. 25 
Clinical diagnosis ................................................................................................ 25 
Clinical management ........................................................................................... 26 
Remove the underlying cause ..............................................................................26 
Provision of analgesia..........................................................................................27 
SUMMARY AND CONCLUSION ............................................................................................................. 27 
TABLES................................................................................................................ ..............................29 
AIMS OF THESIS ........................................................................................................................................ 32 
CHAPTER 2. PHARMACOLOGICAL TREATMENT OF PAINFUL HIV-ASSOCIATED SENSORY 
NEUROPATHY .................................................................................................................................................. 34 
 8 
INTRODUCTION ......................................................................................................................................... 35 
METHODS ..................................................................................................................................................... 35 
Eligibility of data sources and search strategy.................................................... 35 
PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses ......................................................................................................35 
Search terms ......................................................................................................... 37 
Study selection and risk of bias assessment ......................................................... 37 
The modified Jadad scale.....................................................................................37 
Data extraction..................................................................................................... 38 
Statistical analysis............................................................................................... 38 
Meta-analysis........................................................................................................38 
Weighted average..................................................................................................39 
Heterogeneity....................................................................................................... 40 
Determination of Number Needed to Treat (NTT).............................................. 40  
RESULTS ....................................................................................................................................................... 41 
Acetyl-L-carnitine ................................................................................................ 42 
Amitriptyline and Mexilitine ................................................................................ 42 
Smoked Cannabis ................................................................................................. 43 
Topical Capsaicin ................................................................................................ 44 
Gabapentin ........................................................................................................... 45 
Pregabalin ............................................................................................................ 45 
Lamotrigine .......................................................................................................... 45 
Recombinant Human Nerve Growth Factor ........................................................ 46 
Prosaptide and Peptide T ..................................................................................... 47 
DISCUSSION ................................................................................................................................................. 47 
Summary ............................................................................................................... 51 
FIGURES AND TABLES ............................................................................................................................ 53 
CHAPTER 3. PATTERNS OF SENSORY, PSYCHOLOGICAL AND METABOLIC DYSFUNCTION 
IN HIV POSITIVE PATIENTS WITH AND WITHOUT HIV-ASSOCIATED SENSORY 
NEUROPATHY .................................................................................................................................................. 57 
INTRODUCTION ......................................................................................................................................... 58 
METHODS ..................................................................................................................................................... 59 
Study design and participants .............................................................................. 59 
Quantitative sensory testing (QST) ...................................................................... 60 
 9 
          QST equipment...........................................................................................61 
          Thermal threshold detection.......................................................................62 
          Mechanical detection threshold..............................................................,,..62 
          Mechanical pain threshold....................................................................,,,...62 
          Mechanical pain sensitivity and dynamic mechanical allodynia................62 
          Vibration detection threshold......................................................................62 
          Pressure pain threshold...............................................................................62 
          QST data analysis.......................................................................................62 
          Heat suprathreshold nociceptive testing.....................................................63 
          Hierarchical cluster analysis.......................................................................63 
Structured neurological examination (SNE) ........................................................ 64 
Intra-epidermal nerve fibre testing (IENFD) ....................................................... 64 
Clinical electrophysiological testing ................................................................... 65 
Neuropathy screen and severity tools .................................................................. 66 
          The Brief Peripheral Neuropathy Screen (BPNS).....................................66 
          The Toronto Clinical Scoring System (TCSS)..........................................67 
          The Utah Early Neuropathy Scale (UENS)...............................................67 
Pain, sleep disturbance, quality of life and psychological co-morbidity 
measures ............................................................................................................... 68 
          7-day Pain diary..........................................................................................68 
          Brief Pain Inventory (BPI) 7-item pain interference sub-scale…………..68  
          SF-36 instrument…....................................................................................68 
          Pain Anxiety Symptom Scale-20 (PASS-20)…………….........................69  
          Amended Depression Anxiety Positive-Outlook instrument (DAPOS)….69 
          The Pain Catastrophizing Scale (PCS)…....................................................69 
          Insomnia Severity Index (ISI)….................................................................70 
Case definition of HIV-SN .................................................................................... 70 
Sample size calculation ........................................................................................ 72 
RESULTS ....................................................................................................................................................... 73 
Participants .......................................................................................................... 73 
Demographics ...................................................................................................... 73 
Quantitative Sensory Testing healthy participants .............................................. 74 
Anti-retroviral therapy history ............................................................................. 74 
Quantitative Sensory Testing Results.................................................................. 75 
 10 
         Distribution of mean QST z-scores across groups ...................................... 75 
        Frequency of individual QST measure abnormalities: loss and gain of   
        function ......................................................................................................... 76 
       Patterns of loss and gain of sensory function ............................................... 76 
       Suprathreshold heat testing .......................................................................... 77 
      Hierarchical cluster analysis of QST data  .................................................... 77 
Intra-epidermal nerve fibre densities (IENFD) ................................................... 78 
Electrophysiological testing ................................................................................. 79 
Pain and reported symptoms ................................................................................ 79 
Psychological co-morbidity, sleep disturbance and quality of life ...................... 80 
       Pain interference and health related quality of life......................................80 
      Sleep dysfunction...........................................................................................80 
      Depression, Anxiety and Catastrophizing......................................................81 
        Plasma lipid profiles, random glucose, BMI and waist circumference...............81 
Peripheral neuropathy screening and severity instruments: BPNS, UENS and 
TCSS.....................................................................................................................82 
Testing the triumvirate definition and the consequences of using different HIV-SN 
definitions …........................................................................................................82 
DISCUSSION ................................................................................................................................................. 83 
Quantitative Sensory Testing ............................................................................... 83 
Intra-epidermal nerve fibre densities ................................................................... 86 
Metabolic factors ................................................................................................. 87 
Psychological co-morbidity and sleep disturbance ............................................. 87 
Diagnostic tools ................................................................................................... 89 
Epidemiological studies ....................................................................................... 90 
Summary ............................................................................................................... 90 
Study limitations...................................................................................................91 
Further post-hoc exploration of using different HIV-SN definitions on 
QST results............................................................................................................92 
      FIGURES AND TABLES..............................................................................................................................95 
CHAPTER 4. SUMMARY ............................................................................................................................ 117 
REFERENCES ................................................................................................................................................. 123 
SUPPLEMENTAL DOCUMENTS ............................................................................................................. 141 
 11 
SUPPLEMENTAL DOCUMENT 1: THE MODIFIED JADAD SCALE  ...................................... 141 
SUPPLEMENTAL DOCUMENT 2: PINS HIV STUDY CRF  ........................................................ 144 
SUPPLEMENTAL DOCUMENT 3: QST HEAT SUPRATHREHOLD 
PROTOCOL ................................................................................................................................................ 153 
SUPPLEMENTAL DOCUMENT 4: QST DATA CRF ...................................................................... 155 
SUPPLEMENTAL DOCUMENT 5: STRUCTURED NEUROLOGICAL 
EXAMINATION (SNE).................................................................................................. .......................... 156
 12 
Table of Figures and Tables  
Figures 
Figure 2.1. PRISMA flow diagram of included randomised controlled trials..... 53 
Figure 3.1. Scatter plot of z scores of QST parameters in the Healthy control, HIV-No 
SN and HIV-SN groups. ....................................................................................... 95 
Figure 3.2.a. Scatter plot of z scores of QST parameters in the Healthy control, HIV-
No SN and HIV-SN groups .................................................................................. 96 
Figure 3.2.b. Scatter plot of z scores for mechanical QST parameters in the Healthy 
control, HIV-No SN and HIV-SN groups ............................................................. 97 
Figure 3.2.c. Scatter plot of z scores for mechanical QST parameters in the Healthy 
control, HIV-No SN and HIV-SN groups ............................................................. 98 
Figure 3.2.d. Scatter plot of z scores for mechanical QST parameters in the Healthy 
control, HIV-No SN and HIV-SN groups ............................................................. 99 
Figure 3.3. Comparison of mean QST z-scores (SD) of the HIV-SN, No-HIV-SN and 
Healthy control groups.  .................................................................................... 100 
Figure 3.4. Loss and Gain of sensory function: A comparison of the frequency of QST 
abnormalities in participants in the Healthy control, HIV-No SN and HIV-SN groups 
which have QST values outside the 95% CI of the DFNS reference database.  101 
Figure 3.5. Pain intensity response curves for suprathreshold heat stimuli in Healthy 
control subjects, HIV-No SN group and HIV-SN group.  .................................. 102 
Figure 3.6. Hierarchical cluster analysis of participants’ peripheral neuropathy and 
pain status defined by participants QST data .................................................... 103 
Figure 3.7. Two representative skin biopsy samples of HIV infected participants.104 
Tables 
Table 1.1. Summary of clinical studies examining associated factors and the 
development of HIV-SN pre-cART introduction .................................................. 29 
Table 1.2. Summary of clinical studies examining associated factors and the 
development of HIV-SN following introduction of cART (2004 to 09). ............... 30 
Table 1.3. Summary of clinical studies examining associated factors and the 
development of HIV-SN following introduction of cART (2009 to 11) ................ 31 
Table 2.1. Studies excluded from the systematic review. ..................................... 54 
 13 
Table 2.2. Characteristics and results of included studies .................................. 55 
Table 2.3. Summary of RCTs which demonstrated treatment superior to placebo, for 
which Relative Risk and Number Needed to Treat values could be calculated. .. 56 
Table 3.1. Comparison of participants’ demographics, characteristics and co-
morbidities between HIV-No SN and HIV-SN groups enrolled in the study. .... 105 
Table 3.2. Comparison of antiretroviral drug therapy use between HIV-No SN and 
HIV-SN groups. .................................................................................................. 106 
Table 3.3. Mean values of QST parameters after z-score transformation for the three 
groups. Dynamic mechanical allodynia (DMA) and paradoxical heat sensations 
(PHS) are presented as mean number of events. ............................................... 107 
Table 3.4. Frequency of different patterns of sensory loss and gain in the HIV-SN 
group. ................................................................................................................. 108 
Table 3.5. Correlation of IENFD and individual thermal and mechanical QST 
parameters  ........................................................................................................ 109 
Table 3.6. Comparison of participant reported symptoms between HIV-SN and HIV-
No SN groups ....................................................................................................... 10 
Table 3.7. Psychological and Sleep instruments questionnaire returned and completed 
per group. ........................................................................................................... 111 
Table 3.8. Summary of Sleep and Psychological instruments results comparing HIV-
No SN and painful HIV-SN. ............................................................................... 112 
Table 3.9. Comparison of metabolic factors: random plasma lipid profiles, glucose, 
BMI, waist-hip ratio and statin use for HIV-No SN and HIV-SN groups. ......... 113 
Table 3.10. Comparison of using different combinations of the triumvirate criteria for 
the diagnosis of HIV-SN..................................................................................... 114 
Table 3.11. Comparisons of using original PINS study criteria, Brief Peripheral 
Neuropathy Screen (BPNS) and the Structured Neurological Examination (SNE) 
as HIV-SN criteria for QST z-score results; ……………………………………………....115 
Table 3.12. Comparisons of using symptoms of paraesthesia and/or numbness, 
and the presence of pain alone as HIV-SN criteria for QST z-score results. 
respectfully…………………………………………………………………………..….116 
 14 
Publications arising from this work 
Abstracts 
A Meta-analysis of Randomised Controlled Clinical Trials Assessing the 
Effectiveness of Pharmacological Interventions for Painful HIV-
Associated Sensory Neuropathy. Tudor J. C. Phillips, Catherine L. 
Cherry, Sarah Cox, Sarah Marshall, Andrew S. C. Rice 
Abstract and poster presentation IASP 13th World Congress on Pain, 
Montreal, Canada. September 2010. 
 
Sensory Profiles and Epidermal Innervation in Patients with HIV-
Associated Sensory Neuropathy. Matthew R. D. Brown, Tudor J. C. 
Phillips, Juan D. Ramirez, James R. Perkins, Christine Orengo, 
Yohannes W. Woldeamanuel, Sarah Cox, Istvan Bodi, Christoph Maier, 
Elena Krumova, David L. H. Bennett, Andrew S. C. Rice.  
Abstract and poster presentation NeupSIG World Congress, Toronto 
Canada. May 2013. 
 
Assessment of the Utility of Clinical Instruments for Diagnosing HIV-
associated Sensory Neuropathy. Yohannes W. Woldeamanuel, Tudor J. 
C. Phillips, Matthew R. D. Brown, Juan D. Ramirez, James R. Perkins, 
Christine Orengo, Sarah Cox, David L. H. Bennett, Andrew S. C. Rice.  
Abstract and poster presentation NeupSIG World Congress, Toronto 
Canada. May 2013 
Original Papers 
Phillips, T. J. C., Cherry, C. L. , Cox, S. , Marshall, S. J. , et al. (2010) 
Pharmacological treatment of painful HIV-associated sensory 
neuropathy: a systematic review and meta-analysis of randomised 
controlled trials. PloS one. [Online] 5 (12), e14433. 
 15 
Abbreviations 
 
AIDS Acquired Immunodeficiency Syndrome 
ARV Anti-Retroviral agent 
AUC Area Under the Curve 
ATN Antiretroviral Toxic Neuropathy 
BMI Body Mass Index 
BPNS Brief Peripheral Neuropathy Screen 
BPI Brief Pain Inventory 
cART combination Anti-Retroviral Therapy 
CDT Cold Detection Threshold 
CIDP Chronic Inflammatory Demyelinating Polyradiculopathy 
CPT Cold Pain Threshold 
CRF Clinical Record File  
DAPOS Depression Anxiety Positive-Outlook Scale 
ddC 2',3'-dideoxycytidine (Zalcitabine) 
ddI 2',3'-dideoxyinosine (Didanosine) 
DDS Descriptor Differential Scale 
DMA Dynamic Mechanical Allodynia 
dNRTI 2',3'-dideoxy moiety containing class of NRTI drug 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders  
DSP Distal Sensory Polyneuropathy 
d4T 2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) 
 16 
EFNS  European Federation of Neurological Societies   
HDL High Density Lipoprotein 
HIV Human Immunodeficiency Virus 
HIV-No SN HIV infection with No HIV-Associated Sensory Neuropathy 
HIV-SN HIV-Associated Sensory Neuropathy 
HPT Heat Pain Threshold 
IENFD Intra-Epidermal Nerve Fibre Density 
ISI Insomnia Severity Index 
ITT Intention-To-Treat 
LDL Low Density Lipoprotein 
MDT Mechanical Detection Threshold 
MPT Mechanical Pain Threshold 
MPS Mechanical Pain Sensitivity 
NCS Nerve Conduction Studies 
NICE National Institute for Health and Care Excellence 
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor 
NNT Number Needed to Treat 
NPRS Numerical Pain Rating Scale 
NRES National Research Ethics Service 
NRS Numerical Rating Scale 
NRTI Nucleoside Reverse Transcriptase Inhibitor 
OCT Optimal Cutting Temperature compound 
PASS-20 Short Version of the Pain Anxiety Symptoms Scale 
 17 
PCS Pain Catastrophizing Scale 
PEP Post Exposure Prophylaxis  
PHS Paradoxical Heat Sensation 
PI Protease Inhibitor 
PP Per Protocol population 
PPT Pressure Pain Threshold 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
QST Quantitative Sensory Testing  
RCT Randomised Controlled Trial 
rhNGF recombinant human Nerve Growth Factor 
ROC Receiver Operating Characteristic  
RR Relative Risk 
SD Standard Deviation 
SF-36 Short Form (36) Health Survey 
SN  Sensory Neuropathy 
SNE Structured Neurological Examination 
TCSS Toronto Clinical Neuropathy Score 
TNF-α Tumour Necrosis Factor α 
TRG Triglycerides 
TSL Thermal Sensory Limen 
UENS  Utah Early Neuropathy Scale
 18 
 
 
 
 
 
 
 
 
 
Chapter 1   
Introduction to Painful HIV-Associated Sensory 
Neuropathy 
 19 
Introduction to Painful HIV-Associated Sensory Neuropathy 
Pain and HIV disease 
Pain associated with HIV disease is common and multifactorial (Cox & Rice, 2008) 
with different causes possible at different stages of the disease. A frequent cause of 
pain, at all stages of the disease, is neuropathic pain associated with a symmetrical 
sensory polyneuropathy; HIV associated sensory neuropathies (HIV-SN) attributable 
to HIV itself and to some HIV treatments (Verma, 2001). 
HIV-SN is common. Prior to the availability of antiretroviral drugs, estimates of HIV-
SN prevalence varied from <2% if those with very early HIV disease (R. Barohn et 
al., 1993) to 35% among hospitalized patients with AIDS (So, Holtzman, Abrams, & 
Olney, 1988). When ambulatory HIV patients (all stages of disease) were surveyed, 
around 13% were found to have HIV-SN (Woolley, Faragher, Ugoni, & Spelman, 
1993). The prevalence of HIV-SN attributable to the virus itself increases with 
advancing HIV disease (Childs et al., 1999). 
The introduction of combination antiretroviral therapy (cART) in the mid 1990s has 
dramatically reduced the morbidity and mortality associated with HIV among patients 
who have access to treatment (Mocroft et al., 2003). Life expectancy with HIV in 
well-resourced countries is now estimated to be up to two-thirds of the general 
population (Collaboration., 2008; Lohse et al., 2007). While the incidence of most 
neurological complications of HIV has fallen with the introduction of effective 
therapy, rates of HIV-SN have been rising since the first effective antiretroviral drugs 
were developed (Bacellar et al., 1994). It is now clear that some HIV treatments, 
notably particular nucleoside reverse transcriptase inhibitors (NRTI) – stavudine 
(d4T), didanosine (ddI) and zalcitabine (ddC) – are potentially neurotoxic (Keswani, 
Pardo, Cherry, Hoke, & Mcarthur, 2002; Moyle & Sadler, 1998). Recent estimates of 
HIV-SN prevalence among cohorts with access to cART range from 20% to >50% 
(Konchalard, K. Wangphonpattanasiri, 2007; Wright et al., 2008). Importantly, the 
available evidence suggests that HIV-SN prevalence remains high among cART-
treated patients, even in countries where known neurotoxic antiretroviral drugs such 
as stavudine are no longer commonly used (Smyth et al., 2007). In less well-resourced 
centres, use of stavudine, an inexpensive and effective antiretroviral, in first-line HIV 
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treatment remains common despite high rates of toxicity (Joint United Nations 
Programme on HIV/AIDS, 2013). 
Current estimates of global HIV prevalence stand at 33 million, with 2.5 million new 
infections each year and more patients gaining access to cART (Joint United Nations 
Programme on HIV/AIDS, 2013). With high rates of HIV-SN now reported globally, 
and up to 90% of affected patients experiencing potentially debilitating neuropathic 
pain, HIV-SN represent a large, and potentially worsening, source of world morbidity.  
Therefore, there is an urgent need to understand better the pathogenesis of HIV-SN, 
identify risk factors, develop effective preventative strategies and improve symptom 
control among existing sufferers. 
Clinical Presentation of HIV-SN 
The clinical presentation of HIV-SN is similar regardless of whether the syndrome is 
caused by HIV itself (often termed Distal Sensory Polyneuropathy – DSP) or by 
toxicity from antiretroviral drugs (Antiretroviral Toxic Neuropathy – ATN).  In many 
cases, DSP and ATN may co-exist and indeed there may be a level of 
interdependence in their aetiologies. 
Patients with HIV-SN typically present with the classical distal bilateral sensory 
symptoms of an axonal length dependant polyneuropathy, in a “sock and glove” 
distribution with the feet being first affected. Symptom onset is variable; with some 
data suggesting ATN may be more likely to be sudden in onset and rapidly 
progressive, and DSP more insidious (D. Cornblath & McArthur, 1988; Justin C 
McArthur, Brew, & Nath, 2005). 
Quantitative sensory testing of patients with HIV-SN reveals a loss of thermo-
sensation characteristic of a loss of C- fibres (Bouhassira, Attal, Willer, & Brasseur, 
1999; Martin, Solders, Sönnerborg, & Hansson, 2003). This “die back” pattern of 
degeneration of C fibres has been confirmed by analysis of epidermal innervation in 
skin biopsies. Profound motor weakness is a relatively infrequent feature of HIV-SN, 
and if present, is usually a late finding restricted to the intrinsic muscles of the feet 
(D. Cornblath & McArthur, 1988). Indeed, its presence should prompt a search for an 
alternative diagnosis such as Chronic Inflammatory Demyelinating Polyradiculopathy 
(CIDP). 
 21 
Risk Factors For HIV-SN  
Risk factors for HIV-SN in patients not exposed to antiretroviral drug 
Studies examining rates and risk factors for HIV-SN among AVR–naive patients 
typically found that the prevalence of HIV-SN increases with disease progression (see 
Table 1.1). Precise associations with HIV-SN vary among the available studies, but 
have included lower CD4 T-cell count, higher viral load or surrogate markers of 
disease progression, such as Mycobacterium avium infection.  
Risk factors for SN among patients exposed to antiretroviral drugs 
The role of nucleoside reverse transcriptase inhibitors (NRTI) 
Despite the association between HIV-SN and advanced HIV disease in patients not 
receiving antiretroviral therapy, the introduction of effective HIV treatment has not 
been associated with the predicted fall in HIV-SN prevalence.  Indeed, where data are 
available before and after the introduction of cART, the prevalence of HIV-SN has 
risen, probably due ATN (Bacellar et al., 1994; Smyth et al., 2007). 
The potential neurotoxicity of particular NRTI and the development ATN was 
observed in early clinical trials, where SN was a dose limiting toxicity for the NRTIs 
d4T, ddI and ddC (Moyle & Sadler, 1998; Yarchoan et al., 1988). The profound 
neurotoxicity of d4T, the dNRTI most widely used today, was highlighted in a study 
of Post Exposure Prophylaxis (PEP) where healthy, HIV uninfected men were offered 
28 days of antiretroviral therapy as prophylaxis following a possible HIV exposure. 
Six percent of HIV negative adults developed symptoms consistent with neuropathy 
within 28 days of d4T-containing PEP (Winston, McAllister, Amin, Cooper, & Carr, 
2005). In HIV infected individuals on long-term cART, ATN has been observed to 
occur as long as one year after commencement of therapy including a dNRTI 
(Lichtenstein et al., 2005). In the clinical situation, the temporal association between 
dNRTI exposure and the onset of neuropathy symptoms is typically the sole feature 
that suggests a diagnosis of ATN rather than DSP. 
cART-Era risk factors for HIV-SN 
Whilst exposure to dNRTIs, high viral load and low CD4 counts have been previously 
established in the pre-cART era as risk factors (see Table 1.1), in the cART era this 
has become less clear (see Table 2.2). 
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One study has suggested that the use of dNRTI may be protective against SN after a 
year of use (Lichtenstein et al., 2005). This paradox might be explained by the 
observation that individuals susceptible to ATN will often become symptomatic 
within a few months of dNRTI exposure.  Thus, ATN susceptible individuals may be 
switched to alternative ARV when they develop neuropathy symptoms, leaving only 
those who are at intrinsically low risk for ATN on dNRTI therapy after a year. 
The neurotoxic potential of dNRTI is clear but in recent years there has been a 
growing interest in other factors that may place HIV patients at risk for neuropathy. 
This is important for at least two reasons: 
1. Although ddC, the most profoundly neurotoxic NRTI (A. Berger et al., 1993), 
is not longer in clinical use, d4T remains a common component of first-line 
HIV treatment in many low and middle-income countries, largely for 
economic reasons. Understanding which patients are at highest risk for ATN if 
treated with d4T would allow rational prioritization of the highest risk 
individuals for access to more expensive alternatives. 
2. As set out above, rates of HIV-SN remain high even in high-income country 
centres where use of dNRTI has largely ceased. More work is needed to 
understand why particular patients are developing HIV-SN despite effective 
HIV treatment with cART not known to be neurotoxic so that preventative 
strategies and pathogenesis based therapies can be developed (Smyth et al., 
2007). 
Increasing age is associated with HIV-SN risk in almost every published cohort, both 
before and after the introduction of cART (see Tables 1.1-1.3). This is consistent with 
the known vulnerability of the ageing peripheral nervous system to most types of 
polyneuropathy, including diabetic and toxin-induced neuropathies. 
Height is an HIV-SN risk factors (Affandi et al., 2008; C L Cherry et al., 2006, 2009; 
Morgello et al., 2004; Pettersen et al., 2006; Antonia L Wadley, Cherry, Price, & 
Kamerman, 2011; Watters et al., 2004) as it is for other polyneuropathies (Cheng et 
al., 2006). Rates of HIV-SN were associated with age and height in Australian, 
Indonesian and Malaysian patients prescribed stavudine. Using cut off values of 
170cm and 40 years, the authors showed that the rate of stavudine-associated 
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neuropathy was 20% in younger, shorter patients compared with 66% of older, taller 
patients (C L Cherry et al., 2009). It was suggested that these simple criteria could be 
used to determine who should be given priority access to less neurotoxic but more 
expensive ARVs in resource poor settings.  
Demographic and clinical features, other than age, in untreated HIV patients have not 
been consistently associated with SN risk among patients on cART (Table 1.2). For 
example, neither viral load nor CD4 T-cell counts are independently associated with 
SN risk among treated patients (Morgello et al., 2004; Smyth et al., 2007). In contrast, 
evidence of advanced HIV infection prior to initiation of therapy may still be 
relevant, with nadir CD4 count and a history of an AIDS defining illness associating 
with SN risks in some cohorts. As more studies are performed in a range of settings, 
new risk factors for HIV-SN are also emerging. For example, race may be an 
important determinant of the individual’s HIV-SN risk (Jessica Robinson-Papp, 
Gonzalez-Duarte, Simpson, Rivera-Mindt, & Morgello, 2009). 
Host genotype has been associated with SN risk among dNRTI-exposed patients by 
several groups. Consistent with putative pathogenic mechanisms of HIV-SN, 
associations include mitochondrial haplogroups (Hulgan et al., 2005) and genes 
associated with inflammation (Affandi et al., 2008; Catherine L Cherry et al., 2008). 
Associations with haemochromatosis gene polymorphisms are also reported 
(Kallianpur et al., 2006). 
Emerging treatment associations with HIV-SN in the era of cART 
Despite a reduction in the use of dNRTI in well-resourced settings, the available data 
suggest that the expected decline in HIV-SN prevalence has not occurred.  For 
example, repeated cross sectional surveys of an ambulatory Australian HIV 
population showed that SN prevalence rose from 14% in 1993 (pre-cART) to 44% in 
2001 (era of frequent use of dNRTI). Despite a change to mostly dNRTI sparing 
cART regimens, and a reduction in the proportion of patients who had ever been 
exposed to dNRTI, the prevalence of HIV-SN remained unchanged at 42% in 2006 
(Smyth et al., 2007). This and other recent studies suggest that risk factors other than 
dNRTI exposure are important. Exposure to certain protease inhibitors, especially 
indinavir, is associated with SN risk (Lichtenstein et al., 2005; Pettersen et al., 2006; 
Smyth et al., 2007). This is supported by in vitro studies using cultured rodent dorsal 
 24 
root ganglia DRGs from rats expressing the human chemokine receptors required for 
HIV cell entry demonstrate indinavir-associated neurotoxicity from indinavir 
exposure (Pettersen et al., 2006). Whether this is a class effect of PI or is isolated to 
indinavir has yet to be fully explored. 
Putative mechanisms of pathogenesis in HIV-SN development 
The exact mechanism/s by which HIV-SN develops continues to be subject of debate. 
It also remains unclear whether or not DSP and ATN may share some degree of 
interaction and/or synergy in their pathophysiology (Bhangoo, Ripsch, Buchanan, 
Miller, & White, 2009; Wallace, Blackbeard, Pheby, et al., 2007). 
Proposed pathogenesis of DSP 
Direct infection of neurons by HIV rarely, if ever, occurs; consequently hypotheses of 
HIV-SN have focused on neuronal toxicity of HIV secreted proteins and the immune 
dysregulation seen in HIV disease.  
The HIV viral envelope glycoprotein gp120 is required to interact with both CD4 
receptors and with the chemokine receptors CXCR4 or CCR5 in order to enter 
immune cells and replicate. Gp120 shed from HIV virions is thought to interact with 
neuronally expressed CCR5 and/or CXCR4 to induced the neuronal apoptosis which 
is characteristic of HIV dementia (Kaul, Garden, & Lipton, 2001; Kaul & Lipton, 
1999; Kirsh et al., 1990). There is now a reasonable body of evidence to suggest that a 
similar pathological mechanism exists for HIV-SN (Bhangoo et al., 2009; Maratou et 
al., 2009; Melli, Keswani, Fischer, Chen, & Höke, 2006; Oh et al., 2001). GP120 
induces a TNF-α mediated apoptosis and axonal degeneration in sensory neurones 
both directly and indirectly via the stimulation of Schwann cells and macrophages 
that results in the aberrant release of neurotoxins (Kaul & Lipton, 1999; Keswani et 
al., 2003; Melli et al., 2006). Chemokines have been shown to play a key role in the 
pathophysiology of neuropathic pain in the context of multiple diseases (White, Jung, 
& Miller, 2007).  TNF-α 1031*2 was independently associated with an increased risk 
of HIV-SN in both, a population of predominately European descent and an 
Indonesian population (Affandi et al., 2008). In contrast a cytokine polymorphism of 
the proinflammatory IL-12β cytokine was associated with increased risk of 
developing HIV-SN but this was not replicated in an Indonesian population. A recent 
large epidemiological study in a South African population has further established the 
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role of inflammatory response and HIV-SN development by identifying the 
importance of a IL-4 inflammatory cytokine polymorphism (IL-4 590*T) as a risk 
factor for the development of HIV-SN (A L Wadley et al., 2013). 
Proposed pathogenesis of ATN 
dNRTIs have been shown to be neurotoxic to sensory neurones and result in features 
reflecting neuropathic pain in animal models (Bhangoo et al., 2009; Chen & Levine, 
2007; Joseph, Chen, Khasar, & Levine, 2004; Joseph & Levine, 2004, 2006; Wallace, 
Blackbeard, Segerdahl, et al., 2007a): both chemokine-induced  and mitochondrial 
toxicity have been implicated in this pathology.  There is also some evidence of 
indinavir mediated neurotoxicity of sensory neurones (Pettersen et al., 2006). 
Recently established animal models of both stavudine (Wenlong Huang et al., 2013) 
and indinavir mediated neurotoxicity (W Huang, Pheby, & Rice, 2013) will be 
important in further elucidating the pathogenesis of ARV mediated neurotoxicity. 
Clinical assessment of HIV-SN 
HIV-SN is primarily a clinical diagnosis and the general principles of assessing any 
patient with peripheral neuropathic pain should be followed (Cruccu et al., 2010; 
Haanpää et al., 2009). Use of diagnostic tests to investigate primary sensory neurone 
morphology or function (such as quantification of epidermal nerve fibre density, 
thermal threshold testing or nerve conduction studies) may be helpful (Bouhassira et 
al., 1999; Griffin, McArthur, & Polydefkis, 2001; Lauria et al., 2005, 2010; Martin et 
al., 2003; Rolke et al., 2006), but such testing is not always available outside 
specialist centres. Importantly, normal nerve conduction studies do not necessarily 
exclude the diagnosis of HIV-SN, as they primarily survey the function of large 
diameter afferent nerve fibres. Such testing is most often indicated when atypical 
features (such as motor involvement) necessitate the exclusion of alternative 
diagnoses, such as a demyelinating polyneuropathy (Keswani et al., 2002). 
Clinical diagnosis of HIV-SN 
HIV-SN is typically a small fibre, sensory neuropathy.  Common symptoms are often 
accompanied by neuropathic signs such as reduced or absent ankle reflexes, 
diminished vibration sense and altered sensitivity to light tactile or thermal stimuli.   
In a patient with HIV infection, a diagnosis of HIV-SN is supported by symptoms and 
signs that are largely symmetrical and distal in nature, and the absence of significant 
 26 
motor involvement. Investigating a temporal association between symptom onset and 
exposure to potentially neurotoxic ARV is the only method available to assess 
whether ATN is perhaps contributing to a case of HIV-SN (Keswani et al., 2002). 
Screening tools for the diagnosis of HIV-SN in research context have been described, 
including the widely used AIDS Clinical Trials Group Brief Peripheral Neuropathy 
Screen (BPNS). This tool is based on a directed symptom questionnaire and limited 
clinical examination. It takes only minutes to administer and requires no specialized 
equipment.  Importantly, this tool has been validated against objective measures 
including both thermal threshold testing and epidermal nerve fibre density (Catherine 
L Cherry, Wesselingh, Lal, & McArthur, 2005). However, while these features make 
the BPNS a useful research tool (for example, in studies examining risk factors 
associated with HIV-SN) it cannot replace a careful clinical assessment of the HIV 
infected patient presenting with neuropathic symptoms or signs. 
A critical part of the clinical assessment of HIV-SN is to exclude alternative 
diagnoses that may explain the patient’s symptoms – looking particularly for 
reversible causes of peripheral neuropathy. This includes a careful drug history 
(including ARV exposures, use of isoniazid or cytotoxic chemotherapy, use of large 
doses of vitamins that may be neurotoxic, such as pyridoxine (Gdynia et al., 2008), 
and alcohol/recreational drug use) and the exclusion of metabolic disturbances such as 
diabetes, thyroid dysfunction or vitamin B12 deficiency. Treatment of any other 
contributing condition (or removal of a contributing toxin) is important, including in 
patients where HIV-SN is thought to be present. Exclusion of non-neuropathy causes 
of pain such as arthropathy or plantar fascitis is also important.  
Clinical management of HIV-SN 
The clinical management of HIV-SN is primarily directed towards minimising the 
progression of pathology and managing the patient’s symptoms.  
Remove the underlying cause 
When HIV-SN develops in a patient naive to antiretroviral therapy, symptomatic 
improvement may be observed with commencement of (non-neurotoxic) cART to 
control HIV replication.  However, this situation is uncommon today in well-
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resourced settings, with DSP being a disease of advanced HIV and earlier 
commencement of cART recommended in current treatment guidelines.   
When HIV-SN develops in a patient who is on treatment with known neurotoxic ARV 
(again, an uncommon situation in well-resourced settings today), a change to non-
neurotoxic agents may be required. However, this is a complex decision that only 
those with expertise in the management of HIV disease should make. In early clinical 
trials, immediate cessation of dNRTI therapy upon development of neuropathic 
symptoms was associated with symptomatic improvement in around two thirds of 
cases (Blum et al., 1996; Moore, Wong, Keruly, & McArthur, 2000; Pettersen et al., 
2006). Importantly, an initial worsening of symptoms, or “coasting”, commonly 
occurs prior to any improvement and may continue for months (Moyle & Sadler, 
1998). Following this, some improvement in neuropathic symptoms may be seen up 
to a year after discontinuation of the causative agent. Beyond this time, further 
improvement is unlikely. 
As above, minimizing (or removing) any other potential peripheral nerve insults (e.g. 
poorly controlled diabetes, vitamin B12 deficiency) is important to prevent any 
additive or synergistic effect this might have on the continued progression of HIV-
SN. 
Provision of analgesia 
The pharmacological management of pain associated with HIV-SN is an area of 
therapeutic need with few therapies being supported by robust evidence. Until the 
systematic review presented in Chapter 2 was prepared, there were no systematic 
reviews or meta-analysis of evidence for the efficacy of pharmacological agents in 
treating pain in HIV-SN.  
Summary and conclusions 
Sensory neuropathy is a frequent complication of HIV and some HIV treatments. 
With an estimated 33 million people living with HIV, more people gaining access to 
antiretroviral therapy every day, and HIV-SN prevalence ranging from 20% to >50% 
in cART treated cohorts, the burden of HIV-SN pain is a problem of enormous global 
importance. No routinely available therapy has been unequivocally shown to be 
effective for treating HIV-SN pain. There is an urgent need to understand better the 
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pathogenesis of HIV-SN, develop strategies to prevent new cases of this debilitating 
condition and find effective treatments to control the symptoms associated with 
existing cases of HIV-SN. 
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Table 1.1. Summary of clinical studies examining associated factors and the development of HIV-SN pre-cART introduction. 
 
  
Study Studied years Population Type n Prevalence of 
HIV-SN 
Observed Associations with 
HIV-SN 
Comment 
No ARV exposure 
Barohn et al., 1993  1985-89 US Air force recruits. Mostly 
asymptomatic of HIV 
disease.  
 798 12 (1.5%) Advanced HIV disease:  
reduced CD4 count <300 cells/mm3 
 
So et al., 1988  1987 Advanced HIV disease. 
Hospital in-patients USA. 
Cross sectional 37 13 (35%) Advanced HIV disease as indicated by: 
>5 months systemic illness 
 
Woolley et al., 1997 1993 Ambulatory patients at a 
tertiary referral centre 
Australia  
Cross sectional 94 13 (14%) Advanced HIV disease as indicated by: 
Mycobacterium avium complex 
infection 
 
ARV exposure but pre-cART 
Childs et al., 1999  1985-95 Multicentre AIDS Cohort 
Study (MACS) USA. 
Longitudinal 1604 213 (13%) Advanced HIV disease: CD4<200 
cells/mm3 and 
HIV RNA levels >3000 copies/ml 
 
Bacellar et al., 1994  1988-92 Multicentre AIDS Cohort 
Study (MACS) US 
Longitudinal 1992 138 (7%) 
cases over 5 yr 
period 
Advanced HIV disease:  
CD4 <200 cells/mm3 
ddI, ddC and d4T use. 
Risk of HIV-SN associated 
with dNRTIs not 
statistically significant. 
Tagliati et al., 1999 1990-94 Primary care referred USA – 
dNRTI exposure excluded 
Longitudinal 166 63 (38%) Advancing age 
CD4 <100 cells/mm3 
Reduced haemoglobin, albumin, and 
weight. 
Reduced Hb, albumin and 
weight were most 
probably surrogate 
indicators of advanced 
HIV disease. 
Schifitto et al., 2002  1994-96 Dana cohort: HIV patients 
with early symptoms of HIV 
dementia (HIVD) 
Longitudinal 272 93(35%) 
symptomatic 
Advanced HIV disease: 
AIDS diagnosis,   
low CD4 count 
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Table 1.2. Summary of clinical studies examining associated factors and the development of HIV-SN following introduction of cART (2004 to 
2009). 
Study Studied 
years 
Population Type n Prevalence of 
HIV-SN 
Observed Associations with HIV-SN Comment 
cART era  
Morgello et al., 2004  1999-2002 Manhattan HIV Brain Bank – US 
advanced HIV disease 
Longitudinal 187 99 (53%) Advancing age 
Male sex 
No association with: 
viral load, CD4 count, or 
dNRTI exposure. 
Lichtenstein et al., 2005 1992-2003 HIV Outpatients Study (HOPS) 
Multiple clinics US ambulatory 
patients 
Longitudinal 2525 329 (13.5%) Advancing age >40yrs 
Peak viral load 
Nadir CD4 count 
diabetes mellitus 
white race 
In 1st year of exposure: 
didanosine, stavudine, naviripine 
efavirenz, and protease 
inhibitors:(lamivudine, ritonavir, 
nelfinavir, saquinavir) 
 
Following 1 yr exposure all 
ARVs associated with 
reduced risk HIV-SN. 
Pettersen et al., 2006 1998-2004 Ambulatory patients Canada. 
Neurological disease at entry 
(including HIV-SN) 
Longitudinal 221 101 (46%) Advancing age  
CD4 
Peak Viral load 
Alcohol consumption 
dNRTI exposure (d4T, ddC and ddI) 
Protease Inhibitor (PI) -Indinavir  
 
Morgello et al., 2004 1999-2002 Manhattan HIV Brain Bank – US 
advanced HIV disease 
 187 99 (53%) Age 
Male sex 
No association with: 
viral load, CD4 count, or 
dNRTI exposure. 
Cherry et al., 2006 2000-04 2 ambulatory cohorts: US and 
AUS 
Cross 
sectional 
147 77(52%)  Advancing age >40yrs 
ddI, d4T,  
Failed to show HCV, lactate 
or viral load to be 
associated. 
Simpson et al., 2006 2000-02 AIDS Clinical Trial Group (ACTG): 
patients with advanced HIV with 
exposure to ARV.  
Longitudinal 101 53 (52%)  Progression associated with: 
white race 
No association of 
progression with: 
dNRTI exposure 
viral load, and CD4 count. 
Schifitto et al., 2002 1994-96 Dana cohort: HIV patients with 
early symptoms of HIV dementia 
(HIVD) 
Longitudinal 272 93(35%) 
symptomatic 
Advanced HIV disease: 
AIDS diagnosis,  
low CD4 count 
 
Schifitto et al., 2005  NEAD cohort (North East AIDS 
Dementia) -patients with 
advanced HIV disease and/or 
evidence of HIV dementia (HIVD) 
Longitudinal 376 141 (38%) dNRTIs associated with reduced risk 
HIV-SN 
No association with: 
Viral load 
CD4 count 
 
Smyth et al., 2007 2006 Ambulatory patients: Australia Cross 
sectional 
100 42 (42%) Advancing age 
d4T 
indinavir 
No association with: 
Other dNRTIs 
CD4 counts 
Viral load 
 
Cherry et al., 2009  2006 Ambulatory patients: Australia, 
Indonesia and Malaysia. 
Cross 
sectional 
294 94 (32%) Advancing age 
Increased height 
d4T, ddC, indinavir 
No association with: 
Viral load, AIDS diagnosis, 
HCV isoniazide 
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Table 1.3. Summary of clinical studies examining associated factors and the development of HIV-SN following introduction of cART (2009 to 
2011) 
 Study Population Type n Prevalence of 
HIV-SN 
Observed Associations with HIV-
SN 
 
Beadles et al., 2009 Malawi stavudine cART treated 
group 
Retrospectiv
e chart 
review 
3341 35% All had stavudine. No other associations 
tested. 
Saktor et al., 2009 Uganda stavudine cART treated 
group 
Prospective 
cohort 
102 38% All had stavudine. No associations found. 
Maritz et al., 2010 South Africa community based 
HIV clinic 
Cross-
sectional 
598 30% Older age cART use TB treatment 
Ellis et al., 2010 USA ambulatory HIV patients 
(CHARTER) 
Cross-
sectional 
1539 57% Older age, cART use, lower CD4 nadir, 
past dNRTI exposure. 
Evans et al., 2011 USA patients initiating cART 
(ACTG trials) 
Longitudinal 
cohort, 
Annual 
screening 
2141 8.6% Older age, diabetes, past dNRTI 
exposure, use of PIs 
Wadley et al., 2011 South Africa hospital based HIV 
clinic 
Cross-
sectional 
395 57% Older age, use of cART, stavudine, TB 
treatment, height 
Banerjee et al., 2011 USA Ambulatory HIV population Cross-
sectional 
436 27% Older age, lower CD4 nadir, elevated 
triglycerides, type II diabetes mellitus 
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Aims of the thesis 
Many of the important risk factors for the development of HIV-SN identified in the 
pre-cART era were related to poor HIV virus suppression (nadir CD4 counts, high 
viral loads and AIDS) and its treatment with earlier neurotoxic ARV agents (e.g. ‘d’ 
NRTI agents). It was therefore anticipated, with good reason that the prevalence of 
HIV-SN would fall significantly with the introduction of effective HIV management 
with cART in the mid-1990s. However despite both the improved HIV virus control 
and crucially the phasing out of neurotoxic dNRTI drugs, especially in well-resourced 
countries, the prevalence of HIV-SN in both high and low resource HIV populations 
has remained consistently at around 40%. This suggests strongly that drug induced 
neurotoxicity may not be a major aetiological factor for HIV-SN in the cART-era 
(Catherine Louise Cherry, Wadley, & Kamerman, 2012; Ellis et al., 2010; Smyth et 
al., 2007). 
Current estimates of global HIV prevalence stand at 33 million, with 2.5 million new 
infections each year and more patients gaining access to cART (Joint United Nations 
Programme on HIV/AIDS, 2013). With high rates of HIV-SN now reported globally, 
and with between 40 to 90% of affected patients experiencing potentially debilitating 
neuropathic pain, HIV-SN represent a large, and potentially worsening, source of 
world morbidity.  
There is an urgent need to better understand the pathogenesis of HIV-SN, identify risk 
factors, develop effective preventative strategies and improve symptom control 
among existing sufferers. In Chapter 2 this thesis will explore the current evidence 
base for the treatment of pain in HIV-SN by means of a systematic review and meta-
analysis of available randomised controlled trials of pharmacological agents used in 
the treatment of painful HIV-SN. This work is important, as it will aid decision 
making by clinicians treating painful HIV-SN and will potentially direct future 
clinical efficacy trials by identifying any paucity in the literature that might need to be 
addressed.  
Chapter 3 of this thesis will explore in great detail the nature of the phenotype 
associated with HIV-SN, with a view to gain a better understanding of the 
relationships between pain symptomatology, sensory nerve dysfunction, intra-
epidermal nerve fibre density, health related quality of life, psychological co-
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morbidity and sleep disturbance. In addition to collecting detailed medical and drug 
histories, this phenotyping study will employ a battery of techniques: 
 Quantitative Sensory Testing (QST) using the established DFNS protocol. 
 Patient self-reporting instruments to exam the characteristics and existence of 
psychological, health-related quality of life and sleep disturbance co-
morbidity.  
 Intra-epidermal sensory nerve fibre densities (IENFD) through the taking of 
small skin biopsies. 
This study is the first time a single cohort of HIV infected individuals have been 
extensively phenotyped in this manner. Whilst there have been a number of small 
detailed QST studies of HIV-SN in the pre-cART era (Bouhassira et al., 1999; Martin 
et al., 2003), this study will be important as it will explore if the phenotype of HIV-
SN has changed in parallel with the change in risk factors that has occurred in the 
transition from pre-cART to cART eras. The potential identification of phenotypically 
distinct sub-groups, particularly with QST measures, is important as there has been 
some limited evidence to suggest that such sub-groups might have a differential 
response to analgesic drug therapy (D M Simpson, Scott, & Freeman, 2010).  
Useful comparisons between different QST studies have been limited by the lack of 
an established common QST protocol, however by using the DFNS QST protocol the 
work that results from this study will be comparable to other neuropathic pain states 
aiding both the study of HIV-SN and neuropathic pain per se.  
There is also a need for easy to use, robust screening tools for the identification of 
HIV-SN that can be translated for use into resource poor settings. Part of the 
phenotyping study examined the efficacy of a number of neuropathy screening tools 
(and their constituent components), some of which have not been previously validated 
in the context of HIV-SN. This study will hopefully form the basis for future work 
directed at producing a composite screening tool for use in resource poor settings. 
As part of this study it is hoped that a blood and tissue bank for highly phenotyped 
individuals with HIV-SN would be established, which would inform future work 
exploring genetic risk factors for the development of HIV-SN and painful HIV-SN.  
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Chapter 2  
Pharmacological treatment of painful HIV-associated 
sensory neuropathy
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Pharmacological treatment of painful HIV-associated 
sensory neuropathy: a systematic review and meta-analysis 
of randomised controlled trials. 
Introduction 
Evidence-based guidelines for the pharmacological management of neuropathic pain 
tend to focus on a “blanket” approach of recommending therapies across the spectrum 
of neuropathic pain, irrespective of the underlying condition (Finnerup, Sindrup, & 
Jensen, 2010; RH, Dworkin et al., 2007). NICE guidance for the management of 
neuropathic pain in “non-specialist settings” have adopted this approach (Tan, Barry, 
Reken, Baker, & Guideline Development Group, 2010). This may not be appropriate 
for HIV-SN for three main reasons. Firstly, neuropathic pain is a heterogeneous 
phenomenon, both within and across underlying conditions, and evidence obtained 
from the study of an analgesic in one condition cannot necessarily be applied to 
another (Baron, Tölle, Gockel, Brosz, & Freynhagen, 2009; Scholz et al., 2009). 
Secondly, in high, middle and low income countries the pain associated with HIV-SN 
will usually be managed outside of specialist pain management clinics, so appropriate, 
disease specific guidance may be required. Finally, there are a number of randomised 
controlled trials (RCTs) conducted in HIV-SN, which were not identified in the NICE 
guidance. Therefore, I have conducted a systematic review and meta-analysis to 
elucidate the evidence base for pharmacological management of neuropathic pain in 
HIV-SN. 
Methods 
Eligibility, data sources and search strategy  
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)  
Systematic reviews and meta-analysis are important tools for the summary of 
evidence accurately and reliably. They help to keep clinicians up to date, gather 
together and summarise related research for patients and carers; provide a resource for 
the development of clinical practice guidelines; provide summaries of previous 
research to identify paucity of evidence for both researchers and funders wishing to 
support new research. However, prior to the development of QUOROM, and 
subsequently PRISMA, there had been much criticism of the reporting of systematic 
reviews and meta-analysis; in particular poor literature searches, poor evaluation of 
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the quality of RCTs and the poor synthesis of results (Mulrow, 1987; Sacks, Berrier, 
Reitman, Ancona-Berk, & Chalmers, 1987). 
The QUOROM (QUality Of Reporting Of Meta-analyses) Statement, published in 
1999 (Moher et al., 1999), was conceived as a guidance for authors reporting meta-
analysis of randomized trials. The QUOROM statement was developed by an 
international group of thirty clinical epidemiologists, clinicians, statisticians, editors 
and experienced researchers. The original QUOROM statement was subsequently 
updated in 2009 to address conceptual advances in outcome level assessment (detailed 
evaluation of the reliability and validity of the data for each important outcome by 
determining the methods used to assess them in each individual study), and risk of 
bias relevant to systematic review and meta-analysis. This updated statement 
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) was 
published in 2009 and comprises of a 27 item check-list and a flow-diagram 
pertaining to the content of a systematic review and meta-analysis, which includes the 
title, abstract, methods, results, discussion and funding. The flow diagram is four-
phased and depicts the flow of information through the different phases of a 
systematic review and helps to display information about the number of records 
identified in the literature searches, the number of studies included and excluded, and 
the reasons for exclusions in a clear manner. 
The PRISMA statement is not a quality assessment instrument for medical 
intervention RCTs.  
In accordance with PRISMA (Liberati et al., 2009), I sought to identify RCTs that 
included patients with painful HIV-SN and reported at least one clinically relevant 
pain outcome measure.  
A systematic search, without language restrictions, was conducted on 20 June 2008, 
and a follow-up search on 22 February 2010, with the following databases: Medline 
(from 1966 to date searched), The Cochrane central register of controlled trials 
(Cochrane Library 2010, Issue 2), www.clinicaltrials.gov (a US registry of clinical 
trials) and www.controlled-trials.com (a meta-registry of controlled trials). By 
searching registries of clinical trials it was hoped to reduce the risk of missing 
‘negative’ results from unpublished trials, as this is a potential source of publication-
bias in systematic review and meta-analysis reporting.  
 37 
Search terms 
Search and Boolean logic terms used were: {“HIV” or “AIDS”} and {“pain” or 
“painful”} and {“neuropathy” or “neuropathic”}, and {“treatment” or “trial” or 
“random” or “randomised” or “double-blinded”}. Further trials were identified by 
hand searching the reference lists of identified trials and review articles, relevant 
NICE guidelines and Health Technology Assessment reports. 
Study selection and risk of bias assessment 
I excluded animal studies, reviews, letters, abstract-only trials, open-label trials, and 
trials that were not randomised. The identified RCTs then underwent independent 
quality assessment by me and another three reviewers (C. L. Cherry, S. Cox and A. S. 
C. Rice) using the 7-point modified “Jadad” scoring system. 
The modified Jadad scale 
The Jadad assessment scale, also known as the Oxford quality scoring system, was 
developed as a method to systematically assess the quality of medical intervention 
RCTs (Jadad et al., 1996). The Jadad scale is a widely used RCT quality instrument in 
the medical literature (Haynes, 2005).  
The Jadad scale assesses three areas of an RCT that have potential to ‘bias’ its 
conclusions from a ‘true’ result: randomisation, blinding and participant withdrawals/ 
drop-outs (the fate of all participants is known).  
The Jadad scale was modified by the supervisor of this thesis (A.S.C.Rice) in 
collaboration with the original authors of the Jadad scale to include an assessment of 
adequate powering of an RCT. This scale is called the modified Jadad scale (A. Rice, 
Lever, & Zarnegar, 2008).  
The modified Jadad scale asks reviewers to answer the following for each RCT: 
1. Was the study described as randomised (this includes the use of words 
such as randomly, random, and randomisation)? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and drop-outs? 
4. Was there a description of a power calculation? 
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A ‘yes’ answer to each of the above questions receives one point. Questions 1, 2 and 
4 receive an extra point each if the methods used for each is appropriate. A point is 
deducted from 1, 2 or 4 if the method is inappropriate or its description is unclear. A 
maximum score is seven points (Supplemental Document 1: The Modified Jadad 
Score). 
RCTs with a score of less than five points and studies that enrolled fewer than five 
HIV-SN patients were excluded from the systematic review. Scoring discrepancies 
between reviewers were resolved through discussion and consensus. 
Data extraction  
I extracted the data from eligible RCTs. Data extracted included: year of publication; 
study design and duration; study sample population and characteristics; withdrawals; 
interventions; doses; pain and non-pain related primary and secondary outcome 
measures; and adverse events. 
Where possible, dichotomous pain improvement outcome data were extracted from 
RCTs that reported efficacy superior to placebo. Intention to treat (ITT) responder 
rates for 30% and 50% pain relief were sought for the longest follow-up period 
reported in each study. If required, authors were contacted for missing or unreported 
data. 
RCTs in which the primary pain outcome of a studied intervention did not show 
efficacy greater than placebo in the intention to treat population, were not included in 
a subsequent meta-analysis. 
Statistical analysis 
For each intervention the extracted dichotomous outcomes were used to calculate 
numbers needed to treat (NNT) by me and another reviewer (A. S. C. Rice), with 95% 
confidence intervals for 30% and 50% pain improvement responders.  
Meta-analysis 
In the context of medical RCTs, meta-analysis are methods that focus on combining 
results from different studies in order to obtain a quantified synthesis which increases 
the power of statistical analysis by using pooled results.  
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There are three main parts to a meta-analysis: 
1. Production of a pooled estimate and confidence interval for the treatment 
effect after combining all the studies. 
2. To test if the treatment effects seen are statistically significant or not (i.e. does 
the treatment effect differ from no effect more than would be expected by 
chance?) 
3. To test heterogeneity of the effects outcome between the included studies (i.e. 
does the effect vary across the studies more than would be expected by 
chance?) 
To combine the results of more than one study a summary statistic needs to be 
calculated for each. This determines the treatment effect seen in each individual trail. 
This treatment effect then needs to be weighted according to the importance of each 
trial. In the context of RCTs this is most often the size of the trail. 
Weighted average 
There are two statistical models of meta-analysis: 
1. Fixed effect model:  
The fixed effect model provides a weighted average of a series of study effects. The 
model assumes that all included studies investigate the same population, use the same 
variable and outcome definitions, etc. This assumption is typically unrealistic as 
RCTs are often prone to several sources of heterogeneity; e.g. treatment effects may 
differ according to population studies, drug dosage, study conditions, etc . 
2. Random effects model: 
A common model used to synthesize heterogeneous research is the random effects 
model of meta-analysis. This is simply the weighted average of the effect sizes of a 
group of studies. The weight that is applied in this process of weighted averaging with 
a random effects meta-analysis is achieved in two steps: 
Weight =  1/√ variance of the trial estimate 
1/√Standard Error (SE) of the trial 
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This ‘weighting’ is then used to multiple by the effects difference seen in each trial to 
give the weighted average, which can then be used to pool with other studies. 
Heterogeneity 
Ideally, those studies whose results are being combined in the meta-analysis should 
all be conducted in the same way and to the same protocol: study heterogeneity is a 
term used to indicate that this ideal is not fully met. There are several sources of 
heterogeneity. Clinical heterogeneity can be the result of different treatment protocols 
or different study populations being used. Measuring study heterogeneity is 
important, as it indicates where it might not be valid to pool the results of different 
studies. 
Identifying statistical heterogeneity requires testing the null hypothesis that the 
different trials all have the same treatment effect in the population. The test looks at 
the differences between observed treatment effects for the trials and the pooled 
treatment effect estimate. By using the Chi-squared test with degrees of freedom (df) 
and a ‘p’ value, heterogeneity can be estimated. When there are few studies, the test is 
not very good at detecting heterogeneity if it is present. For this reason, a p value of 
less than 0.10 is often used to indicate heterogeneity rather than the conventional cut 
point of p = 0.05. A useful way to identify heterogeneity without having to use 
statistical tables to look up p values is to compare the chi-square statistic with its 
degrees of freedom. If the statistic is bigger than its degrees of freedom then there is 
evidence of heterogeneity (The Cochrane Collaborators Open learning material).  
I originally planned to assess heterogeneity as described above, however, as only 
three studies were used in the meta-analysis, this was felt to be inappropriate by the 
supervisor of this thesis, for reasons outlined above. Similarly, a sensitivity analysis 
was not performed, as there were insufficient data. All calculations were undertaken 
using Microsoft Excel 2007 
Determination of Number Needed to Treat (NNT) 
The NNT is a useful way of expressing the results of a medical intervention trial as it 
indicates the number of patients that would have to be treated in order for one to have 
benefit. To calculate NNT dichotomous outcome measures need to be available. For 
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this systematic review/meta-analysis I used the dichotomous outcome measure of > 
30% or 50% improvement on a pain VAS for a given treatment and its placebo. 
NNT is the inverse of the Absolute Risk Reduction (ARR).  
The ARR = Placebo event rate – Treatment event rate. 
NNT=1/ARR 
Results 
I identified 44 potentially relevant articles (Figure 2.1). Twenty-five articles were 
excluded after screening identified these as being a review article, letter, open-label 
study, case report or other non-RCT study. The remaining 19 RCTs were retrieved 
and independently reviewed by me and other three reviewers (C. L. Cherry, S. Cox 
and A. S. C. Rice). Four articles were excluded at this stage by scoring <5 out of 7-
points with the modified Jadad score. A further RCT was excluded as having <5 HIV-
SN patients enrolled. Details of these excluded RCTs, and therefore of interventions 
that must be regarded as not having been adequately tested, are shown in Table 2.1. 
The remaining 14 RCTs were retained for further analysis (Table 2.2). Of the 14 trials 
retained for further analysis, 13 were of a parallel group design and one a cross-over 
design. All were placebo controlled with one using “active” placebo (David M 
Simpson, Brown, & Tobias, 2008). Data extraction was for the longest follow-up 
period reported by the article. In most cases this was to the end of the treatment phase, 
except for a study of a topical 8% capsaicin (David M Simpson, Brown, et al., 2008) 
that reported data for 12 weeks after a single treatment application. 
In two studies (Paice et al., 2000 and Hahn et al., 2004) no reference to ITT analysis 
was made. In one of these RCTs studying topical capsaicin 0.075% efficacy (Paice et 
al., 2000) no primary outcome data were published, as it was reported that no 
superiority to placebo was seen. In a study of lamotrigine efficacy (D M Simpson et 
al., 2003) only a per protocol (PP) population data analysis was undertaken. This was 
reported to show no superiority over placebo; however no primary outcome data were 
reported.   
Of the four trials that reported superiority of an intervention over placebo, three 
reported dichotomous pain outcome measures. Where possible I used responder rate 
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data for ≥30% and ≥50% improvement in pain as measured using Visual Analogue 
Scale (VAS) or Numerical Pain Rating Scale (NPRS). These data were requested 
from the authors if they had not been reported. 
Acetyl –L-carnitine 
Whilst acetyl-L-carnitine has been the subject of six articles (Chiechio, Copani, 
Gereau, & Nicoletti, 2007; Hart et al., 2004; Herzmann, Johnson, & Youle, 2005; 
Osio et al., 2006; Scarpini, Sacilotto, Baron, Cusini, & Scarlato, 1997; M Youle & 
Osio, 2007) in the treatment of painful HIV-SN, only one was an RCT (M Youle & 
Osio, 2007) and eligible for inclusion. This was a parallel group trial of acetyl-L-
carnitine (1000mg/day) and placebo intramuscular injections. In this RCT acetyl-L-
carnitine, in an analysis of the PP population, showed a modest superiority to placebo. 
However an analysis of the ITT population did not show superiority to placebo: mean 
change in VAS (0-10cm)(SD) from baseline to the end of week 2: acetyl-L-carnitine -
1.32 (1.84); placebo -0.61 (1.55) p=0.07. Consequently we undertook no further 
analysis of this trial. 
Amitriptyline and Mexilitine 
Two trials (Shlay et al., 1998 and Kieburtz et al., 1998) that were included studied the 
efficacy of amitriptyline. Both trials compared amitriptyline to placebo and another 
intervention. One RCT (Shlay et al., 1998) examined efficacy of amitriptyline as part 
of a trial also assessing acupuncture treatment. However despite being described as a 
parallel group, placebo controlled RCT, its design was complex. Consequently the 
results of this trial are difficult to evaluate. In particular bias may have been 
introduced because of unconventional randomisation procedures and because true 
placebo controls were not used. Specifically, patients were allowed to ‘opt-out’ of 
being randomised to the amitriptyline arms of the trial based on personal preference. 
In addition, many participants included in the analysis of amitriptyline efficacy, had 
also received acupuncture or sham acupuncture, further complicating analysis. 
Ignoring the methodological concerns, amitriptyline demonstrated no superiority to 
placebo in the primary outcome measure. The mean change in Gracely pain scores 
from baseline to week 14 was -0.26 with amitriptyline (maximum dose 75mg/day) 
and -0.30 with placebo. The difference between amitriptyline and placebo was: 0.00 
95%CI(-0.18 to 0.19) p=0.99. 
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The second trial (Kieburtz et al., 1998) compared amitriptyline, mexilitine and 
placebo. This trial was terminated early following an interim review of results. It was 
deemed by the trial monitoring board that further enrolment into the study was 
unlikely to detect significant differences in either amitriptyline or mexilitine arms 
compared to placebo. No superiority was reported in reducing mean Gracely pain 
scores (SD) from baseline to the end of treatment week 8 for: amitriptyline (maximum 
dose 100mg/day) -0.31 (0.31); mexilitine -0.23 (0.41); compared to placebo -0.20 
(0.30).  
Smoked Cannabis 
The original literature search found four articles related to cannabinoid use and 
painful HIV-SN. Only two were RCTs (Abrams et al., 2007; Ellis et al., 2009). The 
excluded articles included one clinical survey (Woolridge et al., 2005) and one review 
article (Beaulieu & Ware, 2007). 
One of these included articles (Ellis et al., 2009) was a cross-over study that 
compared the efficacy of smoked cannabis (maximum tolerated dose 1 to 8% ∆-9-
tetrahydrocannabinol q.d.s.) to placebo cigarettes in reducing subjects pain measured 
using the Descriptor Differential Scale (DDS). The DDS is a ratio scale (0 to 20) 
containing 24 words describing pain intensity and unpleasantness. Smoked cannabis 
was reported to be superior to placebo in reducing DDS from baseline to end of 
treatment day five in the PP population. The median difference between cannabis and 
placebo was -3.3 out of 20; p=0.016. No data were reported for the ITT analysis, 
however the authors stated that the PP analysis was similar to the ITT analysis with 
p=0.02.  VAS data not reported by the authors, but was supplied on request, relating 
to cannabis and placebo subjects who reported a ≥30% (18/34 and 7/34 respectively) 
and ≥50% (13/34 and 4/34 respectively) improvement in pain intensity. 
This trial reported a high proportion of inadvertent unblinding amongst subjects 
following dose titration with smoked cannabis cigarettes in the treatment arms, but 
not with placebo cigarettes.  
A second study (Abrams et al., 2007) compared smoked cannabis (3.56% ∆-9-
tetrahydrocannabinol t.d.s.) to placebo cigarettes in a parallel group RCT.  Smoked 
cannabis was shown to be superior to placebo in reducing pain from baseline to end of 
treatment day 5 in the ITT analysis: cannabis -34% (IQR -71 to -16), placebo -17% 
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(IQR -29 to 8) p=0.03.  More subjects reported ≥30% VAS improvement with 
smoked cannabis compared to the placebo: 13/27 and 6/27 respectively. 
Inclusion into the study required subjects to have had previous exposure to cannabis, 
with current users asked to discontinue prior to the study. Of note no attempt was 
made to assess unintentional unblinding during the course of the study, which may 
have been high due to subjects’ previous experience with smoked cannabis.   
Using the ITT analysis dichotomous VAS data from both trials, an NNT for smoked 
cannabis was calculated as 3.38 95%CI (2.19 to 7.50) (Table 2.3) 
Topical Capsaicin 
Four trials (D. B. Clifford et al., 2012; Paice et al., 2000; David M Simpson, 
Estanislao, Brown, & Sampson, 2008 and D. Clifford, Simpson, Brown, Moyle, & 
Brew, 2010) were found that assessed topical capsaicin efficacy in painful HIV-SN. 
Two reports were excluded from further analysis; one was an open-label study (David 
M Simpson, Brown, et al., 2008) and the other has been reported in abstract form only 
(D. Clifford et al., 2010). Of the included trials, one (Paice et al., 2000) examined the 
efficacy of topical capsaicin 0.075% cream in a parallel group RCT. The authors 
stated that no superiority of capsaicin 0.075% over placebo in mean improvement in a 
numeric rating score (NRS) (0-10) was seen, however only graphical data were 
presented. 
A second study (David M Simpson, Brown, et al., 2008) examined topical capsaicin 
8%. Patients received either the 8% patch or an active placebo (capsaicin 0.04%) in a 
single application lasting either 30, 60 or 90 minutes. Following this single 
application patients were followed-up for 12 weeks. Capsaicin 8% was found to be 
superior to placebo in the percentage reduction of the NPRS (SD) from baseline to 
week 2 to 12: 8% capsaicin: -22.8 (30.6); compared to placebo: -10.7 (30.8), 
(p=0.0026). The study also reported responder rates as percentage of patients 
measured on the NPRS who experienced ≥30% mean reduction in pain: capsaicin 8%: 
76/225; placebo (capsaicin 0.04%): 15/82; p=0.0092. It is not possible to calculate an 
NNT that is strictly comparable to those calculated for other studies included in this 
review since the placebo control used here was not pharmacologically inactive. 
However, as an informative exercise using these data, and presuming that the control 
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capsaicin 0.04% is a true placebo, an NNT of 6.46 95%CI(3.86-19.69) was calculated 
for treatment with capsaicin 8% patch.  
Gabapentin 
Only one retrieved report related to treatment of painful HIV-SN with gabapentin was 
an RCT. Four additional articles were excluded. Two were letters (Newshan, 1998; 
Vadivelu & Berger, 1999) one an abstract (Gatti, Antonella, Jann, Stefano, & Sandro, 
1998), and one a case series (La Spina, Porazzi, Maggiolo, Bottura, & Suter, 2001). 
The included study (Hahn et al., 2004) compared gabapentin (titrated to a maximum 
of 2400mg/day) to placebo in a parallel group RCT. At the longest treatment period 
assessed, no difference in efficacy was reported between gabapentin and placebo 
groups for the primary outcome measure, median change in VAS (0-100mm) baseline 
to end of week 4: gabapentin: - 44.1, placebo: -29.8. No indication of variance or p 
value was documented.  
It is noteworthy that this trial demonstrated an unusual placebo response. The placebo 
subjects’ pain VAS baseline remained unchanged for the first two weeks, after which 
a stronger placebo response followed to week 4. This unusual placebo response may 
have contributed to the apparent superiority of gabapentin over placebo at week 2, 
which was not evident at week 4. 
Pregabalin  
One large multi-centre RCT (D M Simpson, Schifitto, et al., 2010)[50] examined the 
efficacy of pregabalin, titrated over 2 weeks to a maximum tolerated dose up to 
1200mg/day, in a multicentre, 14 week parallel group, placebo controlled RCT. No 
superiority of pregabalin over placebo in the primary pain outcome measure was 
reported: mean change in NPRS baseline to end of week 14: pregabalin -2.88; placebo 
-2.63, p=0.39.  
Lamotrigine 
Three trials assessing the efficacy of lamotrigine in painful HIV-SN were identified 
(Silver, Blum, Grainger, Hammer, & Quessy, 2007; D M Simpson et al., 2000 and  D 
M Simpson et al., 2003). One trial (Silver et al., 2007), enrolled only one painful 
HIV-SN patient (to the placebo control group) and was therefore excluded from 
further analysis. The included lamotrigine trials (D M Simpson et al., 2000) and (D M 
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Simpson et al., 2003) were both conducted by the same group; with (D M Simpson et 
al., 2000) being smaller and preceding (D M Simpson et al., 2003). The smaller study 
(D M Simpson et al., 2000) did demonstrate some efficacy superior to placebo when 
the primary outcome for the PP population was analysed. However in the ITT 
analysis with ‘last value carried forward’ (LVCF), lamotrigine was not superior to 
placebo:  improvement in mean Gracely pain score  (SE): lamotrigine: – 0.242 
(0.009); placebo: -0.183 (0.087); (p=0.65). The large number of dropouts in the 
lamotrigine group (n= 11 of 20) compared to placebo (n=3 of 22) suggest a narrow 
therapeutic index and make interpretation of the trial results difficult. 
Similarly the larger trial (D M Simpson et al., 2003), where participants were 
stratified according to previous exposure to neurotoxic ARVs, did not demonstrate a 
superiority of lamotrigine over placebo for the primary outcome measure (mean 
improvement in Gracely pain score) in the total cohort or in either stratum.  However 
lamotrigine did show superiority to placebo in the neurotoxic ARV-exposed stratum 
in a secondary outcome measure, mean improvement in VAS (0-100mm) baseline to 
end of treatment: lamotrigine: -27.1; compared to placebo: -9.0; p=0.003.  
For each stratum the number of responders (≥30% improvement in VAS) were 
calculated from the published data. For the neurotoxic ARV stratum: lamotrigine 
36/62, placebo 7/30 (p=0.02) and for no exposure to neurotoxic ART: lamotrigine 
46/88, placebo 21/47. As an informative exercise using these data the NNT for 
lamotrigine was calculated for each stratum, and for the overall trial.  Subjects with 
exposure to neurotoxic ARVs: 2.88 95%CI(1.84 to 6.57); no exposure to neurotoxic 
ARVs: 13.17 95%CI(3.96 to -9.95) and for the unstratified population: 6.09 
95%CI(3.51 to 23.08)(Not included in Table 2.3 as no superiority of lamotrigine over 
placebo was demonstrated for any primary endpoint). 
Recombinant human Nerve Growth Factor (rhNGF) 
One RCT (J C McArthur et al., 2000) examined the efficacy of subcutaneous 
recombinant human Nerve Growth Factor (rhNGF) in the treatment of painful HIV-
SN. This study assessed two doses (0.1 and 0.3μg/kg) given twice weekly compared 
with placebo for 18 weeks. rhNGF was superior to placebo for the primary outcome 
measure in the ITT analysis; median change of the Gracely pain score from baseline 
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to end of week 18: rhNGF 0.1μg/kg: -0.18 (-0.10 to -0.25) p=0.05,  0.3μg/kg: -0.21 (-
0.14 to -0.29) p=0.04, and placebo: 0.06 (+0.01 to -0.14)  
No significant dose effect was reported and no differential effect was seen based on 
baseline stratification of subjects according to neurotoxic ARV drug exposure. As 
rhNGF was reported to be associated with myalgia, there may have been inadvertent 
breaking of the blinding. 
Dichotomous data were requested from the authors however we were unable to 
calculate RR and NNT values for rhNGF from the data provided. 
Prosaptide and Peptide –T 
Two trials (Evans et al., 2007; D M Simpson et al., 1996) examined the efficacy of 
the novel agents in placebo controlled parallel group RCTs. One (Evans et al., 2007) 
reported the use of subcutaneous prosaptide (maximum dose of 16mg/day) over 6 
treatment weeks and did not report efficacy superior to placebo in the primary 
outcome measure; mean change in Gracely pain score baseline to week 6. The study 
was terminated after a planned interim futility analysis. Another trial (D M Simpson 
et al., 1996) studied efficacy of intranasal peptide T (maximum dose 6mg/day), over 
12 treatment weeks, but reported no superiority over placebo in the primary outcome 
measure; mean change in a modified Gracely pain score baseline to end of week 12. 
Discussion 
This systematic review found that RCT evidence of analgesic efficacy superior to 
placebo in the context of HIV-SN pain exists only for smoked cannabis, rhNGF and 
high dose (8%) topical capsaicin. Several other agents have been examined in high 
quality RCTs and found to be no more effective than placebo for managing HIV-SN 
pain in the doses used, specifically acetyl-L carnitine (1g/day), amitriptyline 
(100mg/day), topical capsaicin 0.075%, gabapentin (2.4g/day), mexilitine 
(600mg/day), peptide –T (6mg/day), pregabalin (1200mg/day), lamotrigine 
(600mg/day) and prosaptide (16mg/day). Therefore, there is evidence that both of the 
first line therapies (pregabalin and amitriptyline) recommended in the NICE guidance 
for non-specialist management of neuropathic pain show no superiority to placebo in 
the management of pain in HIV-SN (Tan et al., 2010). 
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Of the pharmacological interventions shown to be effective for HIV-SN in RCTs, 
only topical capsaicin 8% is currently approved for marketing for neuropathic pain 
indications. In Europe 8% capsaicin has been approved for the treatment of peripheral 
neuropathic pain in non-diabetic adults, whilst the U.S. Food and Drug 
Administration (FDA) has approved its use only for the indication of post herpetic 
neuralgia.  However, it should also be borne in mind that we located a preliminary 
report (conference abstract only and therefore excluded from the systematic review) 
of another parallel group RCT which included 494 patients with HIV-SN in which 
topical 8% capsaicin was compared to 0.04% topical capsaicin (D. Clifford et al., 
2010). No analgesic superiority of 8% capsaicin over 0.04% was demonstrated. 
rhNGF therapy is not currently clinically available and both legal and mental health 
issues preclude routine recommendation of long term smoked cannabis for pain 
management (A. S. C. Rice, 2008). 
This systematic review represents a comprehensive review of the literature relating to 
the pharmacological management of painful HIV-SN. It used a predefined protocol 
for the initial literature search, data extraction and analysis. There was also strict 
adherence to inclusion quality criteria as assessed by four independent reviewers 
using the modified Jadad score, a tool that assesses each study for potential bias as 
well as evaluating study power. 
This systematic review was limited by the paucity of high quality RCTs examining 
pharmacological treatment of painful HIV-SN. Additionally the heterogeneity of the 
included studies design and size made evaluation and comparison of trials difficult. In 
particular, use of the Gracely pain scale (GPS) in five of the 14 included RCTs made 
evaluation and inter-study comparison complicated. The GPS is a log unit pain 
outcome measure that is not a frequently used measure outside trials of HIV-SN. In a 
recent consensus statement regarding core chronic pain outcome measures (Dworkin, 
Katz, & Gitlin, 2005) it was not one of the recommended pain scales. Several of the 
studies utilising the Gracely pain score also included more validated secondary pain 
outcome measures such as either a VAS score or a NPRS. These were used here in 
preference to the Gracely pain score in the calculation of NNT and RR. 
The Jadad tool has been validated and used widely to identify common and major 
sources of experimental bias in RCTs identified in systematic reviews. Nevertheless, 
whilst the use of the modified Jadad score improves the probability that only high 
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quality RCTs were included in the systematic review, its use may conceivably have 
biased our systematic review in favour of more recently tested agents. The RCTs 
associated with these agents now routinely report the information required by the 
modified Jadad tool, because of the nature of the evolution of RCT methodology over 
the past few years.   
Both of the RCTs that examined the efficacy of smoked cannabis, were of high 
quality, however the apparent marked superiority of smoked cannabis to placebo 
cigarettes should be tempered by the high proportion of potential unblinding 
measured in (Ellis et al., 2009) (92% correctly guessing treatment allocation after 
treatment cross-over), and its lack of measurement in (Abrams et al., 2007) despite 
participants having all had previous experience of smoked cannabis. In a similar 
manner, the RCT investigating recombinant human NGF demonstrated a high degree 
of unblinding related to injection site myalgia, which when accounted for in a 
separate analysis reported a more attenuated treatment-related difference which 
consequently lost statistical significance. 
Lamotrigine was the subject of two high quality RCTs. Both failed to show 
superiority over placebo in the primary pain outcome measure, improvement in the 
GPS in the ITT population. However, in the larger of the two RCTs, analysis of a 
secondary pain outcome measure, mean improvement in VAS, did demonstrate 
efficacy superior to placebo in the subpopulation of subjects who had been previously 
exposed to neurotoxic ARTs. If this stratum alone is examined an NNT of 2.88 is 
calculated. 
Most of the included RCTs did not stratify subjects with painful HIV-SN according to 
their exposure to neurotoxic ARTs. This stratification was instrumental in 
demonstrating an efficacy of lamotrigine in neurotoxic ART exposed painful HIV-SN 
subjects. It is possible to speculate that a similar strategy of stratifying other RCTs 
might have elucidated other agents with sub-group efficacy, despite lack of observed 
analgesic efficacy in an unstratified painful HIV-SN subject population. Additionally, 
the included RCTs were not uniform in their approach to the use of concomitant 
analgesics; whilst most allowed continued use of drugs at stable doses, two elected to 
stop them (Evans et al., 2007; Hahn et al., 2004). The use of such concomitant 
analgesics, and also the inclusion of participants with previously failed therapies, may 
conceivably have influenced the outcomes of these RCTs. 
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Gabapentin and pregabalin were the subject of two high quality RCTs in which 
neither agent was shown to be superior to placebo. This contrasts with the efficacy of 
these agents demonstrated in other peripheral neuropathic pain conditions (Finnerup 
et al., 2010; Hempenstall, Nurmikko, Johnson, A’Hern, & Rice, 2005; RH, Dworkin 
et al., 2007; Tan et al., 2010). However the gabapentin study was small, with only 30 
patients randomised (Hahn et al., 2004). This finding may therefore represent a ‘failed 
trial’ rather than a true lack of efficacy. 
Amitriptyline efficacy was examined in two large RCTs. The evaluation of one study 
(Shlay et al., 1998) was made difficult by a complicated study design that may have 
not been truly randomised or placebo controlled. However the finding that 
amitriptyline did not display superior analgesic efficacy than placebo in the context of 
HIV-SN is supported by a similar finding a second, higher quality RCT (Kieburtz et 
al., 1998). Again, this finding directly contrasts with evidence of efficacy for tricyclic 
antidepressants in a range of other peripheral neuropathic pain conditions (Finnerup et 
al., 2010; Hempenstall et al., 2005; RH, Dworkin et al., 2007; Tan et al., 2010).  
Capsaicin 0.075% cream was the subject of a small RCT enrolling only 26 subjects. 
The authors stated that capsaicin 0.075% did not demonstrate statistically significant 
superiority to placebo in the primary pain outcome measure. However, outcome data 
were published only in a graphical representation of mean current pain scores from 
baseline to the end of treatment. From this graph there does appear to be a trend for 
capsaicin to be superior to placebo at this final time point measured at week 4. 
However a high drop-out rate in both arms resulted in only 6/11 patients remaining in 
the capsaicin group, and only 8/15 in the placebo group. It is therefore difficult to 
determine from this study if capsaicin 0.075% was indeed without efficacy. This has 
two implications: the first being that capsaicin 0.075% might have some degree of 
clinically relevant efficacy in painful HIV-SN; and secondly, if capsaicin 0.075% is 
indeed efficacious, then the use of a similar concentration (capsaicin 0.04%) as an 
active placebo in the large capsaicin 8% patch RCT would change the design of this 
study from a placebo controlled to a superiority approach. 
In the treatment of painful HIV-SN, the lack of efficacy compared with placebo of 
many agents with proven efficacy in other forms of neuropathic pain has implications 
in the understanding of neuropathic pain in general. These findings further support the 
hypothesis that neuropathic pain cannot be considered as a single symptom with a 
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single pathogenesis (Baron et al., 2009; Scholz et al., 2009). A more mechanistic 
approach to the treatment of specific types of neuropathic pain is therefore warranted 
as has been established in trigeminal neuralgia and post herpetic neuralgia. Equally, 
caution should be exercised in the use of neuropathic pain treatment algorithms that 
do not consider these potential mechanistic differences, as their rationale may be 
fundamentally flawed. 
The absence of studies examining the efficacy of opioid use in painful HIV-SN is 
notable and mandates additional research. Opioids have shown efficacy in other 
neuropathic pain conditions (Finnerup et al., 2010; Hempenstall et al., 2005; RH, 
Dworkin et al., 2007). Furthermore, the efficacy of duloxetine in diabetic neuropathy, 
a condition that has similarities to HIV-SN, may suggest that it is worth investigating 
(Tan et al., 2010). In addition, the efficacy of cannabis in HIV-SN would suggest that 
cannabinoids with an appropriate therapeutic index when delivered by a mechanism 
other than smoking might be worthy of investigation (A. S. C. Rice, 2008). 
Summary 
On the basis of current published evidence, topical capsaicin 8%, smoked cannabis 
and Nerve Growth Factor have evidence of efficacy in pain associated with HIV-SN. 
However the apparent efficacy of capsaicin is contentious, as a larger RCT, reported 
in abstract form only at the time of this systematic review, suggested this treatment is 
not superior to placebo (D. Clifford et al., 2010). Some commonly recommended 
analgesics, including opioids, have not been formally studied for the management of 
painful HIV-SN. 
The current evidence base available for the treatment of painful HIV-SN is at odds 
with the recommendations made by NICE for neuropathic pain management in the 
non-specialist situation. This indicates the potential dangers of extrapolating efficacy 
from one neuropathic pain condition to another where efficacy has not been directly 
assessed. In particular amitriptyline, pregabalin, and gabapentin have been 
demonstrated to have no superiority to placebo in the treatment of painful HIV-SN. 
With an estimated 33 million people living with HIV and more gaining access to 
ARV every day, the management of HIV-SN associated neuropathic pain is a problem 
of major global significance. There is an urgent need for the development of effective; 
evidence based analgesic strategies for this common condition. On-going evaluation 
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of both novel analgesics and existing untested strategies for HIV-SN is a clear 
research priority. 
Update Search 
On December 15th 2013 follow-up literature search limited to Medline (from 1966 to 
date searched) was conducted using the same search terms used for the above 
systematic review.  
Only two additional RCTs were identified as being potentially relevant to the above 
systematic review.  
One was a high quality RCT that had been previously only reported in abstract form, 
but mentioned in the systematic review discussion (D. B. Clifford et al., 2012). This 
RCT was a high quality active placebo controlled with n=332 painful HIV-SN 
participants for capsaicin 8% patch for either 30 or 60min and n=162 painful HIV-SN 
who received active placebo (0.04% capsaicin patch). The treatment group showed no 
statistically significant superiority to placebo at any time point from week 2 to week 
12 for the primary outcome Numeric Pain Rating Scale score or for the secondary 
outcome measure of Patients Impression of Change at week 12. 
A second RCT of capsaicin 8% patch was identified comparing capsaicin with three 
topical anaesthetic preparations (Webster, Peppin, Murphy, Tobias, & Vanhove, 
2012). This RCT included n=117 participants with neuropathic pain, however only 
one participant with painful HIV-SN was entered; this RCT would therefore not be 
suitable for inclusion in the above systematic review. 
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Table 2.1. Studies excluded from the systematic review. 
Reference Treatment Primary Reason for Exclusion 
(Chiechio et al., 2007) Acetyl-L-carnitine Review 
(Mike Youle, 2007) Acetyl-L-carnitine Review 
(Woolridge et al., 2005) Cannabinoids Review 
(Wiffen & Rees, 2007) Lamotrigine Review 
(Saarto & Wiffen, 2010) Antidepressants Review 
(Liu, Manheimer, & Yang, 2005) Herbal medicine Review 
(David M Simpson, Estanislao, et al., 
2008) 
8% capsaicin patch Open-label 
(D. Clifford et al., 2010) 8% capsaicin patch Abstract 
(Osio et al., 2006) Acetyl-L-carnitine Open-label 
(Scarpini et al., 1997) Acetyl-L-carnitine Open-label 
(G Schifitto et al., 2001) Recombinant human 
NGF 
Open-label 
(von Gunten et al., 2007) Flecainide Open-label 
(Dorfman et al., 1999) 5% lidocaine patch Open-label 
(King, 1999) Acupuncture Letter 
(Ulett, 1999) Acupuncture Letter 
(Kaptchuk, 1999) Acupuncture Letter 
(Valdivelu & Berger, 1999) Gabapentin Letter 
(Newshan, 1998) Gabapentin Letter 
(La Spina et al., 2001) Gabapentin Case report 
(Bradley & Verma, 1996) Prednisolone Case report 
(Gatti et al., 1998) Gabapentin Abstract 
(Woolridge et al., 2005) Smoked cannabis  Other non-RCT 
(Herzmann et al., 2005) Acetyl-L-carnitine Other non-RCT 
(Phillips, Skelton, & Hand, 2004) Acupuncture Other non-RCT 
(Hart et al., 2004) Acetyl-L-carnitine Other non-RCT 
(Estanislao, Carter, McArthur, Olney, 
& Simpson, 2004) 
5% lidocaine patch Modified Jadad score <5 
(Kemper, Kent, Burton, & Deresinski, 
1998) 
Mexiletine Modified Jadad score <5 
(Giovanni Schifitto et al., 2006) Memantine Modified Jadad score <5 
(Navia et al., 1998) Nimodipine Modified Jadad score <5 
(Silver et al., 2007) Lamotrigine < 5 patients enrolled 
 
 
 55 
Table 2.2. Characteristics and results of included studies. ] 
 
GP - Gracely Pain Score, VAS – Visual Analogue Scale, ITT – Intention To Treat population, PP -Per Protocol population, NRS – Numerical Rating Scale, NPRS- Numerical Pain Rating Scale, DDS – Descriptor Differential Scale, LOCF - Last Observation Carried Forward 
Reference Participants 
recruited 
(completed) 
Design and 
duration 
Intervention (n= patient 
episodes) 
Maximum 
dose studied 
Primary Outcome Data  (ITT) Superior 
to 
placebo? 
Youle M et al., 
2007 [36] 
90(76) Parallel: 2 wks  Acetyl-L-carnitine  500 mg bd i.m. 
(n=43); placebo (n=47) 
 
1000mg/day VAS (0-10cm) change: 
baseline to wk 2. 
ITT: Acetyl-L-carnitine: -1.32 (SD 1.84); placebo -0.61 (SD 1.55)(p=0.07) No 
Shlay JC et al., 
1998 [38] 
136 (105) Parallel: 14 wks  Amitriptyline (n=71); placebo 
(n=65) 
75mg/day GP score: change 
baseline to wk 14. 
ITT with LOCF: Amitriptyline: -0.26; placebo: -0.30;difference 0.00 95%CI( -0.18 to 
0.19)(p=0.99) 
No 
Paice JA et al., 
2000 [29] 
26(14) Parallel: 4 wks. Capsaicin 0.075% cream  q.d.s. 
(n=15); placebo (n=11) 
0.075% q.d.s. NRS (0-10): change from 
baseline to wk 4. 
No numeric data given. Stated no statistically significant difference between 
capsaicin 0.075% and placebo (p>0.05) 
No 
Simpson DM 
et al., 2008 
[28] 
307(274) Parallel: 12 wks 
follow-up. 
Capsaicin 8% patch for 30min 
(n=72); 60min (n=78); 90min 
(n=75); placebo (capsaicin 
0.04%) (n=82) 
8% for 90min. NPRS: % change 
baseline to wk 12. 
ITT with LOCF: Capsaicin: -22.8 (SD 30.6); placebo -10.7 (SD 30.8); (p=0.0026) Yes 
Abrams DI et 
al., 2007 [40] 
55(50) Parallel: 5 days Smoked cannabis (n=27); placebo 
(n=28) 
3.56% ∆-9- 
tetrahydrocanna
binol t.d.s. 
VAS: % change from 
baseline to day 5. 
ITT: Cannabis: -34% (IQR -71 to -16); placebo -17% (IQR – 29 to 8) (p=0.03) Yes 
Ellis RJ et al., 
2009 [41] 
34(27) Crossover: 5 
days, 2 wks 
washout, 5 days 
treatment. 
Smoked cannabis (n=28); placebo 
(n= 28) 
Max tolerable: 1 
to 8% ∆-9- 
tetrahydrocanna
binol q.d.s. 
DDS (0-20): median 
change from baseline to 
day 5. 
Difference in DDS reduction cannabis vs placebo for PP: -3.3 p=0.016, no data for 
ITT: said to be ‘similar’ with p=0.020 
Yes 
Hahn K et al., 
2004 [30] 
26(24) Parallel: 4 wks 
treatment. 
Gabapentin (n=15); placebo 
(n=11) 
2400mg/day VAS: median change: 
baseline to wk 4. 
Gabapentin: -44.1;  placebo: -29.8. Stated as being not statistically significant. No 
Simpson DM 
et al., 2010 
[50] 
302(241) Parallel: 14 wks 
treatment.   
Pregabalin (n=151); placebo 
(n=151) 
1200mg/day NPRS: mean change: 
baseline to wk 14. 
ITT: Pregabalin: -2.88; placebo -2.63 (p=0.39) No 
Simpson DM 
et al., 2000 
[51] 
42(29) Parallel: 14 wks 
treatment   
Lamotrigine (n=20); placebo 
(n=22) 
300mg/day GP score: mean change: 
baseline to wk 14. 
ITT with LOCF: Lamotrigine: -0.242 (SE 0.092); placebo: -0.183 (SE 0.087) (p=0.65)  No 
Simpson et al., 
2003 [31] 
227(172) Parallel:12 wks 
treatment. 
Lamotrigine (n=150); placebo 
(n=77) 
600mg/day GP score: change: 
baseline to wk 12. 
PP: Lamotrigine  vs placebo. No data given, stated no statistically significant 
difference seen in all or ARV stratum. 
No 
Keiburtz K et 
al., 1998 [39] 
145(104) Parallel: 8 wks  Mexilitine (n=48); amitriptyline 
(n=47); placebo  (n=50) 
Mexilitine: 
300mg/day 
Amitriptyline: 
100mg/day 
GP score: mean change: 
baseline to wk 8. 
ITT: Amitriptyline: -0.31 (SD 0.31); mexilitine: -0.23 (SD 0.41); placebo -0.20 (SD 
0.30) No p value given, stated no statistical significance 
No 
McArthur JC et 
al., 2000 [53] 
270(235) Parallel:18 wks  Recombinant human NGF 
(n=180); placebo (n=90) 
0.3μg/kg s.c. 
twice weekly 
GP score: median 
change: baseline to wk 
18 
ITT with LOCF: NGF 0.1μg/kg: -0.18 (-0.10 to -0.25)(p=0.05); NGF 0.3μg/kg: -0.21 (-
0.14 to -0.29)(p=0.04); placebo: 0.06 (+0.01 to -0.14)  
Yes 
Simpson DM 
et al., 1996 
[54] 
104(81) Parallel: 12 wks  Peptide-T (n=40); placebo 
(n=41)* PP data 
6mg/day 
intranasal 
Modified GP score: mean 
change: baseline to wk 
12. 
PP: Peptide-T: -0.24 (±0.45); placebo -0.39 (±0.19) (p=0.32). ITT results not 
presented but stated showed the ‘same pattern’. 
No 
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Table 2.3. Summary of RCTs which demonstrated treatment superior to placebo, for which Relative Risk and Number Needed 
to Treat values could be calculated. 
 
 
Active Treatment 
(maximum tested dose) 
Number of patient 
Episodes 
Benefit Efficacy on 
Treatment (≥30% 
improvement VAS 
Efficacy on Placebo 
(≥30% 
improvement VAS) 
RR (95% CI) NNT (95% 
CI) 
Smoked cannabis  
Abrams et al., 2007  Smoked cannabis: 3.56% 
∆-9-tetrahydrocannabinol 
55 (50) 13/27 6/28 2.17 (0.97 to 4.86) 3.86 (1.98 
to 71.11) 
Ellis et al., 2009  Smoked cannabis: 8% ∆-
9-tetrahydrocannabinol 
68 (56) 18/34 7/34 2.57 (1.24 to 5.35) 3.09 (1.98 
to 9.30) 
Abrams et al., 2007 
Ellis et al 2009 
Combined smoked 
cannabis studies 
122 (106) 31/ 61 15/ 61 2.38 (1.38 to 4.10) 3.38 (2.19 
to 7.50) 
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Chapter 3  
Patterns of sensory, psychological and metabolic 
dysfunction in HIV positive patients with and without 
HIV-associated peripheral neuropathy. 
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Patterns of sensory, psychological, and metabolic dysfunction in HIV 
positive patients with and without HIV-associated peripheral 
neuropathy. 
 
Introduction. 
Established risk factors associated with the development of HIV-SN include advancing 
age, height, lower nadir CD4 counts, high viral titres, and exposure to the neurotoxic 
‘d’ NRTI class of antiretroviral agents. Crucially, despite the phasing out of neurotoxic 
dNRTI drugs, especially in well-resourced countries, the prevalence of HIV-SN has 
remained consistently at around 40%, suggesting that drug induced neurotoxicity may 
not be a major aetiological factor for HIV-SN in the cART-era (Catherine Louise 
Cherry et al., 2012; Ellis et al., 2010; Smyth et al., 2007). More recent cART-era 
population and genetic association studies have identified additional patient related risk 
factors such as ethnicity, elevated plasma triglycerides (Banerjee et al., 2011), the 
expression of genes involved in the peripheral inflammatory response and those 
affecting mitochondrial function (Kamerman, Wadley, & Cherry, 2012). Whilst there 
have been several epidemiological studies documenting the prevalence and risk factors 
for HIV-SN in the current cART era; profiling studies directed at describing in detail 
the HIV-SN phenotype are lacking. Specifically, factors which are crucial to 
understanding the nature of HIV-SN, such as the relationships between sensory nerve 
dysfunction, symptomatology, clinical signs, patient quality of life, psychological co-
morbidity and sleep disturbance in HIV-SN are required. 
There have been few studies that have attempted to describe in detail the HIV-SN 
phenotype in the cART era (Bouhassira et al., 1999; Martin et al., 2003). 
I have therefore conducted detailed profiling of a cohort of HIV positive patients, with 
and without HIV-SN, using a battery of techniques directed at understanding the nature 
and pattern of sensory nerve dysfunction in HIV-SN and its relationship to 
symptomatology, psychological and circadian rhythm disruption. 
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Methods. 
Study design and participants 
The Pain In Neuropathy Study - HIV (PINS-HIV) was an observational single cohort 
cross-sectional study conducted at Chelsea and Westminster Hospital NHS Trust 
London. The study protocol was assessed and approved by a local ethics committee 
(Riverside Research Ethics Committee; NRES number: 09/H0706/24). Subjects 
participated in the study after giving written informed consent.  
Participants were recruited between July 7th 2009 and January 25th 2011 from 
ambulatory HIV infected patients attending the St Stephen’s Centre, Chelsea and 
Westminster Hospital NHS Trust London. In order to reflect the population treated at 
one of Europe’s major HIV centres, the inclusion criteria were as inclusive as possible. 
Eligible persons were all HIV infected adults (≥18 yrs of age) irrespective of 
concurrent or previous ARV treatment, or the presence of symptoms of a peripheral 
neuropathy. Exclusion criteria included pregnancy, co-incident major psychiatric 
disorders (DSM-IV), poor or no English language skills, pain ≥4/10 on a numerical 
rating scale (NRS) from a cause other than a peripheral neuropathy at recruitment, 
patients with central nervous system lesions, subjects with insufficient mental capacity 
to obtain informed consent from or complete the study questionnaires. Skin biopsies 
were not conducted on anticoagulated patients, or who had any other contra-indication 
to skin biopsy. 
The study design consisted of a single clinical assessment appointment, at the end of 
which participants were given a questionnaire pack to complete and return to the study 
centre by post. 
During the clinical assessment appointment participants had detailed medical and drug 
histories taken by a study investigator recording: gender, age, ethnicity, past medical 
history, date of HIV diagnosis, presence of a family history of neuropathy, presence of 
other potential causes of neuropathy (hypothyroidism, diabetes, alcohol abuse, vitamin 
B12 deficiency, isoniazid and chemotherapy drug exposure); smoking and alcohol 
consumption assessed using UK Department of Health method (Hedges, 1996). 
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Following this, basic clinical parameters were measured for each participant: weight, 
height and lying/standing blood pressures. Participants then underwent a Structured 
Neurological Examination (SNE), a detailed Quantitative Sensory Testing (QST) 
assessment and skin biopsy sampling as described below. Each participant had 30mls 
of blood drawn and stored for future genotype studies. 
Following the clinical assessment appointment the study investigator collected further 
drug, laboratory and clinical investigation data from the clinical records. The following 
clinical data was collected: detailed ARV drug histories; nerve conduction study data; 
the most recent routine haematological and biochemical tests: HIV-viral load, CD4+ 
counts, plasma electrolytes, liver function enzymes, vitamin B12, thyroid function, 
blood glucose, plasma lipid profiles, and Hepatitis B, Hepatitis C and Syphilis serology 
(Supplemental Document 1: PINS-HIV CRF). 
Quantitative sensory testing (QST) 
Sensory profiles were measured using the German Research Network on Neuropathic 
Pain (DFNS) QST protocol. Measurements were performed bilaterally in the S1 
dermatome at the dorsum of feet. The DFNS has developed and validated a 
comprehensive QST battery which uses standardised equipment, paradigms and verbal 
instructions as described (Rolke, 2006; Rolke et al., 2006). This method has been used 
in multiple investigations of different neuropathic pain conditions to phenotypically 
characterise patterns of sensory nerve dysfunction (Gierthmühlen et al., 2012; 
Konopka et al., 2012; Maier et al., 2010). 
The DFNS QST protocol assesses the functional characteristics of both small and large 
afferent fibres by recording responses to 13 thermal and mechanical stimuli. These are 
described elsewhere in detail and have not been duplicated here (Rolke, 2006; Rolke et 
al., 2006). In brief, the DFNS QST battery test the following modalities in the order: 
cold detection threshold (CDT), warm detection threshold (WDT), thermal sensory 
limen (TSL), the presence of paradoxical heat sensations (PHS), cold pain threshold 
(CPT), heat pain threshold (HPT), mechanical detection threshold (MDT), mechanical 
pain threshold (MPT), a stimulus response function for pinprick sensitivity (MPS: 
mechanical pain sensitivity), allodynia (DMA: dynamic mechanical allodynia), wind-
up ratio (WUR), vibration detection threshold (VDT), and blunt pressure pain 
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threshold (PPT). 
 
Me and the other QST operator (M. R. D. Brown) underwent a formal course of 
instruction in conducting the DFNS QST protocol at Mannheim University using 
healthy volunteers. On return to the UK investigation centre, for quality control 
purposes each investigator was required to produce QST data sets for 18 healthy 
volunteer controls which were age and sex matched to DFNS requirements: equal 
number of male and female participants. Healthy volunteers were recruited through 
local departmental advertisement targeting students and employees of Imperial College 
London. Inclusion as healthy volunteer data required participants to have responses to 
vibration, warm and cold threshold detection, within the normal standardised DFNS 
values. Potential participants were excluded if they presented with a neurological, 
vascular or psychiatric disorder or a chronic pain condition; diabetes mellitus; or were 
taking medication with potential central or peripheral nervous system effects, this 
included benzodiazepines, triptanes or cortisone preparations. 
The healthy volunteer control data were subsequently analysed and critiqued by the 
DFNS to provide quality assurances for the study centre and QST investigators. 
Additionally normative data for suprathreshold heat testing (as outlined below) were 
collected from each healthy control subject after the completion of the DFNS QST 
protocol. 
QST equipment 
 
DFNS specification compliant QST equipment was used in the study as described 
below. 
 
Thermal threshold detection 
Sensory and nociceptive thermal thresholds were determined using a SOMEDIC 
MSA100 thermal stimulator (SOMEDIC AB, Hörby, Sweden) using a fluid cooled 
Peltier element thermode measuring 25 x 50mm. Base line temperature 320C; ramped 
stimuli at 10Cs-1 using method of limits. Threshold values of cold detection (CDT) and 
warm detection (WDT) were first determined in triplicate. A thermal sensory limen of 
alternating warm and cold stimuli determined the presence of paradoxical heat 
sensations to cold stimuli (PHS). 
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Mechanical detection threshold  
MDT was assessed using a standardized set of modified von Frey filaments (Optihair2-
Set, Marstock Nervtest, Schreisheim, Germany) exerting forces between 0.25 and 512 
mN. The contact area of the von Frey hairs with the skin was a rounded tip (0.5 mm in 
diameter) to avoid sharp edges that would cause nociceptor activation.  
 
Mechanical pain threshold 
MPT was assessed using custom-made weighted pinprick stimuli with fixed stimulus 
intensities (8, 16, 32, 64, 128, 256, 512 mN; flat contact area of 0.25 mm diameter; 
The PinPrick, MRC Systems GmbH, Heidelberg, Germany). 
 
Mechanical pain sensitivity and dynamic mechanical allodynia 
A stimulus-response function for MPS was determined using the same weighted 
pinprick stimuli as for mechanical pain threshold. Additionally, pain in response to 
light touch (DMA) was tested by light stroking with a cotton wisp (3 mN), a cotton 
wool tip fixed to an elastic strip (100 mN), and a brush (200–400 mN).  
 
Vibration detection threshold 
VDT was assessed with a Rydel–Seiffert tuning fork (128/64 Hz, 8/8 scale; 
Model:AB-125A,  A. Barthelmes & Co. GmbH, Tuttlingen, Germany) applied at 
suprathreshold vibration intensity over the subjects medial malleolus until the 
participant indicated the sensation of vibration had ceased. 
Pressure pain threshold 
PPT was assessed by using a pressure gauge device (FDN200, Wagner Instruments, 
Greenwich, CT, USA) with a probe area of 1 cm2 that exerts pressure up to 2000 kPa. 
  
QST data analysis 
QST data entry was into an Excel-based (Excel 2007, Microsoft USA) data analysis 
system (EQUISTA, Casquar GmbH Germany) provided by the DFNS. This system 
allowed entry of basic patient demographics and QST data. EQUISTA performed z-
score transformations of raw QST data values by comparing against normative 
reference data published by the DFNS (n=180 subjects, bilateral assessment of 560 test 
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areas; Magerl et al., 2010). The DFNS normative reference data is age, gender and 
anatomical test site matched. The mathematical transformation of QST data to z-scores 
has been described elsewhere in detail (Rolke, 2006) 
 
Heat suprathreshold nociceptive testing 
The DFNS protocol is largely threshold based, but includes a stimulus response 
function for detection of dynamic mechanical allodynia. However, it does not include 
such a function for thermal stimuli. This was considered necessary by the supervisor of 
this thesis (A. S. C. Rice) on the basis of his clinical observations from employing 
QST for routine clinical diagnosis of HIV-SN for several years. This includes HPT, 
and sometimes WDT, often being above the range the maximum temperature (> 500C) 
in the DFNS protocol and that hyperpathia is reported once threshold was reached. 
Therefore, after completion of the standard DFNS QST protocol, we conducted an 
additional bespoke heat suprathreshold testing protocol designed in collaboration with 
Prof Didier Bouhassira. Participants were subjected to 14 suprathreshold heat stimuli 
of 2s duration each in a temperature range between 440C and 520C, at 20C intervals 
(Supplemental Document 3: Heat Suprathreshold Protocol). During each stimulus, 
patients recorded pain experienced using an electronic visual analogue scale (eVAS) 
transducer (SENSEbox™ 450-010, SOMEDIC AB, Sweden). The anchors used were 
0mm - ‘No Pain’ and 100mm - ‘Maximum pain imaginable’. The protocol ensured that 
each temperature was tested twice, in a fixed, but random order to prevent participants 
anticipating stimulus temperatures. All the patient responses for QST were recorded in 
the QST CRF (Supplemental Document 4: QST CRF). 
 
Hierarchical cluster analysis  
The extent to which specific groups of participants with similar QST profiles also 
associate according to other measures was tested using hierarchical cluster analysis.  
DAISY function of R (version 2.1.2; R Foundation for Statistical Computing, Vienna, 
Austria; http://www.r-project.org/) was used to calculate a distance matrix based on 
Gower’s general dissimilarity coefficient. Binary variables were treated as asymmetric. 
Ward’s method was applied to perform a hierarchical cluster analysis on the distance 
matrix. In the resulting dendrogram, an arbitrary separation threshold was set so that 
the resulting clusters would not include fewer than 10% of the total participants. 
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Structured Neurological Examination (SNE) 
 
A comprehensive structured upper and lower limb neurological examination was 
devised to detect clinical signs of a peripheral neuropathy. The examination was 
performed on each patient and included assessment of: light touch and pin-prick 
sensation, joint position proprioception, vibration perception, deep-tendon reflexes, 
muscle wasting and motor power (Supplemental Document 5: Structured Neurological 
Examination).  
 
Sympathetic nervous system function was examined by testing for the presence of 
orthostatic hypotension, as assessed by measuring lying and standing blood pressure in 
accordance with established protocols (The Consensus Committee of the American 
Autonomic Society and the American Academy of Neurology, 1996). Lying and 
standing blood pressures were each measured in triplicate using a non-invasive blood 
pressure measuring system (Patient Transport Monitor HP M1275A, Hewlett-Packard, 
USA). Lying blood pressures were measured first, following which the subject was 
asked to stand for a timed three minutes after which standing blood pressures were 
measured. Orthostatic hypotension was determined to be present in subjects in whom 
either at least a 20mmHg reduction in systolic or a 10mmHg reduction in diastolic 
blood pressure was observed. 
 
Intra-epidermal nerve fibre density testing (IENFD) 
 
The determination of IENFD in skin biopsies is a validated and sensitive diagnostic 
tool for the assessment of small fibre neuropathies including HIV-SN (Griffin et al., 
2001; Lauria et al., 2005, 2010; M. Polydefkis et al., 2002; Michael Polydefkis, 2006). 
Punch biopsies of skin were taken immediately after the completion of QST. Biopsies 
were taken in accordance with the consensus document produced by the European 
Federation of Neurological Societies/ Peripheral Nerve Society Guideline (Lauria et 
al., 2005, 2010) on the utilization of skin biopsies in the diagnosis of peripheral 
neuropathies. Following the local infiltration of tissues with 1% lidocaine and under 
sterile conditions, skin biopsies were taken from a site 10cm proximal to the lateral 
malleolus with a disposable 3mm punch biopsy circular blade (Stiefel Laboratories 
Inc/ GSK Plc NC, USA).  
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The freshly harvested biopsies were fixed for 12 to 24 hours in 2% paraformaldehyde/ 
lysine/ periodate (PLP) fixative at 4°C and rinsed with 0.08% Sorensen’s phosphate 
buffer. Samples underwent cryoprotection with 15% and then 30% sucrose solutions 
for 24 hours each. Samples were then embedded in OCT (Fisher Scientific UK Ltd), 
snap-frozen by submersion in liquid nitrogen and stored at -20oC. Each biopsy was cut 
into 50μm sections using a sliding microtome. Immunohistochemistry for PGP 9.5 
(Ultraclone Ltd, Isle of White, UK; dilution 1:15000) was performed on sections using 
the immunoperoxidase method. Sections from each patient were processed in two 
separate staining runs to eliminate the risk of tissue loss and to ensure staining quality. 
All sections were allocated an individual code and three sections per subject were 
selected randomly to undergo analysis of IENFD using random sequences generated 
by http://www.random.org/. 
 
IENFD was assessed using a double bright-field microscope at 40× magnification 
using established counting rules (Lauria et al., 2005, 2010). The two IENFD assessors 
(M. R. D. Brown and J. D. Ramirez) underwent instruction and technical validation in 
IENFD assessment at a clinical diagnostic laboratory run by Dr I. Bodi. The study 
biopsy samples were coded, so that the assessors were unaware of the participant’s 
neuropathy status. For the study materials, each assessor independently determined 
IENFD values on three biopsy sections for each participant; the resulting mean value 
was used. Inter-observer Pearson’s product-moment correlation co-efficacies were 
determined for all the samples between the two microscopists; in addition intra-
observer reliability scores were also determined for 20 of these study sample selected 
randomly (http://www.random.org/). 
 
In accordance with previously published data, IENFD values below 7.63 fibre/mm 
were considered to be abnormal (Bakkers et al., 2009). This value has been shown to 
be associated with a specificity of 90% and sensitivity of 82.8% for the diagnosis of 
small fibre neuropathies (Devigili et al., 2008). 
 
Clinical Electrophysiology testing 
Electrophysiological data were extracted where available from the electronic hospital 
record of participants who had had lower limb electrophysiology clinical tests as part 
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of their routine medical care. This clinical data was evaluated for peripheral 
neuropathies by an experienced neurologist (D. L. H. Bennett) who was blinded to the 
peripheral neuropathy status of the participants evaluated. 
Neuropathy Screening and Severity Tools 
The Brief Peripheral Neuropathy Screen (BPNS) 
The Brief Peripheral Neuropathy Screening tool was developed to detect HIV-SN and 
has been used in several studies of HIV-SN (Affandi et al., 2008; C L Cherry et al., 
2009; Catherine L Cherry et al., 2008, 2005; Wright et al., 2008). The BPNS was 
designed to be utilised by non-specialist medical personnel for the detection of HIV-
SN and consists of a set of questions relating to patient reported symptoms of a 
peripheral neuropathy and a brief examination of the distal lower limb vibration 
perception and deep tendon reflexes. The sensitivity and specificity of the BPNS has 
been measured on several occasions, most notably by Simpson et. al, 2006 in a group 
of 101 subjects: sensitivity 73% and specificity of 68% (D M Simpson et al., 2006). 
The subjective elicited symptoms questions ask patients to report (i) the presence of 
pain, aching, burning in the feet and/or legs and (ii) the presence of ‘pins and needles’ 
and numbness in feet and/or legs. Symptom severity is scored on an 11-point Likert 
scale 0 (absent) to 10 (severe). The total response is then graded Grade 0 (score 0), 
Grade 1 (score 1 -3), Grade 2 (score 4 – 6), Grade 3 (score 7-10). 
The lower limb examination consists of vibration perception evaluation using a 128 Hz 
tuning fork maximally struck and placed on the top of the distal inter-phalangeal (DIP) 
joint on one great toe. The time for a patient to lose vibration perception is graded: 
Grade 0 - >10 sec, Grade 1 - felt for 6 -10 sec, Grade 2 - felt for 5 sec or less, Grade 3 - 
no perception of vibration. Ankle reflexes are assessed relative to knee reflexes and 
graded: Grade 0 - absent, Grade 1 - hypoactive, Grade 2 - normal, Grade 4 - clonus. 
Subjects are considered to have HIV-SN if they have at least one symptom and either 
reduced or absent vibration sensation or ankle reflexes using the BPNS as revised by 
Simpson et al 2006 (D M Simpson et al., 2006). 
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The Toronto Clinical Scoring System (TCSS) 
The TCSS was developed as a screening tool for diabetic peripheral neuropathy (B. a 
Perkins, Olaleye, Zinman, & Bril, 2001). Subsequent studies validated its utility in 
reflecting diabetic neuropathy severity, its correlation with clinical 
electrophysiological measures and microscopic morphological changes in peripheral 
nerve biopsies (Bril & Perkins, 2002) . The TCSS utilises a simplified neurological 
examination assessing peripheral sensory perception, deep tendon reflexes, and the 
presence of neuropathy symptoms.  
Sensory testing is performed on the first toe for: pinprick sensation using a Neurotip™ 
(Owen Mumford, Oxford U.K.); temperature discrimination (warm and cool water 
filled test tubes); light touch 10g monofilament and vibration with a maximally struck 
128Hz tuning fork; position and rated as normal or abnormal, 0 or 1 point respectively. 
Scores range from 0 to a maximum of 19. 
Deep tendon reflexes scores are graded as loss - 2, reduced -1 and normal - 0 for each 
side. The presence of each following neuropathy symptom scores 1 point: pain, 
numbness, tingling and weakness in the feet; the presence of similar upper limb 
symptoms and the presence of unsteadiness on ambulation. 
The Utah Early Neuropathy Scale (UENS) 
The UENS is a physical examination scale developed specifically for the detection of 
early, sensory predominant, diabetic polyneuropathy (Singleton et al., 2008). The 
UENS emphasis is on the severity and spatial distribution of pin sharp sensation loss in 
the lower limb. The scale was developed and validated in a population with early 
diabetic peripheral neuropathy.  
The UENS assesses sharp sensation in the lower leg relative to an unaffected portion of 
skin. A Neurotip™ pin (Owen Mumford, Oxford U.K.) is applied to the dorsum of the 
first toe and, working centripetally in 2cm increments, the subject is asked at each 
application if they feel “any sharpness” and if they do “is it as sharp as they would 
expect?” This is performed on both lower limbs. The lower limbs are divided into 6 
regions for testing; 2 points are scored for each region in which the subject fails to feel 
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any sharpness. This is conducted and scored on both lower limbs. One additional point 
is scored for each additional region in which the pin feels less sharp than expected. 
Vibration is tested using a 128Hz tuning fork maximally struck and applied to the 
dorsum of the great toe at the interphalangeal joint.  
The UENS has also been correlated with data from electrophysiological and QST 
testing (Singleton et al., 2008). Moreover, the UENS has recently been used in a small 
HIV-SN population, where it was shown to correlate with autonomic dysfunction 
measures (quantitative sudomotor axon reflex testing) and pain severity, but it was not 
validated in the diagnosis of HIV-SN (Boger et al., 2012). 
Pain, sleep disturbance, quality of life and psychological co-morbidity measures  
Participants were given a questionnaire pack to complete and return to the 
investigation centre following their clinical assessment appointment.  
7-day Pain diary 
Patients were also asked to keep a pain diary for seven days, recording pain at 8am and 
8pm daily on an 11-point Likert scale with 0 being ‘no pain’ and 10 the ‘worst pain 
imaginable’.  
Brief Pain Inventory (BPI) 7-item pain interference sub-scale  
Pain related interference in activities of daily living was assessed using the 7-item Pain 
Interference Sub-scale of the Brief Pain Inventory (BPI-PIS; Cleeland & Ryan, 1994). 
The BPI-PIS assesses pain interference within 7 domains: general activity, walking, 
work, relationships, mood, life enjoyment and sleep which participants score on a 11 
point Likert scale ranging from 0 to 10. The composite score was calculated as the sum 
of the 7 interference items. 
 
SF-36 instrument 
The short-form 36 questions (SF-36) is an established instrument used for the 
assessment of health-related quality of life (Ware & Sherbourne, 1992). Participants 
complete a questionnaire consisting of 36 questions. As per convention, SF-36 
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responses were regrouped, into 8 domains of physical functioning: physical 
functioning, role - physical, bodily pain, general health, vitality, social functioning, 
role - emotional, and mental health. SF-36 scores range from 0 to 100: representing 
extreme dysfunction/ symptom severity to optimal function respectively.  
Pain Anxiety Symptom Scale-20 (PASS-20)  
Pain-related anxiety was assessed with the Pain Anxiety Symptom Scale-20 (PASS-20; 
L. McCracken & Dhingra, 2002) which is a shortened version of PASS (M. L. 
McCracken, Zayfert, & Gross, 1992). It is comprised of 20 questions assessing four 
facets of pain-related anxiety: fearfulness of pain, cognitive anxiety, escape/avoidance, 
and physiological anxiety. Each subscale score ranges from 0 ‘no interference’ to 25 
‘maximum interference’. Additionally summation of the sub-scales provides a general 
measure of pain related anxiety. 
Amended Depression Anxiety Positive-Outlook instrument (DAPOS) 
We used the depression and anxiety sub-scales of the Depression Anxiety Positive-
Outlook (DAPOS) instrument (Pincus, Williams, Vogel, & Field, 2004). The DAPOS 
instrument was designed to measure mood in pain populations, and consists of 3 
subscales. The subscale for depression (DAPOS-D) contains 5 items with scores 
ranging from 5 to 25, indicating normal mood to severe depression. The subscale for 
anxiety (DAPOS-A) contains 3 items, which ranges from 3 to 15 (no anxiety to 
maximal anxiety). 
 
The Pain Catastrophizing Scale (PCS) 
Pain Catastrophizing Scale assesses the cognitive process by which pain is seen as an 
extreme threat and from which the patient suffers exaggerated negative consequences 
(Osman et al., 1997). The PCS questionnaire consists of 13 statements of descriptions 
of pain experiences. Respondents are asked to indicate whether they agree with these 
statements by using a 5-point rating scale scored from 0 (not at all) to 4 (always). A 
high total score indicates a high level of pain catastrophizing. The instrument 
comprises three dimensions: rumination, magnification and helplessness. Rumination 
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refers to the patients’ inability to apart the pain from his mind; magnification expresses 
the exaggerated cognitions of pain as a threat and hopelessness is the estimation that 
the patient cannot do anything to influence in his pain. 
Insomnia Severity Index (ISI) 
To assess the prevalence of sleep dysfunction we used the Insomnia Severity Index 
(ISI; Bastien, Vallières, & Morin, 2001). The ISI was specifically designed to assess 
insomnia and is a brief self-report instrument, which measures a patient’s perception, 
subjective symptoms and consequences of their insomnia. Its content corresponds, in 
part, to the diagnostic criteria of insomnia. The ISI comprises of seven items assessing 
the severity of sleep-onset and sleep maintenance difficulties, satisfaction with sleep 
patterns, interference with daily functioning, noticeability of impairment due to sleep 
dysfunction and the degree of distress experienced by the patient. 
Case definition of HIV-SN for PINS-HIV; rationale and implications for the study. 
There is no gold standard test for the presence of HIV-SN (Brew, 2003; Catherine L 
Cherry et al., 2005). This lack of gold standard for HIV-SN and other predominately 
small fibre neuropathies, has been identified as a factor hindering the progress in 
understanding HIV-SN (Evans et al., 2008) and small fibre neuropathy 
pathophysiologies per se (Devigili et al., 2008). 
The most frequently employed neuropathy screening instruments used to assess the 
presence of HIV-SN, were the Total Neuropathy Score (TNS) and Brief Peripheral 
Neuropathy Screen (BPNS) (Catherine L Cherry et al., 2008; Maritz et al., 2010; J 
Robinson-Papp et al., 2010; D M Simpson et al., 2006; Smyth et al., 2007). These 
instruments were conceived for use in larger epidemiological studies and are designed 
to be brief and require little specialist equipment or training to use. These screening 
tools focus predominately on large sensory nerve fibre function, such as vibration 
sensation and deep tendon reflexes. Consequently these scales may be less sensitive to 
the small fibre dysfunction characteristics of HIV-SN (Boger et al., 2012) which have 
been hypothesized to be important in the early pathogenesis of HIV-SN (Catherine L 
Cherry et al., 2005; D. R. Cornblath et al., 1999) which is an area of interest in the 
PINS-HIV study. The use of these established screening instruments would potentially 
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lead to an over representation of participants with later, established HIV-SN and fail to 
diagnose early HIV-SN. 
Other diagnostic tests such as nerve conduction studies, (R. J. Barohn et al., 1996; P. 
Y. Chavanet et al., 1988; P. Chavanet et al., 1989; Fuller, Jacobs, & Guiloff, 1991; 
Husstedt et al., 2000; Jakobsen, Smith, Gaub, Helweg-Larsen, & Trojaborg, 1989; 
Malessa et al., 1996; T. Smith, Jakobsen, Gaub, Helweg-Larsen, & Trojaborg, 1988) 
QST testing, (Bouhassira et al., 1999; Huengsberg, Winer, Ross, & Shahmanesh, 1998; 
Tagliati, Grinnell, Godbold, & Simpson, 1999; Winer et al., 1992) and IENFD 
quantification (D N Herrmann, Griffin, Hauer, Cornblath, & McArthur, 1999; Holland 
et al., 1997; McCarthy et al., 1995; Pittenger et al., 2004; M. Polydefkis et al., 2002; 
Michael Polydefkis et al., 2004) may be abnormal in the context of HIV-SN. However, 
normal results to these tests occur frequently in patients with clinically apparent HIV-
SN (M. Polydefkis et al., 2002; Tagliati et al., 1999; Winer et al., 1992). Similarly, 
some subclinical abnormalities, not necessarily indicative of neuropathy 
pathophysiology are also described in these tests (R. J. Barohn et al., 1996; Bouhassira 
et al., 1999; P. Y. Chavanet et al., 1988; P. Chavanet et al., 1989; Fuller et al., 1991; 
David N Herrmann et al., 2004; Huengsberg et al., 1998; Husstedt et al., 2000; 
Jakobsen et al., 1989; Malessa et al., 1996; T. Smith et al., 1988; Tagliati et al., 1999).  
As no single testing paradigm could be identified that would have an acceptable 
reliability, sensitivity and specificity for the aims of the PINS-HIV study, a novel 
composite definition was constructed in discussion with the collaborating neurologist. 
The PINS-HIV study used a definition of HIV-SN requiring ≥2 out of the following 
triumvirate:  
 Clinical signs of distal neuropathy on the Structured Neurological Exam (SNE). 
 ≥2 abnormal QST findings using DFNS protocol. 
 Intra-epidermal-nerve-fibre-density of ≤7.63 fibres/mm on skin biopsy examination. 
Such a composite definition has been previously proposed for use in the study of other 
small fibre neuropathies, but has not been used in studies of HIV-SN (Devigili et al., 
2008). 
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By using three different test modalities and requiring more than one ‘positive’ finding 
for defining HIV-SN, it was hoped to negate many of the shortcomings of the 
individual tests if used in isolation. 
A limitation of using this method is that there is potential for a circular argument for 
some of the outcome measures of interest in the study, which partly rely on the 
diagnostic tests used in the case definition. To explore this potential problem a post-
hoc analysis of altering the case definition was planned to investigate the impact on 
individual participant neuropathy diagnosis designation (Table 3.10). A further 
exploration of using different definitions of HIV-SN on the QST results has also been 
conducted post-hoc below (Table 3.11, 3.12 and Figures 3.2.a,b,c and d). 
Sample Size Calculation 
At the time of the study there were few data available regarding the diagnostic value 
for HIV-SN for each of the two primary measurements of interest (QST and IENFD) 
on which to base a sample size calculation. Nevertheless, such a calculation in relation 
to these measures has been performed in order to guide study conduct (t test for power 
calculation, Sigma v 3.5, Systat Software Inc). 
For QST the ΔWDT data for HIV positive patients versus healthy controls from Martin 
et al were used (Martin et al., 2003). This calculation revealed a minimum sample size 
of 11 was required per group for a power > 0.8 (Power 0.828; Difference in Means 4.3; 
Standard Deviation 3.3; α 0.05). 
For IENFD data for patients with small fibre neuropathies verses healthy controls from 
Nebuchennykh et al were used (Nebuchennykh, Løseth, Lindal, & Mellgren, 2009). 
This calculation revealed a minimum sample size of 16 was required per group for a 
power > 0.8 (Power 0.816; Difference in Means 4.7; Standard Deviation 4.5; α 0.05). 
However, because of the uncertain assumptions inherent in such calculations a 
minimum group size of 25 was used. 
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Results 
Participants  
Between July 7th 2009 and January 25th 2011 66 volunteers who were living with HIV 
were recruited to participate in the study. They were all receiving routine clinical care 
for their HIV disease as ambulatory patients attending the St Stephen’s Centre out 
patients department, Chelsea and Westminster Hospital NHS Foundation Trust, 
London, United Kingdom 
All 66 participants attended the clinical assessment appointment. Two participants (one 
from the HIV-SN and the other from the HIV-No SN group) produced only partial 
QST datasets (missing thermal parameters) due an isolated equipment problem that 
was resolved. These subjects were excluded from the subsequent thermal parameter 
QST data analysis. 
IENFD were determined on 57 participants out of the total 66; 6 participants did not 
consent to a skin biopsy (4 from the HIV-No SN and 2 from the HIV-SN group), one 
participant from the HIV-SN group was anticoagulated with warfarin and so a skin 
biopsy was contra-indicated.  Two samples (one from each group) were of insufficient 
quality to allow IENFD determination. Participants with missing IENFD data were not 
included in the IENFD data analysis. 
Demographics 
Participant demographic data are presented in Table 3.1. The groups were evenly 
matched in terms of demographic and related clinical factors. The majority of 
participants were white (86.4%), male (86.4%) and middle aged (mean 49.23 yrs SD 
8.78), broadly reflecting the patient population of the highly resourced United 
Kingdom recruitment centre in the current cART era (personal communication Dr 
Marta Boffito and Dr David Asboe). Using the triumvirate criteria for HIV-SN 
diagnosis the study group was divided into ‘HIV-SN’ and ‘HIV-No SN’ groups. 
Twenty-eight (42.4%) of participants were determined to have HIV-SN and 38 
(57.6%) to have HIV-No SN. Twenty-one (75.0%) of the 28 HIV-SN patients 
complained of a painful peripheral neuropathy. No statistically significant difference 
 74 
was seen between the HIV-SN and HIV-No SN groups for sex, ethnicity, height, or 
weight. There was also no difference between the groups in terms of age, height and 
years since HIV diagnosis. 
There was also no difference between the two groups for the frequency of co-
morbidities which might potentially affect the peripheral neuropathy status of 
participants; diabetes, hepatitis B and C, syphilis or exposure to chemotherapy agents. 
Quantitative Sensory Testing healthy control participants 
Healthy control data was collected to meet the DFNS group’s requirements for 
investigation centre quality assurance, and to provide normal values for suprathreshold 
heat responses. To fulfil DFNS requirements 36 healthy controls were recruited with a 
mean age of 34.60 yrs of age (SD 9.45) of which 21 (58.3%) were male. These 
participants underwent the DFNS QST protocol after which the additional 
suprathreshold heat testing was conducted on each. 
Anti-retroviral therapy history 
ARV therapy histories of the participants are presented in Table 3.2. Only 2 
participants (3%) had no previous exposure to ARVs; both were in the HIV-No SN 
group. The majority had previous ARV exposure and were all still currently receiving 
cART (n=64, 97%). No statistical difference was observed between the two groups for 
either, individual agents or classes of agents in relation to exposure or mean years 
exposed. There was also no difference between the two groups for the total number of 
‘drug years’ a patient received a class of agent for, or the maximum number of 
consecutive years of exposure to a given drug class (data not shown).  
There was no difference between the two groups for exposure to NRTI agents. 
Between 52% and 71% of participants had been exposed at some point to neurotoxic 
“dNRTIs” and the average exposure was about 12 years. This was independent to the 
duration of time since HIV diagnosis. The groups were also matched for exposure to 
the potentially neurotoxic protease inhibitor indinavir (Catherine Louise Cherry et al., 
2012; Ellis et al., 2010; Pettersen et al., 2006; Smyth et al., 2007) with 13-32 % of 
subjects having been exposed to the drug for an average of about 13 years. 
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Quantitative Sensory Testing results 
Distribution of mean QST z-scores across groups  
Mean z-score values for HIV-No SN and HIV-SN groups (Figure 3.1, Figure 3.3 and 
Table 3.3) showed a loss of sensory function for all three thermal sensory QST 
parameters CDT, WDT, and TSL compared to DFNS values, indicating a degree of 
thermal detection hypothesia (p<0.05 Kruskal-Wallis, Dunn’s post-hoc; HIV-No SN 
and HIV-SN and HC groups). This general shift across all thermal parameters towards 
hypothesia was largest in the HIV-SN group. A similar shift in thermal nociceptive 
parameters was not seen, with only HPT demonstrating a shift in mean z–scores 
towards loss of function. Mean z-scores for CPT were similar to DFNS control values 
in both groups. 
Mechanical detection parameters also showed a shift of the group mean towards loss of 
function in the HIV groups; again, the largest difference was observed in the HIV-SN 
group (see Figures 3.1 and 3.3 and Table 3.3). This was particularly marked in the 
HIV-SN group for MDT and VDT mean values compared to the HIV-No SN, HC and 
DFNS control values (p<0.05 Kruskal-Wallis, Dunn’s post-hoc). MDT and VDT were 
the only QST parameters that showed a mean group value outside of the DFNS defined 
normal range.  
Whilst the difference in mean WUR was small in the HIV-SN compared to the other 
groups it had a large SD value (1.66) suggestive of a high degree of heterogeneity for 
this parameter within the HIV-SN group. This heterogeneity was evident in the scatter 
plot of WUR for HIV-SN, where a small group of 4 HIV-SN participants (14.3%) 
number showed high (gain of function) z-scores for WUR (p <0.05 Chi squared test of 
association compared to HIV-No SN group). 
Mean healthy control QST participant data closely matched that expected by DFNS 
control values for 12 of the 13 DFNS QST parameters (see Table 3.3). This is 
indicated by the fact that the z-transformed QST mean values in the healthy control 
group are all close to zero, with standard deviations of near to one or less. Healthy 
control MPS values showed a slight shift in mean values, with 5 (13.9%) participants 
more than expected showing abnormal values compared to DFNS healthy control data.  
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Frequency of individual QST measure abnormalities: loss and gain of sensory function.  
The frequency of abnormal QST values in each group are shown in Figure 3.4 and 
Table 3.3. The majority of abnormal parameters were loss of sensory function in any of 
the QST parameters with 34.2% and 85.7% in the HIV-No SN and HIV-SN groups 
respectively. A smaller number of participants in the HIV-No SN and HIV-SN group 
showed gain of function in any parameter: 26.3% and 28.6% respectively. – but this 
was similar to the Healthy control groups at 30.6%, there was no statistical difference 
between all three groups. 
The most frequent sensory abnormalities seen in the HIV-SN group were loss of MDT 
and VDT both of which were independently absent in 50% of the HIV-SN subjects, 
with 32.14% demonstrating the loss of both. In contrast, the healthy control and HIV-
No SN group showed a loss of MDT in only 5.6% and 5.3%, and VDT in 5.6% and 
10.5% respectively. 
Within the thermal sensory parameters the HIV-SN participants showed a loss of CDT 
function (28.6%) compared to HIV-No SN group (5.3%), most frequently followed by 
WDT and TSL (14.3%, 2.6% in both HIV groups). Loss of HPT was the most frequent 
abnormal thermal nociceptor parameter in the HIV-SN group (32.1%) and in the HIV-
No SN group (7.9%). No participants in either HIV group displayed abnormalities of 
CPT. The presence of PHS was considered a loss of thermal discrimination and 
therefore a loss of sensory function (Rolke, 2006). PHS phenomena were observed in 
7.9% and 14.3% of the HIV-No SN and HIV-SN groups respectively.  
The presence of gain of function in QST parameters was rare across all groups, but was 
seen most frequently in the mechanical WUR parameter, with 14.3% of HIV-SN 
patients demonstrating it, compared to only 5.3% and 5.6% of the healthy control and 
HIV-No SN groups respectively (p<0.05 Chi squared test of association against HIV-
No SN group). No participants in any of the groups were found to have DMA. 
Patterns of loss and gain of sensory function 
We utilized the DFNS coding system (Maier et al., 2010) to display combinations of 
sensory dysfunction in HIV-SN (Table 3.4). Accordingly, a value for a QST parameter 
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within the normal DFNS reference range was designated ‘0’; the presence of thermal 
hypoesthesia (i.e. loss of WDT or CDT) was designated as L1; and the presence of 
hypoesthesia to mechanical modalities (i.e. loss of MDT or VDT) was designated L2. 
Gain of sensory function to thermal modalities was designated G1 and gain of sensory 
function to mechanical modalities designated as G2. When both thermal and 
mechanical abnormalities were present they were designated as L3 and G3 
respectively. 
HIV-SN abnormal QST parameters were dominated by loss of sensory function. The 
majority of HIV-SN participants (85.7%) had at least one abnormality on QST testing, 
and had, at a minimum, the loss of one sensory parameter. Different combinations of 
sensory loss and gain did occur across the HIV-SN group, however the majority 
involved just sensory loss (L1+L2+L3: 78.6%). Indeed, the most frequent combination 
was the loss of at least one thermal and one mechanical QST parameter in 42.9% of 
participants (L3G0). HIV-No SN participants demonstrated loss or gain of thermal 
modalities in isolation (L1 or G1; see Table 3.4). The second most frequent 
combination was loss of just mechanical sensory modalities (L2G0: 21.4%).  
Suprathreshold heat testing 
Figure 3.5 displays the cumulative mean pain VAS responses to suprathreshold heat 
stimuli from 48oC to 52oC for the three groups: healthy controls, HIV-No SN and HIV-
SN groups. Health control patients had an earlier take off in pain VAS responses – i.e. 
this occurred at lower temperatures, however at higher suprathreshold temperatures 
there was little difference in the VAS responses elicited from all the three groups 
tested. No statistically significant difference was seen between the three groups, or in 
the painful HIV-SN subgroup of HIV-SN (not shown) for pain response at any 
suprathreshold temperature. 
Hierarchical cluster analysis of QST data 
The results of hierarchical cluster analysis of individual participant’s DFNS QST data 
did show a tendency for HIV-SN patients to cluster according to neuropathy and pain 
status (see Figure 3.6). A distinct cluster of 25 subjects, containing 20 (71.4%) of the 
HIV-SN participants, of whom the majority (80%) complained of pain symptoms, was 
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observed. No other discernible clusters were found relating to any other participant 
outcome measures examined using hierarchical cluster analysis of QST data (Figure 
3.6). 
Intra Epidermal Fibre Densities (IENFD) 
A total of 57 skin punch biopsy samples were available for IENFD measurement from 
the 66 participants (see above for details). Figure 3.7 shows representative images of 
two participants, one with normal fibre counts (Figure 3.7A) and the other with 
reduced IENFD counts (Figure 3.7B). 
The associated intra-observer correlation co-efficients for 20 randomly selected 
samples for quality assurance exercise was 0.88 (J. D. Ramirez) and 0.89 (M. R. D. 
Brown), both of which are high. A high inter-observer Pearson’s product-moment 
correlation co-efficient of 0.93 was determined between the two microscopists for all 
study samples (n=55).  
The median values of IENFD for HIV-No SN group was 9.2 fibres/mm (range 1.7 - 
14.4 fibres/mm) compared to 6.3 fibres/mm (range 0.7 - 12.4 fibres/mm) for the HIV-
SN group (p<0.001). In accordance with previously published literature, an IENFD 
value of < 7.63 fibres/mm was taken as being abnormal (Lauria et al., 2005); this was 
seen in 8 subjects (21.1%) of the HIV-No SN and in 17 subjects (60.7%) of the HIV-
SN group (p<0.05) with an associated sensitivity and specificity of detecting HIV-SN 
in isolation of 61% and 79% respectively. 
Table 3.5 shows Pearson’s correlation coefficients for individual QST parameters and 
IENFD. Little correlation between the measured QST parameters and IEFND can be 
seen.  
As would be expected, IENFD was inversely correlated to the severity of the 
peripheral neuropathy as measured by the TCSS instrument (r=-0.343, 95%CI -0.56 to 
-0.88; p<0.01). 
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Electrophysiological testing 
Suitable lower limb electrophysiology clinical studies were available for 18 (27.3%) of 
the 66 HIV positive participants; 5 subjects (13.2%) in the HIV-No SN group and 13 
subjects (46.4%) in the HIV-SN group. Within the HIV-SN group, nine of the thirteen 
participants (64.3%) were diagnostic of an axonal peripheral neuropathy in comparison 
to only one in the HIV-No SN group. 
Pain and patient reported symptoms 
Results of the structured patient symptom and medical history interview, and 7-day 
pain diary are presented in Table 3.6.  
More patients reported experiencing pain in their hands and/or feet in the HIV-SN 
compared to HIV-No SN (75% vs 28.95% respectively; p<0.001). The mean 7-day 
pain score for patients experiencing pain was also greater in the HIV-SN group (5.65, 
SD 1.76) compared to the HIV-No SN group (2.8, SD 2.34; p<0.001). The mean 
number of years from HIV diagnosis and the mean duration of pain were similar in the 
two groups. Although there was no difference between groups in the reporting of ‘pins 
and needles’, the reporting of ‘numbness’ in feet and/or hands was more frequent in 
the HIV-SN group (75%) compared to the HIV-No SN group (36.8%; p<0.05).  
More participants with HIV-SN compared to those without HIV-SN, reported suffering 
from symptoms of postural hypotension (50% vs 24.6% respectively; p <0.01), 
however participants’ reported symptoms of orthostatic hypotension correlated to 
measured orthostatic hypotension in only 33.3% of HIV-No SN and 7.1% of HIV-SN 
participants. No difference was seen in measured orthostatic hypotension between the 
two groups (14.8% vs 18.4% for HIV-SN and HIV-No SN groups respectively; 
p=0.702).  
Patients reported symptoms of urinary dysfunction more commonly in the HIV-SN 
group (42.9%) compared to participants in the HIV-No SN (15.8%; p<0.05). The 
frequency of participants reporting erectile dysfunction and nocturnal diarrhoea were 
similar for both groups respectively (Table 3.6) 
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Psychological co-morbidity, sleep disturbance and health related quality of life. 
The return of questionnaires and completion of individual scores within each group are 
shown in Table 3.7. Of the 66 participants, 57 (86.3%) returned completed 
questionnaire booklets to the test centre for analysis. Results from the psychological 
and insomnia instrument battery are presented in Table 3.8. 
Pain interference and health related quality of life 
As expected the Brief Pain Interference (BPI) subscale mean total score was 
significantly higher in the painful HIV-SN group (46.11, SD 13.69) compared to the 
HIV-No SN group (15.20, SD 16.22; p<0.001; see Table 3.8). The high scores present 
in the painful HIV-SN group indicate that participants’ pain has an important 
detrimental impact on their day to day living and their quality of life.  
The SF-36 data further emphasises this point, showing participants with painful HIV-
SN displayed significantly more morbidity when compared to the HIV-No SN group 
across all of the domains of the SF-36 (Table 3.8). In particular HIV-SN patient’s 
physical functioning (RP), perceptions of their physical selves (RP), general vitality 
(VT) and social functioning (SF) were dramatically poorer in the participants in the 
painful HIV-SN group compared to patients in the HIV-No SN group. 
Sleep dysfunction 
Analysis of data from the self-report ISI instrument indicated that both groups suffered 
from mild sub-clinical insomnia. However, at the group level there was no independent 
effect of HIV-SN in this regard. Nevertheless, at the individual level, more participants 
in the painful HIV-SN group reported degrees of sleep disturbance equating to clinical 
insomnia (ISI ≥15): 13 participants (68.4%), with 7 (36.8% overall) of these suffering 
severe insomnia (ISI ≥ 22). In contrast, 7 participants (22.6%, p <0.001) of the HIV-
No SN group suffered from clinical insomnia, and 3 participants (9.7% overall, p 
<0.001) with severe insomnia (Table 3.8). 
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Depression, Anxiety and Catastrophizing 
Participants with painful HIV-SN were more depressed (11.21, SD 4.22 vs 8.38, SD 
4.10, p<0.05) and anxious (4.47 SD 2.97 vs 5.45 SD 2.89, p<0.05) as measured with 
the DAPOS instrument, than those in the HIV-No SN group (see Table 3.8).  
Overall, there was no difference between the groups with regards to the total PASS-20 
scores (see Table 3.8). However, differences were evident in some domains of the 
PASS-20. The HIV-SN group reported more features of cognitive impairment in 
response to pain compared to the HIV-No SN group (PASS-20 cognitive sub-scale - 
mean 8.45, SD 5.28 vs 14.95, SD 5.64 respectively; p < 0.001). There was more 
psychological anxiety and fear as measured with the PASS subscales in the painful 
HIV-SN group compared to the HIV-No SN group: physiological anxiety (9.21 SD 
7.54 vs 4.83 SD 6.45 respectively; p < 0.05) and fear (11.79, SD 6.75 vs 6.97, SD 7.11 
respectively: p < 0.05). 
Catastrophizing as measured using the PCS instrument revealed a significant 
difference in PCS total scores between the groups (see Table 3.8; 14.3, SD 11.81 in the 
HIV-No SN group compared to 23.74, SD 12.64 in the painful HIV-SN group; 
p=0.009). This difference was mostly attributable to a difference in the PCS 
helplessness sub-scale (6.03, SD 5.52 in the HIV-No SN group compared to 11.16, SD 
6.13 in the HIV-SN group; p=0.004). No statistically significant differences were seen 
in the other PCS sub-scores for rumination or magnification.  
Plasma lipid profiles, random glucose, BMI and waist-hip circumference ratios. 
A higher mean triglyceride plasma (TRG) concentration was measured in the HIV-SN 
group compared to the than the HIV-No SN group (see Table 3.9; 2.18mmol/l, SD 1.09 
vs 1.61mmol/l, SD 0.77 respectively; p <0.05). There was no significant difference 
between the two groups in statin drug use. Despite this difference in TRG 
concentrations we did not find a correlation between the severity of neuropathy (using 
the TCSS instrument) and plasma TRG concentrations (rs = -0.155 (-0.514 to 0.250); p 
= 0.439). No significant differences were found between the two groups for other 
plasma lipids, BMI or waist-hip circumference ratios, although all were the upper-end 
of normal (see Table 3.9). 
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Peripheral neuropathy screening and severity instruments: BPNS, UENS and TCSS.  
Mean scores were determined and ROC plots were generated for each of the three 
neuropathy screening instruments examined in the study. Optimal cut-off values for the 
diagnosis of HIV-SN in the study population were determined from these plots, giving 
equal weight for sensitivity and specificity.  
Using the standard BPNS scoring method (D M Simpson et al., 2006), which adds 
weight to the loss of deep tendon reflexes and vibration perception, the BPNS 
instrument shows a specificity and sensitivity in the detection of HIV-SN of 75% and 
79% respectively (p<0.001).For the ROC analysis the numerical component of the 
BPNS was used in its raw form, weighting sensitivity and specificity equally. A cut-off 
value of 19 was determined as optimal which was associated with a sensitivity and 
specificity of 76%. 
The mean TCSS values in the HIV-SN were higher when compared to those in the 
HIV-No SN group (9.26, SD 3.28 vs 3.36, SD 3.65 respectively; p<0.001). ROC 
analysis found a value of 8 provided the best accuracy in HIV-SN detection; 
sensitivity/ specificity 81%.  
The UENS median values were also significantly higher in the HIV-SN group when 
compared to the HIV-No SN group (11.26, SD 5.66 vs 3.64, SD 2.98 respectively; 
p<0.001). Following a ROC analysis a cut-off value of 7 was selected as providing the 
best accuracy in our study population. This provides a sensitivity and specificity of 
84% in detection of HIV-SN. 
Using the ROC plots for each instrument, AUC was used as a measure of accuracy; 
with a smaller AUC equating to greater accuracy. The instrument found to have the 
greatest accuracy was the UENS (AUC 0.91), followed by TCSS (AUC 0.86) and then 
the BPNS (AUC 0.69). 
Testing the HIV-SN triumvirate definition and the consequences of using 
different HIV-SN definitions. 
As this study’s case definition of HIV-SN used a triumvirate utilising QST, IENFD 
and a Structured Neurological Examination (SNE), we tested the consequences of 
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using different combinations of the triumvirate on the HIV-SN designation of 
participants in the study (see Table 3.10). Removal of QST and IENFD individually 
from the triumvirate resulted in sensitivity and specificity of 71%, 100% and 79%, 
100% respectively when compared to using the full triumvirate diagnosis. Not using 
QST in the diagnosis resulted in 8 participants (12.1%) having a different diagnosis; 
not using IENFD results in a change in 6 subject’s diagnosis (9.1%) and removal of 
SNE resulted in the largest number of diagnosis changes at 17 (25.8%).  
The criteria most effective in isolation is SNE - with a sensitivity and specificity of 
1.00 and 0.740 respectively, followed by QST, (0.786 sensitivity, 0.816 specificity) 
and IENFD (0.607 sensitivity, 0.790 specificity). 
Discussion 
Quantitative Sensory Testing  
To our knowledge, this is the first detailed profiling of the HIV-SN phenotype in a 
cART era population. This study has shown that the pattern of sensory nerve 
dysfunction that occurs in HIV-SN is profoundly heterogeneous. Across sensory and 
nociceptive mechanical and thermal modalities, the predominant picture was that of 
loss of sensory function; 86% of HIV-SN participants were observed to have a loss of 
function of at least one sensory modality. However the degree to which individual 
modalities were affected across the HIV-SN group did not correlate to either the 
symptoms experienced (including pain) or the severity of neuropathy. Equally, no 
single sensory QST parameter was found to have a useful diagnostic utility for HIV-
SN diagnosis in isolation.  
Unexpectedly it was the large fibre mediated modalities of MDT and VDT (both 
mediated by larger myelinated Aβ fibres) which were most frequently lost in HIV-SN 
(see Table 3.4; loss of 50% for each modality). Moreover 32% of HIV-SN participants 
demonstrated a loss of both MDT and VDT modalities together. HIV-SN has often 
been described to be a predominately small fibre neuropathy, i.e. affecting mostly 
small unmyelinated C and Aδ sensory fibres. Therefore, it would be expected that this 
would be reflected in QST testing as more in a loss of thermal detection thresholds 
(CDT and WDT) and an elevation in the heat pain threshold (HPT), as these modalities 
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are mediated by the smaller unmyelinated sensory fibres. Whilst these modalities are 
indeed affected on a group level (see Figures 3.2-3.3 and Table 3.3), HIV-SN mean 
CDT and WDT showed a significant reduction in function compared to both the HIV-
No SN and DFNS values. Individually only a smaller number of HIV-SN participants 
showed a large enough loss in function of these modalities to be considered as 
‘abnormal’ by the DFNS definitions used. As mechanical QST parameters are more 
often affected in HIV-SN, the inclusion of thermal QST parameters as part of 
diagnostic testing for HIV-SN would appear to not be necessary. This has significant 
resource implications, as the equipment involved in such thermal testing is, to date, 
expensive and not easily portable. Consequently the use of QST outside of well-
resourced research centres has been limited. VDT can be tested with an appropriate 
128Hz tuning fork and MDT with von Frey filaments, both of which are relatively 
inexpensive and do not require specialist training to use. 
Whilst the diagnostic limitations of electrophysiological methods for small fibre 
neuropathies is well know, this study shows the limitations of QST for the diagnosis of 
HIV-SN. Forteen per cent of participants determined to have HIV-SN by the 
multimodal definition used in this study did not demonstrate dysfunction of any of the 
QST modalities measured. This is broadly similar to an earlier DFNS study examining 
the QST phenotype of painful polyneuropathies (HIV- SN participants), which found 
17% of subjects that did not present QST abnormalities (Maier et al., 2010). 
An observation in routine clinical QST testing by the supervisor of this thesis (A.S.C. 
Rice) was that patients with HIV-SN appeared to express higher pain on the routine 
testing of heat pain thresholds (HPT). The heat suprathreshold testing protocol was 
designed to detect the presence of thermal hyperpathia in HIV-SN participants. No 
statistically significant difference was seen between the three groups (Healthy 
volunteers, HIV-No SN and HIV-SN) at any of the temperatures tested. The HC and 
HIV-No SN groups did have early takes offs of the VAS/ temperature stimulus 
response curves (see Figure 3.5), but at higher temperatures little difference was seen 
between the groups. A similar finding was seen in an earlier study, which employed an 
analogous heat suprathreshold protocol during the pre cART era (Bouhassira et al., 
1999).  
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This current study found no evidence of gain of function features of neuropathic pain 
for dynamic mechanical allodynia (DMA) or static mechanical hyperalgesia (MPS), 
but did find a small group (14%) of HIV-SN participants who demonstrated high wind-
up ratios (WUR) to pin-prick stimuli (discussed below). In contrast, the group of 
Bouhassira demonstrated mechanical hyperalgesia in HIV-SN (Bouhassira et al., 
1999), however, the current study did not replicate this finding. There are two potential 
reasons for this: firstly the DFNS QST protocol tests for mechanical hyperalgesia uses 
a method that is different to Bouhassira’s group; secondly, and more fundamentally, 
the HIV-SN participants examined in Bouhassira’s study were from the pre-cART era. 
It has been demonstrated that different risk factors for the development of HIV-SN 
operated in the pre-cART era to present day (e.g. CD4 counts, d NRTI drug exposure; 
Catherine Louise Cherry et al., 2012), consequently the HIV-SN phenotype might be 
substantially different now in the c-ART era. 
Simpson and collaborators found a raised pin-prick punctate hyperalgesia present in 
13% of HIV-SN participants screened for a large pregabalin efficacy RCT (D M 
Simpson, Scott, et al., 2010). This study measured the pain response to a single (non-
standardised) strength pin-prick stimulus to measure pin-prick hyperalgesia. In 
contrast, the DFNS protocol uses a stimulus pain response curve to different 
(standardised strength) pin-prick stimuli, consequently comparing the two measures is 
difficult. However one of the tests used in the DFNS QST protocol does exam the pain 
response to a single strength pin-prick applied multiple times to exam for the presence 
of wind-up phenomenon; and whilst not strictly the same, this is perhaps a more 
comparable test to the one used by Simpson and collaborators. Interestingly the current 
study’s sub-group of raised WUR in 14% subjects (n=4) in painful HIV-SN 
participants, is of similar proportion to the pin-prick hyperalgesia sub-group seen in 
Simpson and collaborators’ work (13%) and therefore the raised WUR sub-group 
might represent the same pin-prick hyperalgesia sub-group seen in the Simpson and 
collaborators’ study. The pin-prick hyperalgesia group of the Simpson and 
collaborators’ study is important as this group demonstrated a greater therapeutic 
response to pregabalin. Future studies would need to determine if these two findings 
indeed represent the same sub-group, as it would potentially have important 
mechanistic and therapeutic implications for HIV-SN and neuropathic pain per se.  
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As higher levels of catastrophization have been previously shown to correlate with the 
presence of wind-up phenomenon (Vase et al., 2011), a post-hoc analysis of 
catastrophization was undertaken for this high wind-up sub-group. It was found that 
this sub-group of participants demonstrated higher levels of catastrophization (PCS 
total=26.0 (IQR 22.5 - 31.5) vs the other participants, PCS total=2.0 (IQR 0 - 22.0); p 
< 0.05; Mann Whitney Rank Sum Test). A correlation between raised wind-up 
phenomena and catastophising traits has previously been seen in a study of an upper-
limb amputees with phantom limb pain, but this is, to our knowledge, the first time this 
has been shown in a painful peripheral neuropathy population. This is additionally 
interesting as it shows that wind-up and catastrophizing are associated in two very 
different forms of neuropathic pain, perhaps showing a common mechanism of 
interaction between spinal pain processing (wind-up) and higher centres 
(catastrophizing) in different types of neuropathic pain.   
The hierarchical cluster dendrogram of QST data (Figure 3.6) shows that the majority 
of the participants divide at a high level broadly into HIV-SN and HIV-No SN: 71% of 
all HIV-SN participants are contained within a cluster of 25 subjects. The hierarchical 
cluster analysis shows that HIV-SN neuropathy participants tend to cluster together. 
Interestingly participants with HIV-SN but no pain (n=7) were more evenly distributed 
and did not appear to associate with the HIV-SN dominant cluster or each other. This 
suggests that non-painful HIV-SN perhaps have different QST characteristics to 
painful HIV-SN. Whilst its difficult to say that this is a robust finding as the study was 
not powered primarily for such a hierarchical cluster analysis, the differences between 
painful and non-painful HIV-SN seen here suggest that this should be investigated by 
future larger studies. 
Intra-epidermal nerve fibre densities 
Mean IENFD counts were significantly lower in the HIV-SN group (9.2 fibres/mm vs 
6.3fibres/mm), and the severity of neuropathy was inversely correlated to IENFD. 
However the diagnostic utility of IENFD counts <7.63 fibres/mm can only be 
considered moderate at best with a sensitivity and specificity of 61% and 79% in 
isolation of detecting HIV-SN (Table 3.10). Consistent with several other studies, no 
convincing correlation was found between IENFD and sensory nerve fibre dysfunction 
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for individual QST parameters (Table 3.5), even in the small fibre modalities of CDT, 
WDT, HPT, MPT and PPT (Cruccu et al., 2010).  
Metabolic factors  
This study found significantly higher random plasma TRG concentrations in the HIV-
SN group compared to the HIV-No SN group. Whilst no correlation was identified 
between TRG concentrations and the neuropathy severity, this finding further 
underlines the emerging understanding in the literature that dyslipidaemia is important 
in the development of HIV-SN (Ances et al., 2009; Banerjee et al., 2011) as well as 
diabetic peripheral neuropathy (Vincent, Hinder, Pop-busui, & Feldman, 2009; Wiggin 
et al., 2009). In this study there was no difference in statin use between the two groups, 
however, an important future question is if more effective or earlier suppression of 
raised TRGs might reduce the risk or delay the progression of HIV-SN development. 
The role of other metabolic factors in this study is less clear, as no differences were 
seen in BMI, random plasma glucose, waist-hip circumferences or other plasma lipids 
between the HIV-SN and HIV-No SN groups. 
Psychological co-morbidity and sleep disturbance 
Participants with painful HIV-SN show significant interference from pain on the BPI 
instrument and had significantly reduced quality of life compared to participants 
without neuropathy across most of the domains of the SF-36. The largest differences 
seen between the two groups were in domains of physical functioning (PF) and social 
functioning (SF); indicating that painful HIV-SN profoundly interferes with everyday 
tasks, social interaction and relationships. This is comparable to changes seen in other 
painful peripheral neuropathies, however, HIV-SN appear to have lower mean scores 
across all domains implying greater disability (Poliakov & Toth, 2011). Compared to 
other painful peripheral neuropathies, a difference was seen in participants perception 
of general health (GH; HIV-SN= 26.58, SD 19.8 vs HIV-No SN=50.3, SD 10.7) This 
low general health perception has been previously identified as characteristic of 
individuals with HIV infection (Drewes, Gusy, & Rüden, 2013), but appears to be 
further reduced by HIV-SN. Interestingly bodily pain (BP) perception values were very 
comparable to other painful peripheral neuropathies that did not include HIV-SN, this 
is despite HIV-SN participants having a higher mean VAS (HIV-SN=5.65, SD 1.76 vs 
HIV-No SN=4.6, SD 2.4) to that study. 
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Pain related anxiety symptoms measured using the PASS-20 were similar across most 
domains to that previously seen in a recent study using the same instrument comparing 
lower back pain (LBP) and post-herpetic neuralgia (PHN) patients (Daniel et al., 
2008). However HIV-SN patients would appear to be less likely to have 
escape/avoidance behaviour in response to pain than either PHN or LBP patients. 
Whilst depression and anxiety symptoms were more common in the HIV-SN group, a 
greater difference was seen in catastrophizing behaviours in the HIV-SN compared to 
those who did not suffer with a painful neuropathy. The majority of this difference was 
seen in the PCS helplessness domain. This may well be a reflection of the relatively 
low levels of less escape/avoidance behaviour seen in HIV-SN compared to other pain 
states (Daniel et al., 2008; Poliakov & Toth, 2011). 
There have been numerous sleep laboratory and self report studies examining insomnia 
in HIV infected individuals (Reid & Dwyer, 2005). However the current significance 
of insomnia in HIV-infection is unclear, as its reported prevalence ranges from the 
same as the general population (D. Perkins et al., 1995) to 73% of HIV infected 
individuals (Rubinstein & Selwyn, 1998). Early pre-cART era studies suggested that 
CD4 count (Brown, Mitler, & Atkinson, 1991), cognitive impairment (Rubinstein & 
Selwyn, 1998) and ARV therapy (Nokes & Kendrew, 2001) were important risk 
factors for insomnia in HIV positive patients. More recent studies continue to 
demonstrate insomnia in HIV positive individuals, but do not correlate as convincingly 
with earlier risk factors (Cruess et al., 2003; Lee, Portillo, & Miramontes, 2001). Few 
studies have discussed the role of pain or neuropathy in HIV-associated insomnia. In 
the present study we have shown a large difference in the incidence of insomnia 
between the patients with HIV-SN (68%) and those without (23%; p < 0.001). As it is 
established that other forms of neuropathic pain have a high co-incidence of insomnia 
(Langley, Van Litsenburg, Cappelleri, & Carroll, 2013), the role neuropathic pain and 
insomnia in HIV-SN would appear to be a useful area to explore in future studies. 
The PINS-HIV study demonstrates that the presence of painful HIV-SN has a marked 
impact on individuals’ quality of life as measured by the SF-36, DAPOS, ISI and BPI. 
In particular participants with painful HIV-SN have reduced vitality, social 
functioning, emotional functioning. 
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If time had allowed I would have liked to have performed a more detailed analysis of 
the psychological outcomes to see if there was indeed any clustering of certain 
psychological attributes or dysfunction that could be corresponded to severity of pain 
or neuropathy. The presence of high catastrophising scores (PCS) within the high 
WUR group supports the idea that perhaps testing for high WUR groups through the 
use of simple psychological testing is possible. It is clear that further exploration of 
this area would be useful.  
Diagnostic tools 
The use of a robust composite HIV-SN definition is useful for research purposes, but 
would prove too time consuming and require expensive diagnostic equipment for 
routine use in most clinical practices. This is especially so in poorly resourced settings. 
Part of the objectives of this study was to investigate the utility of neuropathy 
screening tools that might be useful in such situations. Therefore in this study the 
BPNS, TCSS and the UENS were compared.  
The BPNS has been used as the screening tool for several HIV-SN studies (C L Cherry 
et al., 2009; Catherine L Cherry et al., 2008; Smyth et al., 2007; Antonia L Wadley et 
al., 2011). Whilst its utility is clear, we found that both, the TCSS and the UENS were 
superior in the diagnosis of HIV-SN in our population in a head-to-head comparison 
against this study’s triumvirate diagnostic criteria. The UENS has been used in a 
proportion of one study of HIV-SN where it showed correlation with measures of 
cutaneous autonomic function and pain (Boger et al., 2012). This current study is, to 
our knowledge, the first validation of the UENS and TCSS in HIV-SN diagnosis. 
The original validation study for the UENS did not suggest a cut-off score for 
determining the presence of a peripheral neuropathy (Singleton et al., 2008). However, 
in the present study, giving equal weight to sensitivity and specificity, a cut off value 
of 7 was selected. In that studies population it is associated with a sensitivity and 
specificity of 84%. The utility of the UENS was superior to both the TCSS (79%) and 
the BPNS (76%) in detecting HIV-SN when tested against the triumvirate multimodal 
scoring system. The utility of the BPNS as determined in this population is similar to 
that seen in previous larger studies (D M Simpson et al., 2006) and underlines that this 
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relatively small study population behaved as expected, and also that the triumvirate 
definition used as a gold standard in the study was a valid one.  
Epidemiological studies 
Using the triumvirate criteria definition for HIV-SN, in this study, HIV-SN showed a 
prevalence of 43% with 75% of these participants suffering with a painful neuropathy. 
This is very similar to that seen in recent large epidemiological studies of HIV 
populations in both well and poor resourced countries (Catherine Louise Cherry et al., 
2012). In the cART era HIV-SN prevalence is consistently found to be approximately 
40% in many different HIV populations (Wenlong Huang et al., 2013; Kamerman, 
Moss, et al., 2012; Maratou et al., 2009; Wallace, Blackbeard, Pheby, et al., 2007; 
Wallace, Blackbeard, Segerdahl, et al., 2007b). This reinforces the face validity of the 
triumvirate criteria used in this work and makes it likely that this study’s findings 
would be applicable to larger HIV populations and in different settings. However, this 
study did not find important some of the well-established risk factors for the 
development of HIV-SN in the cART era in this study population. In particular, no 
significant difference or correlation with HIV-SN severity was seen between the HIV-
SN and HIV-No SN group for height and age. The reasons for these are probably two-
fold: Firstly, the study reflects the studied population, which is generally white, middle 
aged, male and tall and therefore, it would be difficult for this study to elucidate risk 
factors that have been found in much more heterogeneous epidemiological studies. 
Secondly, the current study was powered as a detailed phenotyping study and was not 
large enough to elucidate these risk factors compared to substantially larger 
epidemiological studies (C L Cherry et al., 2009; Ellis et al., 2010; Maritz et al., 2010; 
Smyth et al., 2007; Wright et al., 2008).  
Summary 
This study has demonstrated that the sensory nerve dysfunction that occurs in HIV-SN 
is heterogenic as measured with QST. The most frequent changes seen in QST where 
loss of function in the large fibre parameters of mechanical and vibration detection. 
This further emphasises the large sensory nerve fibre involvement that occurs in HIV-
SN despite it frequently being considered a small fibre neuropathy in the literature. The 
diagnostic utility and limitation of QST, IENFD and clinical examination in isolation 
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has been demonstrated. This study has validated the use of UENS and TCSS in the 
diagnosis of HIV-SN both of which were found to be superior in HIV-SN diagnosis in 
this study population. This study also further supported the growing evidence that lipid 
dyslipidaemia is an important factor in the development of HIV-SN. Moreover, painful 
HIV-SN also appears to have a greater negative impact on quality of life when 
compared to other painful polyneuropathies, post-herpetic neuralgia and lower back 
pain. 
Future work should determine the triumvirate diagnostic criteria’s validity and utility 
in other HIV populations. Detailed examination of individual components of 
diagnostic tools should be investigated as there is an urgent need to produce a simple 
and robust diagnostic tool for both large epidemiological studies in low resource 
environments and for the use in future therapeutic efficacy trials. 
Study limitations 
A potential criticism of the study is that after the start of study recruitment, the joint 
EFNS/ PNS guidelines on the use of skin biopsies for the diagnosis of small fibre 
neuropathies was updated (Cruccu et al., 2010) to recommend the use of sex and age 
matched healthy control data (Bakkers et al., 2009). However, Nebuchennykh and 
collaborators identified that the method used in determining IENFD cut-off values is 
very important to the IENFD test’s final sensitivity and specificity (Nebuchennykh et 
al., 2009). In this study, comparisons were made using less than fifth-percentile values, 
a ROC analysis or using fifth-percentile of age and decade matched normal values (z-
scores) as “cut-off” values as recommended by the EFNS/PNS 2010 guidelines. Age 
and sex adjusted cut-off values produced the best specificity (98%) but resulted in 
much poorer sensitivity (31%); using a ROC analysis with a higher “cut-off” value of 
10.3 fibres/mm produced improved sensitivity (78%) but resulted in a poorer 
specificity (64%). The lower “cut-off” value of 7.63 fibres/mm proposed by Devigili 
and collaborators (Devigili et al., 2008) is associated with a specificity of 90% and a 
sensitivity of 80% and represents a compromise between the z-score and ROC methods 
of Nebuchennykh and collaborators’ study.  
My opinion was that the use of age and sex matched “cut-offs” would improve 
specificity from 90 to 98%, but sensitivity would be excessively reduced to 
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approximately 30% and this was not acceptable for the aims of the current study. 
Consequently, 7.63 fibres/mm continued to be used as the cut-off value in the 
triumvirate HIV-SN definition. 
To explore the impact of using the newer guidelines on IENFD use a post-hoc analysis 
of using the EFNS/PNS 2010 guideline age and sex matched values was performed 
using the recommended normative values (Bakkers et al., 2009) in conjunction with 
this study’s diagnostic triumvirate. This analysis demonstrated no change in the 
participants originally allocated to HIV-No SN group, however five participants 
(7.6%) previously allocated to HIV-SN group were now allocated to HIV-No SN. This 
was felt to be acceptable as the difference is proportional to that which would be 
expected using this more conservative definition of HIV-SN. Additionally, 3 of the 5 
(60%) participants who’s diagnosis was altered by the re-analysis to HIV-No SN 
complained of a painful peripheral neuropathy, confirming that the diagnosis of HIV-
SN was indeed the correct one for these participants. 
A further potential limitation of the study is that several items of the multimodal 
triumvirate definition for HIV-SN are compared and contrasted between the HIV-No 
SN group and the HIV-SN group. There is therefore potential for a circular argument 
relating to the QST and IENFD findings of this study; however this is minimal, as a 
post-hoc re-analysis using different combinations of the triumvirate (Table 3.10) shows 
that the neuropathy diagnosis of individual participants was not dramatically altered by 
the removal of individual items from the definition. Removal of QST resulted in 12% 
of the study participants having an altered diagnosis, and IENFD only 9%. The single 
most important factor of the definition was found to be the SNE which when removed 
from the definition altered the diagnosis of 26% of the participants. 
Further post-hoc exploration of using different HIV-SN definitions on QST results 
A post-hoc exploration of the impact of the HIV-SN case definition on one of the main 
outcome measures of the study, QST evaluation was undertaken. 
Three additional different case definitions were used: 
1. Using the BPNS definition of HIV-SN alone to determine neuropathy status. 
2. Using the Structured Neurological Examination (SNE) alone to determine neuropathy 
status. 
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3. Using only the reported symptoms of paraesthesia and/or numbness to determine 
neuropathy status. 
BPNS 
The BPNS was chosen for further exploration, as it is a well-established screening tool 
for HIV-SN that has been used in many previous studies of HIV-SN. Using the BPNS 
to determine HIV-SN status resulted in similar proportions to that when using PINS-
HIV criteria: n=37 for HIV-No SN and n=29 for HIV-SN (Table 3.11 and Figure 
3.2.b). However there are larger differences in individual neuropathy allocations: eight 
individual allocations are changed from HIV-No SN to HIV-SN, and seven from HIV-
SN to HIV-No SN. The mean z score values are similar for HIV-SN and HIV-No SN 
however the proportion of individuals demonstrating loss and gain of sensory function 
on QST is different. Interestingly the high WUR ‘cluster’ seen with the PINS criteria is 
larger using the BPNS (five/six with BPNS versus four participants with PINS). The 
high WUR cluster also appears more separated from the lower WUR HIV-SN group. 
Whilst the overall conclusions regarding QST changes seen in HIV-SN would be 
similar  
The finding that using the BPNS as a HIV-SN criteria produces similar results, and 
demonstrates a similar interesting feature of a cluster of HIV-SN participants with 
raised WUR is supportive of the findings seen in the PINS study, as it demonstrates 
that this novel high WUR is not a result of the new HIV-SN definition used.  
Structured Neurological Examination (SNE) 
The use of the SNE tended to ‘over’ diagnose HIV-SN in comparison to the PINS 
criteria, with ten more subjects being allocated to HIV-SN compared to PINS; n=38 
for HIV-SN and n=28 for HIV-No SN. The allocation of individuals with HIV-SN 
however resulted in a smaller cluster of high WUR in the HIV-SN.  
Paraesthesia and numbness symptoms 
Using self reported symptoms of peripheral neuropathy (paraesthesia and /or numbness 
symptoms) tended to over diagnose HIV-SN compared to using the PINS criteria. 
HIV-SN n=43 and HIV-No SN n=23. Despite a larger group of HIV-SN the high 
WUR remained similar with four participants present. 
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Pain  
Using pain as the definition of HIV-SN interestingly produced identical proportions of 
patients allocated to HIV-SN and HIV-No SN; however seven participants were 
reallocated from HIV-SN to No SN and seven from HIV-No SN to HIV-SN so the 
situation is not identical. Once again similar mean z score values were seen and a 
similar high WUR cluster in HIV-SN group  
The overall QST findings for each of the different criteria tested are similar to using 
the PINS criteria: i.e. a ‘loss’ of sensory function dominated picture, with the most 
affected modalities being MDT and VDT in the HIV-SN groups (Table 3.11 and 3.12). 
More affected by the changes of definition however is the detail of the number of 
individuals who show loss and gain in areas of interest such as WUR. The relatively 
small number of participants in the PINS-HIV study probably heightens this sensitivity 
to the definition of HIV-SN. 
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Figure 3.1. Scatter plot of z scores for QST parameters in the Healthy control, HIV-No SN and HIV-SN groups using the PINS-HIV triumvirate 
criteria. *Kruskal-Wallis, Dunn’s post-hoc one way analysis of variance: * p <0.05, NS = p > 0.05. 
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Figure 3.2.a. Scatter plot of z scores for QST parameters in the Healthy control, HIV-No SN and HIV-SN groups using an alternative definition 
for HIV-SN using the BPNS only. *Kruskal-Wallis, Dunn’s post-hoc one way analysis of variance: * p <0.05, NS = p > 0.05 
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Figure 3.2.b. Scatter plot of z scores for QST parameters in the Healthy control, HIV-No SN and HIV-SN groups using an alternative definition 
for HIV-SN using Structured Neurological Examination (SNE) only. *Kruskal-Wallis, Dunn’s post-hoc one way analysis of variance: * p <0.05, 
NS = p > 0.05 
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Figure 3.2.c. Scatter plot of z scores for QST parameters in the Healthy control, HIV-No SN and HIV-SN groups using an alternative definition 
for HIV-SN using paraesthesia and numbness symptoms only. *Kruskal-Wallis, Dunn’s post-hoc one way analysis of variance: * p <0.05, NS = 
p > 0.05 
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Figure 3.2.d. Scatter plot of z scores for QST parameters in the Healthy control, HIV-No SN and HIV-SN groups using an alternative definition 
for HIV-SN using pain symptoms only. *Kruskal-Wallis, Dunn’s post-hoc one way analysis of variance: * p <0.05, NS = p > 0.05 
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Figure 3.3. (i): Comparison of mean QST z-scores (SD) of the HIV-SN, No-HIV-SN and Healthy control groups. (ii): Occurrence of paradoxical heat 
sensation (PHS) and dynamic mechanical allodynia (DMA). Cold detection threshold (CDT), warm detection threshold (WDT), thermal sensory limen 
(TSL), cold pain threshold (CPT), heat pain threshold (HPT), pressure pain threshold (PPT), mechanical pain threshold (MPT), mechanical pain 
sensitivity (MPS), wind-up ratio (WUR), mechanical detection thresholds (MDT), vibration detection threshold (VDT) and numerical rating scale 
(NRS). * p<0.05 Threeway ANOVA (Holm-Sidak). 
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Figure 3.4. Loss and Gain of sensory function: A comparison of the frequency of QST abnormalities in participants in the Healthy control, HIV-No 
SN and HIV-SN groups which have QST values outside the 95% CI of the DFNS reference database. The y-axis shows the percentage of patients in 
each group (HIV-SN n=38, No HIV-SN n=28 and Healthy controls n=36) with 'gain' of sensory function plotted upwards, and 'loss' of sensory 
function plotted downwards. Chi squared test of association: * P < 0.05,  ** P < 0.01 comparison to Healthy controls; † P < 0.05, ††P < 0.01 
comparison to HIV-No SN. 
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Figure 3.5. Pain intensity response curves for suprathreshold heat stimuli in Healthy 
control subjects (n=36), HIV-No SN group (n=38) and HIV-SN (n=28) group. Data are 
presented as mean (SD). No statistically significant difference present between groups. 
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Table 3.1. Comparison of participants’ demographics, characteristics and co-
morbidities between HIV-No SN and HIV-SN groups enrolled in the study. 
*Continuous data if normally distributed were analysed with Student t test. Means and 
SD values are shown. ** No participants with Type I Diabetes. †Categorical data 
were analysed using 2 association. Values and percentages shown. 
 HIV-No SN n=38  HIV-SN n=28 p value 
Mean age yrs 
(SD) 
47.69 (8.87)  51.32 (8.36) 0.097* 
 
Male (%) 32 (84.21)  25 (89.28) 0.553§ 
Height cm 
(SD) 
175.08 (8.82)  177.14 (7.76) 0.321* 
 
Weight kg 
(SD) 
77.11 (15.08)  80.50 (12.19) 0.334* 
 
Years since 
HIV diagnosis 
(SD) 
14.71 (7.79)  17.79 (7.02) 0.094* 
 
Ethnicity  
White 
European (%) 
33 (86.84)  24 (85.71) 0.553† 
African 
Origin (%) 
4 (10.53)  3 (10.71) 0.553† 
Asian (%) 1 (2.63)  0 (0) 0.553† 
Mixed 
ethnicity (%) 
0 (0)  1 (3.57) 0.553† 
Co-
morbidities  
 
Type II 
Diabetes** 
3 (7.89)  5 (17.86) 0.220† 
Hepatitis C 
infection 
9 (23.68)  6 (21.43) 0.829† 
Hepatitis B 
infection 
3 (7.89)  5 (17.86) 0.220† 
Syphilis 6 (15.79)  4 (14.29) 0.497† 
Chemotherapy 
exposure 
1 (2.63)  3 (10.71) 0.174† 
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Table 3.2. Comparison of antiretroviral drug therapy use between HIV-No SN and 
HIV-SN groups. ARV - Antiretroviral drugs, dNRTIs - deoxy-Nucleoside Reverse 
Transcriptase Inhibitors, NNRTI – Non Nucleoside Reverse-transcriptase Inhibitor.   
* All NRTIs including ‘d’ NRTIs **Continuous data if normally distributed were 
analysed with Student t test. Means and SDs shown. §Continuous data not normally 
distributed were analysed using Mann-Whitney Rank Sum test. †Categorical data 
were analysed using 2 test of association. Values with percentages shown. 
 
 HIV-No SN n=38  HIV-SN n=28 p value 
On ARV therapy (%) 36 (94.74)  28 (100.00) 0.218† 
Mean yrs on ARV 
(SD) 
9.90 (6.43)  11.77 (5.90) 0.361§ 
 
‘d’ NRTIs drugs 
Ever used d NRTIs 
(%) 
20 (52.63)  20 (71.43) 0.122† 
Mean yrs on ‘d’ 
NRTIs (SD) 
12.89 (2.32)  12.63 (3.72) 0.989§ 
Ever used  zalcitabine 
(ddC) (%) 
4 (10.53)  6 (21.43) 0.222† 
Mean yrs on 
zalcitabine (ddC) (SD) 
14.90 (1.68)  16.54 (1.50) 0.142** 
Ever used stavudine 
(d4T) (%) 
18 (47.37)  17 (60.71) 0.283† 
Mean yrs on stavudine 
(d4T) (SD) 
12.02 (1.40)  12.31 (1.77) 0.577** 
Ever used didanosine 
(ddI) (%) 
12 (31.58)  14 (50.00) 0.130† 
Mean yrs on 
didanosine (ddI) (SD) 
11.49 (2.84)  10.81 (3.35) 0.579** 
NRTIs* 
Ever used NRTIs(%) 36 (94.74)  27 (96.43) 0.744† 
Mean yrs on NRTIs 
(SD) 
9.15 (6.45)  11.99 (4.99) 0.053** 
NNRTIs 
Ever used NNRTIs 
(%) 
28 (73.68)  25 (92.59) 0.115† 
Mean yrs on NNRTIs 
(SD) 
8.17 (6.53)  10.53 (6.53) 0.192** 
Protease Inhibitor drugs 
Ever used PI drug (%) 21 (55.26)  21 (75.00) 0.099† 
Mean yrs on protease 
inhibitor drugs (SD) 
21.56 (14.02)  28.55 (21.10) 0.687§ 
Ever used indinavir 
(IDV) (%) 
5 (13.16)  9 (32.14) 0.062† 
Mean yrs on indinavir 
(IDV) (SD) 
13.28 (0.68)  12.64 (1.15) 0.280** 
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Table 3.3. Mean values of QST parameters after z-score transformation for the three groups. Dynamic mechanical allodynia (DMA) and 
paradoxical heat sensations (PHS) are presented as mean number of events. * z-score transformed values outside 95% CI range of the DFNS 
normal values, percentages in brackets. ‡ comparison of number of participants HIV-No SN and HIV-SN using Chi-squared. 
 Healthy controls n=36  HIV-No SN n=38   HIV-SN n=28 
   Number of 
participants with: 
   Number of 
participants with: 
   Number of 
participants with: 
 
 
mean SD 
Loss  Gain  
mean SD 
Loss Gain  
mean SD 
Loss Gain p-value‡ 
< -1.96 
CI* 
>1.96 
CI* 
< -1.96 
CI* 
>1.96 
CI* 
 < -1.96 CI* >1.96 
CI* 
Loss Gain 
CDT 0.02 0.83 1(2.8) 1 (2.8)  -0.68 0.75 2(5.3) 0  -1.34 0.93 8(28.6) 0 - - 
WDT -0.01 0.75 0 0  -0.79 0.69 1(2.6) 0  -1.31 0.56 4(14.3) 0 0.009 - 
TSL -0.26 0.75 1(2.8) 0  -0.86 0.54 1(2.6) 0  -1.29 0.67 4(14.3) 0 0.080 - 
CPT -0.69 0.75 0 1(2.8)  0.24 0.71 0 0  -0.18 0.37 0 0 - - 
HPT 0.41 0.88 0 2(5.6)  -0.59 1.01 3(7.9) 1(2.6)  -1.47 1.05 9(32.1) 0 0.01 0.393 
PPT -0.38 1.04 2(5.6) 0  -1.09 0.87 7(13.2) 0  -1.29 1.13 7(25) 1(3.6) 0.518 0.240 
MPT 0.33 0.71 0 1(2.8)  0.42 0.88 0 1(2.6)  -0.01 0.99 1(3.6) 0 0.240 0.387 
MPS 0.86 1.17 0 7(19.4)  0.36 1.21 0 5(13.2)  -0.32 1.06 0 1(3.6) - 0.385 
WUR -0.08 0.84 0 2(5.6)  -0.13 1.12 1(2.6) 2(5.3)  -0.21 1.66 2(7.1) 4(14.3) 0.385 0.208 
MDT -0.67 0.85 2(5.6) 0  -0.77 0.77 2(5.3) 0  -2.17 1.06 14(50) 0 <0.01 - 
VDT -0.06 0.81 2(5.6) 0  -0.84 1.01 4(10.5) 0  -2.24 1.62 14(50) 0 <0.01 - 
  
DMA Not 
present 
- - -  Not 
present 
- - -  Not 
present 
 - - - 
PHS 
events 
0.07 0.24 NA NA  0.62 0.92 NA NA  0.67 0.87 NA NA  
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Table 3.4. Frequency of different patterns of sensory loss and gain in the HIV-SN 
group. Loss 0 = no loss of detection, Loss 1 = Loss of only thermal loss, Loss 2= Loss 
of only mechanical, Loss 3 = Loss of both thermal and mechanical. Gain 0 = No gain 
of thermal, Gain 1 = Gain of only thermal, Gain 2 = Gain of only mechanical, Gain 3 
= Gain of thermal and mechanical.  
HIV-SN 
n=28 
Gain 0(no) Gain 1 
(thermal) 
Gain 2 
(mechanical) 
Gain 3 
(both) 
Gain All 
Loss 0 (no) 4 (14.3%) 0 0 0 4 (14.3%) 
Loss 
1(thermal) 
0 0 0 0 0 
Loss 2 
(mechanical) 
6(21.4%) 0 4(14.3%) 0 10(35.7%) 
Loss 3 (both) 12(42.9%) 0 2(7.1%) 0 14(50%) 
Loss All 22(78.6%) 0 6(21.4%) 0 28(100%) 
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Table 3.5. Correlation of IENFD and individual thermal and mechanical QST parameters. Pearson’s correlation r values 
 Thermal QST parameters  Mechanical QST parameters 
 CDT WDT TSL CPT HPT  MDT MPT MPS WUR VDT PPT 
r -0.22 <0.01 -0.43 -0.21 -0.13  0.10 0.00 0.59 <0.01 -0.10 -0.05 
p 0.29 0.99 <0.05 0.33 0.55  0.63 0.98 <0.05 0.70 0.67 0.83 
 
 110 
Table 3.6. Comparison of participant reported symptoms between HIV-SN and HIV-
No SN groups. *Continuous data if normally distributed were analysed with Student t 
test. Mean values and SDs shown.§ Continuous data not normally distributed were 
analysed using Mann-Whitney Rank Sum test. Mean values and SDs shown. 
†Categorical data were analysed using Chi squared test of association. 
Reported 
Symptom  
HIV-No SN n=38  HIV-SN n=28 p value 
Any pain in 
hands and/or 
feet. 
11 (28.95)  21 (75.00) <0.001† 
If 
experiencing 
pain: 7-day 
pain diary 
NRS (0-10) 
2.8 (2.34)  5.65 (1.76) <0.001* 
Pain onset 
yrs after 
HIV 
diagnosis 
12.29 (5.94)  9.5 (7.59) 0.358* 
Pain 
duration 
years 
9.5 (7.59)  8.25 (7.23) 0.811* 
‘Pins and 
needles’ in 
feet and/or 
hands 
19 (50.00)  17 (60.71) 0.388† 
‘Numbness’ 
in feet 
and/or hands 
14 (36.84)  21 (75.00) <0.02† 
Perceived 
‘Weakness’ 
in upper or 
lower limbs 
10 (26.32)  10 (35.71) 0.412† 
Postural 
hypotension 
9 (24.68)  14 (50.00) <0.02† 
Urinary 
dysfunction 
6 (15.79)  12 (42.86) <0.02† 
Erectile 
dysfunction 
12 (31.58)  14 (50.00) 0.152† 
Nocturnal 
diarrhoea 
10 (26.32)  8 (28.57) 0.839† 
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Table 3.7. Psychological and Sleep instruments questionnaire returned and completed 
per group. Numbers completed or returned with percentages in brackets. 
 HIV-No SN 
n=38 
HIV-SN no 
pain n=7  
HIV-SN 
with pain 
n=21  
    
Questionnaire 
booklets 
returned  
 
32 (84.2) 
 
6 (85.7) 
 
19 (90.5) 
ISI 31 (81.6) 6 (85.7) 19 (90.5) 
DAPOS 29 (76.3) 6 (85.7) 19 (90.5) 
PASS-20 29 (76.3) 6 (85.7) 19 (90.5) 
PCS 31 (81.6) 6 (85.7) 19 (90.5) 
BPI 30 (79.0) 6 (85.7) 19 (90.5) 
SF-36 32 (84.2) 6 (85.7) 19 (90.5) 
 
 112 
Table 3.8. Summary of Sleep and Psychological instruments results comparing HIV-
No SN (n=38) and painful HIV-SN (n=21). *Statistical significance taken as p ≤ 0.05. 
 HIV-No SN  HIV-SN with pain  
Instrument Mean SD Mean SD p-value 
ISI   
Mean ISI total 
score (/28) 
10.16 7.86  14.05 8.86 0.112 
Participants with 
Clinical insomnia 
(ISI ≥15) (%) 
7 (22.6%)  13 (68.4%)  <0.001** 
Participants with 
Severe insomnia 
(ISI ≥22) (%) 
3 (9.7%)  7 (22.6%)  <0.001** 
DAPOS  
DAPOS 
depression (/25) 
8.38 4.10  11.21 4.22 <0.05* 
DAPOS anxiety 
(/15) 
5.45 2.89 7.47 2.97 <0.05* 
PASS-20  
PASS cognitive 
(/25) 
8.45 5.28  14.95 5.69 <0.001** 
PASS escape-
avoidance (/25) 
9.07 7.15 11.84 6.38 0.177 
PASS fear (/25)  6.97 7.11 11.79 6.75 <0.05* 
PASS 
psychological 
anxiety (/25) 
4.83 6.45 9.21 7.54 <0.05* 
PASS total (/100) 35.84 29.84 47.79 21.94 0.136* 
PCS  
PCS rumination 
/16 
5.68 4.85  8.84 5.11 0.330 
PCS magnification 
/12 
3.97 3.66 5.63 3.39 0.115 
PCS helplessness 
/24 
6.03 5.52 11.16 6.131 <0.02* 
PCS total /52 14.13 11.81 23.74 12.64 <0.02* 
BPI  
BPI interference 
/70 
15.20 16.22  46.11 13.69 <0.001** 
SF-36  
Physical 
Functioning (PF) 
74.03 24.65  34.47 21.74 <0.001** 
Role Physical (RP) 50.78 43.76 11.84 28.10 <0.001** 
Bodily Pain (BP) 69.43 24.47 29.42 18.06 <0.001** 
General Health 
(GH) 
43.78 26.96 26.58 19.88 <0.05* 
Vitality (VT) 49.53 24.08 25.79 24.45 <0.001** 
Social Functioning 
(SF) 
67.98 27.31 32.24 24.41 <0.001** 
Role Emotional 
(RE) 
54.17 46.18 15.79 32.14 <0.05* 
Mental Health 
(MH) 
63.25 21.25 47.79 17.05 <0.05* 
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Table 3.9. Comparison of metabolic factors: random plasma lipid profiles, glucose, 
BMI, waist-hip ratio and statin use for HIV-No SN and HIV-SN groups. Plasma lipid 
and glucose concentrations are displayed as mmol/l. Number of participants taking 
statins displayed with percentages in brackets. *Continuous data if normally 
distributed were analysed with Student t test. Means and SDs shown. §Continuous 
data not normally distributed were analysed using Mann-Whitney Rank Sum test. 
Means and SDs shown.†Categorical data were analysed using 𝜒2 test of association. 
Values and percentages shown. TRG - Triglycerides, HDL - High Density 
Lipoprotein, LDL - Low Density Lipoprotein, BMI - Body Mass Index. 
 HIV-No SN n=38  HIV-SN n=28 p value 
Total 
cholesterol 
4.56 (1.08) 5.01 (1.07) 0.100* 
Triglyceride 1.61 (0.77) 2.18 (1.09) <0.020§ 
HDL 1.06 (0.36) 1.24 (0.44) 0.069* 
LDL 2.75 (0.93) 2.71 (0.95) 0.860* 
Cholesterol : 
HDL ratio 
4.53 (1.57) 4.42 (1.27) 0.769 * 
Random 
glucose 
5.31 (1.20) 5.31 (1.07) 0.863§ 
      
BMI kg.m-2 25.28 (5.34) 25.68 (3.69) 0.223§ 
Waist-hip 
circumference 
ratio (SD) 
0.98 (0.09) 0.96 (0.12) 0.739§ 
Current statin 
use (%) 
9 (23.70) 9 (32.14) 0.446† 
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Table 3.10. Comparison of using different combinations of the triumvirate criteria for 
the diagnosis of HIV-SN. The case definition used in the study required the presence 
of ≥2 out of the triumvirate: clinical signs of distal sensory neuropathy, ≥2 abnormal 
QST parameters or IENFD of ≤7.63 fibres/mm (1st column). Each column shows the 
consequences of changing the case definition. Data are displayed as absolute numbers 
with percentages of the groups in brackets. QST - Quantitative Sensory Testing 
criteria, SNE - Structured Neurological Examination, IENFD - Intra-Epidermal Nerve 
Fibre density criteria. *Sensitivity and specificity compared to using triumvirate of 
QST + CNE + IENFD criteria for the diagnosis of HIV-SN.  
 QST + 
SNE + 
IENFD 
QST + 
SNE 
QST + 
IENFD 
SNE + 
IENFD 
QST SNE IENFD 
Changed 
diagnosis 
       
‘HIV-No 
SN’ 
changed to 
‘HIV-SN’ 
(%) 
0 (0) 0 (0) 0 (0) 0 (0) 7 
(18.42) 
10 
(26.32) 
8 
(21.05) 
‘HIV-SN’ 
changed to 
‘HIV-No 
SN’ (%) 
0 (0) 6 
(21.43) 
17 
(60.07) 
8 
(28.57) 
6 
(21.43) 
0 (0) 11 
(39.29) 
Number 
Changed (% 
of total 
participants) 
0 (0) 6 (9.09)  17 
(25.76) 
8 
(12.12) 
13 
(19.70) 
10 
(15.15) 
19 
(28.79) 
Sensitivity* 1.000 0.786 0.393 0.714 0.786 1.000 0.607 
Specificity* 1.000 1.000 1.000 1.000 0.816 0.740 0.790 
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Table 3.11. Comparisons of using original PINS study criteria, Brief Peripheral 
Neuropathy Screen (BPNS) and the Structured Neurological Examination (SNE) 
as HIV-SN criteria for QST z-score results; mean values (SD),‘Loss’ and ‘Gain’ of 
function: number of participant z scores ≤ -1.96, and ≥ 1.96 respectfully. 
 
 
Original PINS criteria 
               
  CDT WDT TSL CPT HPT MDT MPT MPS WUR VDT PPT PHS DMA 
HIV-No SN 
n=38 
 
Mean 
(SD) 
-0.68 
(0.75
) 
-0.79 
(0.69) 
-0.86 
(0.54
) 
0.24 
(0.71
) 
-0.59 
(1.01
) 
-0.77 
(0.77) 
0.42 
(0.88) 
0.36 
(1.21) 
-0.13 
(1.12) 
-0.84 
(1.01) 
-1.09 
(0.87) 
0.62 
(0.92
) 
 
0 
 Loss  2 1 1 0 3 2 0 0 1 4 7 0 0 
 Gain  0 0 0 0 1 0 1 5 2 0 0 0 0 
               
HIV-SN n=28 
Mean 
(SD) 
-1.34 
(0.93
) 
-1.31 
(0.56) 
-1.29 
(0.67
) 
-0.18 
(0.37
) 
-1.47 
(1.05
) 
-2.17 
(1.06) 
-0.01 
(0.99) 
-0.32 
(1.06) 
-0.21 
(1.66) 
-2.24 
(1.62) 
-1.29 
(1.13) 
0.67 
(0.87
) 
0 
 Loss  8 4 4 0 9 14 1 0 2 14 7 0 0 
 Gain  0 0 0 0 0 0 0 1 4 0 1 0 0 
 
BPNS as criteria 
               
  CDT WDT TSL CPT HPT MDT MPT MPS WUR VDT PPT PHS DMA 
HIV-No SN 
n=37 
Mean 
(SD) 
-0.84 
(0.82
) 
-0.85 
(0.73) 
-0.95 
(0.62
) 
0.17 
(0.68
) 
-0.88 
(0.94
) 
-0.94 
(1.06) 
0.39 
(0.90) 
-0.26 
(1.17
) 
-0.26 
(1.09) 
-0.98 
(1.35) 
-1.11 
(0.79) 
0.57 
(0.84
) 
0 
 Loss 4 2 2 0 6 4 0 0 2 3 4 0 0 
 Gain 0 0 0 0 0 0 1 5 0 0 0 4 0 
               
HIV-SN 
n=29 
Mean 
(SD) 
-0.84 
(0.78
) 
-0.85 
(0.89) 
-0.9 
(1.00
) 
0.16 
(0.98
) 
-0.87 
(1.14
) 
-0.94 
(1.22) 
0.39 
(0.67) 
0.30 
(1.03
) 
0.26 
(1.27) 
-0.98 
(0.69) 
-1.12 
(0.88) 
0.57 
(0.95
) 
0 
 Loss  4 3 3 0 6 12 1 0 1 15 9 0 0 
 Gain  0 0 0 0 1 0 0 1 5 0 1 5 0 
 
Structured Neurological Exam (SNE) as criteria 
               
  CDT WDT TSL CPT HPT MDT MPT MPS WUR VDT PPT PHS DMA 
HIV-No SN 
n=28 
Mean 
(SD) 
-0.78 
(0.75
) 
-0.76 
(0.43) 
-0.90 
(0.41
) 
-0.26 
(0.73
) 
-0.82 
(1.19
) 
-0.94 
(1.19) 
0.48 
(0.72) 
0.35 
(1.17
) 
-0.02 
(1.50) 
-1.46 
(1.61) 
-1.03 
(0.94) 
0.54 
(0.78
) 
0 
 Loss  1 0 0 0 4 2 0 0 2 7 3 0 0 
 Gain 0 0 0 0 1 0 0 3 2 0 1 2 0 
               
HIV-SN  
n=38 
Mean 
(SD) 
-1.09 
(0.75
) 
-1.19 
(0.43) 
-1.14 
(0.41
) 
-0.07 
(0.73
) 
-1.08 
(1.19
) 
-1.73 
(1.19) 
0.04 
(1.19) 
-0.15 
(0.71
) 
-0.25 
(1.17) 
-1.44 
(1.50) 
-1.28 
(1.61) 
0.77 
(0.95
) 
0 
 Loss  7 5 5 0 8 14 1 0 1 11 10 0 0 
 Gain  0 0 0 0 0 0 1 1 1 0 0 6 0 
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Table 3.12. Comparisons of using symptoms of paraesthesia and/or numbness, 
and the presence of pain alone as HIV-SN criteria for QST z-score results; mean 
values (SD),‘Loss’ and ‘Gain’ of function: number of participant z scores ≤ -1.96, 
and ≥1.96 respectfully.
Paraesthesia and/ or numbness as criteria 
               
  CDT WDT TSL CPT HPT MDT MPT MPS WUR VDT PPT PHS DMA 
HIV-No SN 
n=23 
Mean 
(SD) 
-0.82 
(.079) 
-0.78 
(0.47) 
-0.93 
(0.44) 
0.35 
(0.80
) 
-0.71 
(1.18
) 
-0.74 
(0.87
) 
0.26 
(1.00) 
0.25 
(1.36) 
-0.30 
(1.40) 
-0.26 
(1.12) 
-1.14 
(0.97) 
-1.35 
(0.85) 
0 
 Loss 1 0 0 0 3 1 1 0 2 4 5 0 0 
 Gain 0 0 0 0 1 0 0 4 1 0 0 2 0 
               
HIV-SN 
n=43 
Mean 
(SD) 
-1.05 
(0.93) 
-1.14 
(0.75) 
-1.10 
(0.71) 
-0.08 
(0.46
) 
-1.10 
(1.05
) 
-1.76 
(1.12
) 
0.22 
(0.93) 
-0.12 
(1.08) 
-0.10 
(1.35) 
-1.62 
(1.63) 
-1.08 
(1.00) 
0.75 
(0.94) 
0 
 Loss 7 5 5 0 9 15 0 0 1 14 8 0 0 
 Gain  0 0 0 0 0 0 1 2 4 0 1 7 0 
 
Pain Symptoms as criteria 
               
  CDT WDT TSL CPT HPT MDT MPT MPS WUR VDT PPT PHS DMA 
HIV-No SN 
n=38 
Mean 
(SD) 
-0.63 
(0.77) 
-0.73 
(0.62) 
-0.80 
(0.55) 
0.32 
(0.69
) 
-0.59 
(1.08
) 
-0.82 
(0.81
) 
0.25 
(0.92) 
0.32 
(1.22) 
-0.29 
(1.21) 
-1.16 
(1.11) 
-1.15 
(0.97) 
0.55 
(0.89) 
0 
 Loss  1 0 0 0 4 2 1 0 2 6 6 0 0 
 Gain 0 0 0 0 1 0 0 5 1 0 0 4 0 
               
HIV-SN 
n=28 
Mean
(SD) 
-1.42 
(0.83) 
-1.38 
(0.58) 
-1.37 
(0.60) 
-0.22 
(0.38
) 
-1.46 
(0.94
) 
-2.14 
(1.09
) 
0.20 
(1.06) 
-0.29 
(1.55) 
0.01 
(1.80) 
-1.81 
(1.02) 
-1.2 
(0.90) 
0.85 
(0.90) 
0 
 Loss 7 5 5 0 8 14 0 0 1 12 7 0 0 
 Gain  0 0 0 0 0 0 1 1 4 0 1 5 0 
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Summary 
Chapter 2: Findings and implications of the systematic review of pharmacological 
agents in the treatment of painful HIV-SN Chapter 2. 
The systematic review and meta-analysis presented in Chapter 2 demonstrates that the 
pharmacological management of the painful symptoms of HIV-SN is at present 
unsatisfactory. There is currently no evidence of efficacy for many agents commonly 
used to treat other neuropathic pain states in the treatment of painful HIV-SN: 
amitriptyline, topical capsaicin (0.075%), gabapentin or lamotrigine all failed to show 
efficacy greater than placebo in the doses tested in the included RCTs.  
The conclusion of the systematic review is that only recombinant human NGF (a 
commercially unavailable agent) and smoked cannabis are better than placebo in the 
management of pain in HIV-SN. An NNT for smoked cannabis was calculated as 3.38 
with a 95% CI (2.19 – 7.50). This apparent efficacy should be tempered by the high 
proportion of inadvertent unblinding that occurred in at least one trial (92% of 
participants correctly guessing treatment allocation) (Ellis et al., 2009), and the 
potential for this to have occurred in the other included cannabis RCT, where 
previous recreational exposure to cannabis was an inclusion criteria for participants. 
Limitations of this study and future work 
The systematic review used the modified Jadad scale to assess the quality of RCTs 
entered into it. The Jadad scale has been previously criticised as being over-simplistic, 
showing low consistency between different raters (Hartling et al., 2009)  and it places 
too much emphasis on blinding (V. W. Berger, 2006). Furthermore, it does not take 
into account allocation concealment. 
Quality scales and resulting scores are not an appropriate way to appraise clinical 
trials. They tend to combine assessments of aspects of the quality of reporting with 
aspects of trial conduct, and to assign weights to different items in ways that are often 
difficult to justify (J. P. T. Higgins et al., 2011). If I was repeat the systematic review 
I would use the Cochrane Collaborations Risk of Bias Tool (CCRNT) for the above 
reasons (J. Higgins & Altman, 2008). Whilst no assessment tool is infallible, the 
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CCRNT has taken into consideration advances in the understanding risk of bias in 
RCT and appears to be currently the most complete instrument available. 
The systematic review in Chapter 2 also underlines the need for disease specific 
analgesic efficacy RCTs, as guidelines drawn up to treat neuropathic pain per se, 
based on RCTs for other conditions, do not reflect the response of HIV-SN to 
conventional analgesics or neuropathic pain adjuvants. 
Cannabinoids have been extensively investigated and whilst useful in certain 
neuropathic pain states, their use is limited by the significant psychotropic effects of 
cannabinoid compounds (A. S. C. Rice, 2008). A notable exception is multiple 
sclerosis (MS) where cannabinoids have been shown to be useful in the treatment of 
MS associated spasticity and pain in at least a subset of patients (P. F. Smith, 2007). 
The apparent efficacy of smoked cannabis in the treatment of pain in HIV-SN would 
suggest that the use of cannabis extracts and synthetic compounds would be worthy of 
further investigation. 
Unfortunately it is unlikely if there will be further work using recombinant NGF in 
the treatment of painful HIV-SN. Recombinant NGF is commercially unavailable 
after it proved disappointing in the treatment of painful diabetic neuropathy at Phase 
III trials and was so abandoned by the pharmaceutical company investigating it 
(Apfel, 2002). 
Whilst high dose 8% capsaicin patches initially showed promise in the treatment of 
pain associated with HIV-SN, a subsequently published larger RCT showed no 
superiority of high dose capsaicin patches to placebo (D. B. Clifford et al., 2012).  
If painful HIV-SN was an occasional complication of a rare condition, painful HIV-
SN might remain an academic oddity. However as argued in Chapter 1, HIV-SN 
represents probably the largest cause of pain morbidity worldwide, potentially 
affecting more than a third of the 34 million persons infected with HIV. The 
conclusions of the systematic review underline the urgent need to seek out novel 
agents to treat this pain.  
The systematic review was hampered by the paucity of good quality RCTs 
particularly for older neuropathic pain adjuvant drugs which are off-patent. Modern 
high quality RCTs suitable to assess the efficacy of pharmacological agents, are 
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complex and expensive to conduct. Unfortunately, the majority of these high quality 
RCTs are currently conducted by pharmaceutical companies who have the financial 
and logistical resources to undertake them. Consequently, this biases newer, on-patent 
agents where there is a financial incentive to find efficacy. It has been suggested that 
it should be the role of governmental research agencies, such as the National Institute 
of Health Research (NIHR) in both the US and UK to fund modern RCTs examining 
older agents against placebo, each other (head-to-head) and in combination therapies 
in a clinically meaningful way. 
New evidence related to the use of high dose capsaicin patches has been published 
whilst this thesis was in preparation (D. B. Clifford et al., 2012). As suggested in an 
abstract assessed in the systematic review, the outcome of these trials demonstrates 
that high dose capsaicin patch is not superior to placebo in the treatment of painful 
HIV-SN. A new systematic review should be conducted and this high dose capsaicin 
study included formally assessed and integrated into the systematic review. 
Chapter 3: Patterns of sensory, psychological and metabolic dysfunction in HIV 
positive patients with and without HIV-associated peripheral neuropathy.  
Findings, implications and future work 
One of the key findings of the phenotyping study is that the sensory dysfunction seen 
in HIV-SN is heterogeneous. Comparing the HIV-SN population to the HIV-No SN 
group the most profound difference is that of sensory loss across all modalities 
measured. Most frequently, this was seen in the large fibre modalities of MDT and 
VDT. Whilst differences were seen in small fibre function the picture across the 
group was quite mixed, with no discernable patterns evident. This highlights the fact 
that HIV-SN is not a pure small fibre neuropathy (as it has been widely considered) 
and potentially opens a new line of research in the mechanisms underlying HIV-SN. 
Moreover, this finding would support the use of MDT and VDT in low resource 
settings in preference to expensive thermal parameter QST equipment. In addition, the 
absence of gain of function phenomena is consistent with QST studies of other painful 
peripheral neuropathies. Nevertheless, a small sub-group with wind-up phenomenon 
was seen in 14% of the HIV-SN group patients (n=4) – whilst this is a small number, 
it is a comparable proportion of HIV-SN participants seen to have mechanical 
hyperalgesia in previous studies. However, as this thesis used the standardised DFNS 
 121 
protocol, it is difficult to draw direct conclusions with this specific study (D M 
Simpson, Schifitto, et al., 2010). A future phenotyping study should actively look for 
this phenomenon, especially as the sub-group seen in the pregabalin RCT work of 
Simpson and collaborators in 2010 had a differential response to analgesics. The 
presence of high levels of catastrophising in this high WUR is another interesting 
phenomenon as would be useful to explore further.  
This thesis showed that patients with HIV-SN had significantly higher triglyceride 
levels than patients without HIV-SN. This is a finding that further supports recent 
work in both HIV-SN and Diabetic neuropathy which suggests lipid dysfunction is an 
important factor in the development of painful peripheral neuropathies(Banerjee et al., 
2011; Vincent et al., 2009; Wiggin et al., 2009). This opens an interesting question 
about the role of lipid lowering agents such as statins to act as disease modifying 
agents to prevent or slow the development of HIV-SN. 
Strengths of this study 
This comprehensive phenotyping of HIV-SN is important for the future development 
of animal models.  
Although the phenotyping study presented in Chapter 3 produced a wealth of 
information, it will take a lot more time to fully explore its implications. Further 
analysis of the diagnostic utility of individual components tested in this study should 
be undertaken to yield a composite refined diagnostic protocol using the best of the 
sensory testing, screening tools and specific symptom questioning to produce a robust 
tool for screening and early detection of HIV-SN. This had been part of the original 
aims of the thesis but could not be completed due to time restrictions. Colleagues who 
intend to build on the work of this thesis have already started this work. 
As part of this thesis a blood and tissue bank has been established. This is an 
important resource as these tissue samples have extensive phenotyping information 
associated with them. The hope is that this will be potentially useful in future genetic 
analysis studies examining painful HIV-SN. 
Limitations of this study 
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One of the weaknesses of the phenotyping study was that the relatively small number 
of HIV infected participants recruited (n=66) into the study meant that a useful 
comparison between participants with non-painful (n=7) and painful HIV-SN (n=21) 
was not possible to do with meaning full statistical significance. Another potential 
consequence of small recruitment numbers was that many of the established risk 
factors for the development of HIV-SN were not confirmed in this study – most 
notably age and height. As argued in Chapter 3 some of this failure to see established 
risk factors can be accounted for in the population. Compared to many larger 
epidemiological studies, the population we recruited was quite homogeneous: male, 
white, tall and middle aged. Unfortunately, the labour intensive nature of phenotyping 
individuals over three to four hours each, meant that recruiting greater numbers was 
not practical. A future phenotyping study could utilise the work here and use a smaller 
number of components to reduce both participant and investigator work loads to allow 
a greater number of individuals to be recruited.  
The use of a composite definition for HIV-SN, using abnormal QST (2 or more 
abnormal modalities), reduced IENFD (<7.63 fibres/mm) and a structured clinical 
examination meant that comparing these measures between the two groups might risk 
a circular argument. Reasons for this to be unlikely are outlined in the discussion of 
Chapter 3, however if a more robust definition for HIV-SN can be produced as 
described as above, future phenotyping studies might be free from this potential 
criticism.  
There is also a need for ease to use, robust screening tools for the identification of 
HIV-SN that can be translated for use into resource poor settings. Part of the 
phenotyping study examined the efficacy of a number of neuropathy screening tools 
(and their constituent components), some of which have not been previously validated 
in the context of HIV-SN. This study will hopefully form the basis for future work 
directed at producing a composite screening tool for use in resource poor settings. 
As part of this study a blood and tissue bank for each highly phenotyped individual 
with HIV-SN was established; this valuable resource will inform future work 
exploring genetic risk factors for the development of HIV-SN and painful HIV-SN. 
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SUPLEMMENTAL DOCUMENTS 
Supplemental Document 1:  
Instrument To Measure The Likelihood Of Bias And Insufficient Statistical “Power” 
In Pain Research Reports (modified Jadad scale) 
This is not the same as being asked to review a paper.  It should not take more 
than 10 minutes to score a report and there are no right or wrong answers. 
 
Please read the article and try to answer the following questions (see attached 
instructions): 
 
1. Was the study described as randomised (this includes the use of words such as 
randomly, random, and randomisation)? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
4. Was there a description of a power calculation? 
 
Scoring the items: 
 
Either give a score of 1 point for each “yes” or 0 points for each “no”.  There are no 
in-between marks. 
 
Give 1 additional point if:  For question 1, the method is to generate the sequence of  
    randomisation was described and it was appropriate  
    (table of random numbers, computer generated, etc). 
 
And/or:   If for question 2 the method of double blinding was 
described 
    and it was appropriate (identical placebo, active 
placebo, 
    dummy etc). 
 
And/or: If for question 4 the method and assumptions for power 
calculation was described and it was appropriate and 
the number of patients who were randomised and 
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analysed on an intention to treat basis was in 
concordance with this calculation. 
 
 
Deduct 1 point if:-  For question 1, the study was described as randomised 
the  
    method of randomisation was inappropriate (patients 
were allocated 
alternately, or according to date of birth, hospital 
number, etc) or the description was unclear. 
 
And/or    For question 2, the study was described as double 
blind but the 
method of blinding was inappropriate (e.g., comparison 
of tablet vs. injection with no double dummy) or the 
description unclear. 
 
 
And/or: If for question 4 the method and assumptions for power 
calculation was described and it was inappropriate or 
the number of patients who were randomised and 
analysed on an intention to treat basis did not reached 
the level required by the power calculation. 
 
Guidelines for Assessment 
 
1. Randomization 
A method used to generate the sequence of randomization will be regarded as 
appropriate if it allowed each study participant to have the same chance of receiving 
each intervention and the investigators could not predict which treatment was next.  
Methods of allocation using date of birth, date of admission, hospital numbers, or 
alternation should not be regarded as appropriate. 
 
2. Double blinding 
A study must be regarded as double blind if the word “double blind” is used.  The 
method will be regarded as appropriate if it is stated that neither the person doing 
the assessments nor the study participant could identify the intervention being 
assessed, or if in the absence of such a statement the use of active placebos, identical 
placebos, or dummies is mentioned. 
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3. Withdrawals and dropouts 
Participants who were included in the study but did not complete the observation 
period or who were not included in the analysis must be described.  The number 
and the reasons for withdrawal in each group must be stated.  If there were no 
withdrawals, it should be stated in the article.  If there is no statement on 
withdrawals, this item must be given no points. 
 
4. Power calculations 
 
The method for calculating the statistical power must be described and the 
assumptions regarding effect size, the alpha value (min. 0.05) and the power level 
(min. 0.8). The group sizes in the intention to treat analysis must be a minimum of 
that indicted by the power calculation. 
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Supplemental Document 3: QST Suprathreshold Heat 
Protocol 
 
Suprathreshold testing was conducted after the completion of the DFNS QST 
protocol. 
As with the DFNS QST protocol Surpathreshold thermal stimuli were generated using 
a SOMEDIC MSA100 thermal stimulator (SOMEDIC AB, Hörby, Sweden), which 
uses a fluid cooled Peltier element thermode measuring 25 x 50mm.  
From a base line temperature of 320C, suprathreshold temperatures were reached by a 
ramped temperature increase of 10Cs-1. The temperature sequence used was 46, 42, 
40, 48, 50, 52, 44, 42, 48, 40, 44, 46, 50 and 520C. The supratheshold temperature 
being tested would then be held constant for 2 sec, during which the participant was 
requested to rate the greatest pain experienced for the temperature being tested using a 
100mm electronic visual analogue scale (eVAS) transducer (SENSEbox™ 450-010, 
SOMEDIC AB, Sweden). VAS anchors were defined for the patient prior to testing, 
and were also written on the VAS scale: from left to right on eVAS: 0mm - No pain, 
and 100mm - Worst pain they could imagine. 
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Supplemental Document 5: Structured Neurological 
Examination (SNE) 
 
The structured neurological examination of the upper and lower limb was designed by 
an experienced neurologist (DB), to exam in detail, clinical neurological signs which 
might be present in a peripheral neuropathy.  
 
Upper and Lower Limb Examination 
Inspection 
The presence of any muscle wasting is noted, with special attention given to the First 
Dorsal Interosseous muscle in the upper limb and Extensor Digitorium Brevis in the 
lower limb. The presence of ulcerations and deformities is also noted. 
Motor 
Motor strength is assessed using the expanded MRC grading system (see below table 
for details) for shoulder abduction, elbow flexion/ extension and wrist extension in the 
upper limb. In the lower limb Hip flexion, Knee extension and Extensor Hallucis 
Longus power are assessed. 
Sensory 
Joint position proprioception – The subject’s index finger at the level of the distal-
interphalangeal joint is placed in the ‘up’ and ‘down’ position, with the examiner 
explaining to the subject the position the joint is in when the subject’s eyes are open. 
The procedure is repeated with the subject’s eyes closed for 3 different joint positions. 
If the subject fails to recognize 3 out of 3 positions, the examiner repeats the 
examination on the next proximal joint and so on, until a level is reached where the 
subject demonstrates normal joint proprioception. This level is then recorded. 
Vibration perception – the examiner applies a maximally struck 128Hz tuning fork to 
the distal inter-phalangeal joint of the subject’s index finger in the upper limb, and the 
distal interphalangeal joint in the first toe in the lower limb. The examiner asks the 
subject to indicate if they can feel the vibration. If they are able to detect vibration, 
the examiner asks if it feels the same as when applied to the subject’s sternum. If the 
subject indicates that it does not feel the same, the assessment is repeated at the next 
most proximal joint until the subject indicates that the vibration sensation felt is the 
same when applied distally as when applied to the sternum. This level is then 
recorded. 
Light touch – The examiner touches the palmer aspect of fingers 1 to 5 with a cotton 
wisp and asks the subject to point to the finger being touched with their eyes closed. 
The light touch stimulus is demonstrated first to the subject on their sternum with 
their eyes open. 
Pin-prick perception – The examiner uses a Neurotip™ pin (Owen Mumford, Oxford 
U.K.) asking the subject to identify if the blunt or sharp part of the Neurotip pin is 
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being applied to the palmer aspect of the subjects index fingers. If the subject is not 
successful on 3 out of 3 applications, the examiner would repeat the assessment at the 
next most proximal joint. The level at which normal pin-prick sensation is recorded. 
The pin-prick examination is demonstrated first to the subject on their sternum with 
their eyes open 
Temperature perception - The examiner uses cold and warm water filled test tubes, 
asking the subject to indicate if the test tube applied is warm or cold when applied to 
first the subjects palmer aspect of their finger tips with their eyes are closed. If the 
subject is unable to correctly identify the temperature, the assessment is repeated at 
the next most proximal joint. The examiner first demonstrates the test on the subjects 
sternum with their eyes open. 
Reflexes 
Using a standard 40 cm ‘Queen Square’ style reflex hammer. Reflexes assessed: 
biceps, triceps and brachioradialis in the upper limb; patella, Achilles’ and plantar in 
the lower limb. The examiner records if the reflex was normal, absent, brisk or only 
present with a reinforcement maneuver. Plantar reflexes are recorded as up or down. 
 
 
